462 results on '"D'Arminio Monforte A"'
Search Results
2. Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
- Author
-
Giulia Marchetti, Roberta Rovito, Valeria Bono, Paola Bonara, Francesca Bai, and Antonella d’Arminio Monforte
- Subjects
Microbiology (medical) ,Infectious Diseases ,General Medicine - Published
- 2023
- Full Text
- View/download PDF
3. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA Study–authors’ response
- Author
-
Antonella d’Arminio Monforte, Alessandro Tavelli, Andrea Antinori, and Alessandro Cozzi-Lepri
- Subjects
Pharmacology ,Microbiology (medical) ,Infectious Diseases ,Pharmacology (medical) - Published
- 2023
- Full Text
- View/download PDF
4. Six-month immune responses to mRNA-1273 Vaccine in cART-treated late presenter people living with HIV according to previous SARS-CoV-2 Infection
- Author
-
Matteo Augello, Valeria Bono, Roberta Rovito, Camilla Tincati, Antonella D’arminio Monforte, and Giulia Marchetti
- Subjects
Infectious Diseases ,Immunology ,Immunology and Allergy - Published
- 2023
- Full Text
- View/download PDF
5. HIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies
- Author
-
Tom Loosli, Stefanie Hossmann, Suzanne M. Ingle, Hajra Okhai, Katharina Kusejko, Johannes Mouton, Pantxika Bellecave, Ard van Sighem, Melanie Stecher, Antonella d’Arminio Monforte, M. John Gill, Caroline A. Sabin, Gary Maartens, Huldrych F. Günthard, Jonathan A. C. Sterne, Richard Lessells, Matthias Egger, and Roger Kouyos
- Abstract
SummaryBackgroundThe widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) in first- and second-line antiretroviral therapy (ART) may facilitate emerging resistance. We combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for DTG resistance.MethodsEight cohorts from Canada, Europe, and South Africa contributed data on individuals with genotypic resistance testing on DTG-based ART. Resistance levels were categorised using the Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic regression models.ResultsWe included 750 people with genotypic resistance testing on DTG-based ART between 2013 and 2022. Most had HIV subtype B (N=444, 59·2%) and were treatment-experienced; 134 (17.9%) were on DTG dual and 19 (2.5%) on DTG monotherapy. INSTI DRMs were detected in 100 (13·3%) individuals; 21 (2·8%) had more than one mutation. Most (N=713, 95·1%) were susceptible to DTG, 8 (1·1%) had potential-low, 5 (0·7%) low, 18 (2·4%) intermediate and 6 (0·8%) high-level DTG resistance. The risk of DTG resistance was higher on DTG monotherapy (adjusted odds ratio (aOR) 37·25, 95% CI 11·17 to 124·2) and DTG lamivudine dual therapy (aOR 6·59, 95% CI 1·70 to 25·55) compared to combination ART, and higher in the presence of potential-low/low (aOR 4.62, 95% CI 1.24 to 17.2) or intermediate/high-level (aOR 7·01, 95% CI 2·52 to 19·48) nucleoside reverse transcriptase inhibitors (NRTI) resistance. Viral load on DTG showed a trend towards increased DTG resistance (aOR 1·42, 95% CI 0·92 to 2·19 per standard deviation of log10area under the viral load curve).InterpretationAmong people experiencing virological failure on DTG-based ART, INSTI DRMs were uncommon, and DTG resistance was rare. DTG monotherapy and NRTI resistance substantially increased the risk for DTG resistance, which is of concern, notably in resource-limited settings.FundingUS National Institutes of Health, Swiss National Science Foundation.Research in contextEvidence before this studyWe searched SCOPUS on 20 March 2023 for all publications from inception using the terms “dolutegravir” or “DTG”, “resistant” or “resistance”, and “HIV”. The available evidence on resistance evolution in people living with HIV (PLHIV) with virological failure on DTG-based ART is limited. Most studies assessed the efficacy of DTG-based regimens in clinical studies and reported drug resistance in individuals experiencing virological failure as a secondary objective or reported single or multiple cases of patients developing resistance on DTG-based ART. Clinical trials such as the NADIA trial showed a high degree of viral suppression even in people with NRTI resistance. Consequently, previous analyses included only a small number of people experiencing failure on DTG; the SINGLE trial with 39 people with virologic failure on DTG was the largest. The highest number of individuals with DTG resistance was nine study participants in the NADIA trial. There is evidence that DTG resistance in PLHIV on a DTG monotherapy may be more likely. Other studies suggest that HIV subtype and mutations acquired during a first-generation INSTI-based regimen might affect the risk of DTG resistance.Added value of this studyTo our knowledge, this is the first study systematically investigating resistance in PLHIV experiencing virologic failure on DTG-based ART using a multi-cohort collaboration design reflecting real-world routine care. We collected genotypic resistance tests and clinical data from eight observational HIV cohorts. This resulted in a large dataset of PLHIV experiencing virologic failure on a DTG regimen (over 700 individuals). It allowed a robust assessment of drug resistance mutations and risk factors for DTG resistance. Cross-resistance of first-generation INSTIs does not appear to explain the mutation patterns in HIV-infected individuals who experience virological failure on DTG-based ART regimens. PLHIV who received DTG monotherapy or DTG lamivudine dual therapy and those infected with non-B subtypes were more likely to develop resistance. Resistance to NRTIs was a major risk factor for DTG resistance, indicating that PLHIV receiving functional monotherapy are more likely to develop DTG resistance.Implications of all the available evidenceHIV drug resistance is a significant threat to the sustainability of current and future antiretroviral therapy for combating the ongoing HIV pandemic. Our collaborative analysis shows that cases of DTG resistance are so far rare but not negligible. Given the global DTG roll-out, this might lead to increased frequencies and transmission of DTG resistance, particularly in PLHIV with resistance to NRTIs. While the evidence regarding subtype differences is tentative, it indicates that non-B subtypes, which are most relevant for the global roll-out of DTG, might be associated with an increased risk of resistance.
- Published
- 2023
- Full Text
- View/download PDF
6. Differences in clinical characteristics and quantitative lung CT features between vaccinated and not vaccinated hospitalized COVID-19 patients in Italy
- Author
-
Davide Chiumello, Alessandro Tavelli, Lorenzo Serio, Sara De Benedittis, Tommaso Pozzi, Roberta Maj, Mara Velati, Serena Brusatori, Rosanna D’Albo, Carmelo Zinnato, Giulia Marchetti, Luigi Camporota, Silvia Coppola, and Antonella D’Arminio Monforte
- Subjects
Critical Care and Intensive Care Medicine - Abstract
Background To evaluate the differences in the clinical characteristics and severity of lung impairment, assessed by quantitative lung CT scan, between vaccinated and non-vaccinated hospitalized patients with COVID-19; and to identify the variables with best prognostic prediction according to SARS-CoV-2 vaccination status. We recorded clinical, laboratory and quantitative lung CT scan data in 684 consecutive patients [580 (84.8%) vaccinated, and 104 (15.2%) non-vaccinated], admitted between January and December 2021. Results Vaccinated patients were significantly older 78 [69–84] vs 67 [53–79] years and with more comorbidities. Vaccinated and non-vaccinated patients had similar PaO2/FiO2 (300 [252–342] vs 307 [247–357] mmHg; respiratory rate 22 [8–26] vs 19 [18–26] bpm); total lung weight (918 [780–1069] vs 954 [802–1149] g), lung gas volume (2579 [1801–3628] vs 2370 [1675–3289] mL) and non-aerated tissue fraction (10 [7.3–16.0] vs 8.5 [6.0–14.1] %). The overall crude hospital mortality was similar between the vaccinated and non-vaccinated group (23.1% vs 21.2%). However, Cox regression analysis, adjusted for age, ethnicity, age unadjusted Charlson Comorbidity Index and calendar month of admission, showed a 40% reduction in hospital mortality in the vaccinated patients (HRadj = 0.60, 95%CI 0.38–0.95). Conclusions Hospitalized vaccinated patients with COVID-19, although older and with more comorbidities, presented a similar impairment in gas exchange and lung CT scan compared to non-vaccinated patients, but were at a lower risk of mortality.
- Published
- 2023
- Full Text
- View/download PDF
7. Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex
- Author
-
A, Cingolani, A, Tavelli, G V, Calvino, F, Maggiolo, E, Girardi, A, Cozzi-Lepri, A, Perziano, P, Meli, A, Camposeragna, S, Mattioli, D, Calzavara, R, Gagliardini, S, Nozza, A, Antinori, and A, d'Arminio Monforte
- Subjects
Health (social science) ,Social Psychology ,Public Health, Environmental and Occupational Health - Abstract
Evidences on the absence of risk of sexual transmission of HIV by persons living with HIV/AIDS (PLWHA) with undetectable plasma HIV-RNA (HIV-RNA200 copies/ml) led to the worldwide campaign "U = U" (undetectable = untransmittable). The purpose of this study was to evaluate the perceived accuracy of this message among PLWHA, HIV-negative people having unprotected sex (PHUS) and infectious diseases' (ID) physicians in Italy. A nationwide survey has been conducted using three different anonymous questionnaires (for ID physicians, PLWHA and PHUS). A total of 1121 participants filled the questionnaires: 397 PLWHA; 90 physicians; 634 PHUS. Awareness of U = U message has been reported in 74%, 92% and 47% of PLWHA, ID physicians and PHUS, respectively. The perception of accuracy of the U = U message among those aware was reported as high in 80.4%, 79.5% and 67.3% of PLWHA, ID physicians and PHUS, respectively. Physicians perceived that 11% of PLWHA have a high rate of perception of U = U, whereas among PLWHA, only 34% reported definitive positive messages from physicians. Discrepancies between awareness and perception of accuracy of the message U = U in PLWHA and physicians have been found, suggesting still low confidence in the community regarding the message itself.
- Published
- 2022
- Full Text
- View/download PDF
8. One‐year cognitive follow‐up of COVID‐19 hospitalized patients
- Author
-
Roberta Ferrucci, Michelangelo Dini, Chiara Rosci, Antonella Capozza, Elisabetta Groppo, Maria R. Reitano, Elisa Allocco, Barbara Poletti, Agostino Brugnera, Francesca Bai, Alessia Monti, Nicola Ticozzi, Vincenzo Silani, Stefano Centanni, Antonella D’Arminio Monforte, Luca Tagliabue, and Alberto Priori
- Subjects
cognition ,Settore M-PSI/02 - Psicobiologia e Psicologia Fisiologica ,Neurology ,COVID-19 ,long-COVID ,neuropsychological evaluation ,Cognition ,Follow-Up Studies ,Humans ,Neuropsychological Tests ,Cognition Disorders ,Cognitive Dysfunction ,Neurology (clinical) - Abstract
Cognitive dysfunction has been observed following recovery from COVID-19. To the best of our knowledge, however, no study has assessed the progression of cognitive impairment after 1 year. The aim was to assess cognitive functioning at 1 year from hospital discharge, and eventual associations with specific clinical variables.Seventy-six patients (aged 22-74 years) who had been hospitalized for COVID-19 were recruited. Patients received neuropsychological assessments at 5 (n = 76) and 12 months (n = 53) from hospital discharge.Over half (63.2%) of the patients had deficits in at least one test at 5 months. Compared to the assessment at 5 months, verbal memory, attention and processing speed improved significantly after 1 year (all p 0.05), whereas visuospatial memory did not (all p 0.500). The most affected domains after 1 year were processing speed (28.3%) and long-term visuospatial (18.1%) and verbal (15.1%) memory. Lower PaOOur study expands the results from previous studies showing that cognitive impairment can still be observed after 1 year. Patients with severe COVID-19 should receive periodic cognitive follow-up evaluations, as cognitive deficits in recovered patients could have social and occupational implications.
- Published
- 2022
- Full Text
- View/download PDF
9. Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process
- Author
-
João Marques‐Gomes, Matthew J. Salt, Rita Pereira‐Neto, Franca S. Barteldes, Vera Gouveia‐Barros, Alexandre Carvalho, Antonella d’Arminio‐Monforte, Alethse De‐la‐Torre‐Rosas, Amy Harris, Catarina Esteves, Carcom Maor, Cristina Mora, Carla Oliveira, Cristina Sousa, Douglas D. Richman, Esteban Martinez, Fábio Cota‐Medeiros, Filipa Gramacho, Georg M. N. Behrens, Graça Gonçalves, Helena Farinha, Isabel Nabais, Inês Vaz‐Pinto, Juan Sierra‐Madero, Joaquim Sousa‐Gago, John Thornhill, José Vera, Maja Erceg‐Tusek, Margarida Tavares, Miguel Vasconcelos, Nuno Fernandes, Nicola Gianotti, Nienke Langebeek, Paulo Anjos, Raquel Couto, Ricardo Fernandes, Reena Rajasuriar, Rosário Serrão, Shaun Watson, Teresa Branco, Tiago Teixeira, Vicente Soriano, and Repositório da Universidade de Lisboa
- Subjects
Adult ,Consensus ,Outcome Assessment ,Health Personnel ,Clinical Sciences ,8.1 Organisation and delivery of services ,Patient-centred care ,HIV Infections ,Outcomes ,outcomes ,Value-based healthcare ,Clinical Research ,Virology ,Outcome Assessment, Health Care ,Behavioral and Social Science ,Scopus ,Humans ,Pharmacology (medical) ,Patient Reported Outcome Measures ,CD4-CD8 ratio ,Health Policy ,abacavir ,HIV ,Health Services ,Health Care ,AIDS ,Treatment Outcome ,Infectious Diseases ,patient-centred care ,JCR ,value-based healthcare ,HIV/AIDS ,human immunodeficiency virus 1 - Abstract
© 2021 British HIV Association, Objectives: HIV outcomes centre primarily around clinical markers with limited focus on patient-reported outcomes. With a global trend towards capturing the outcomes that matter most to patients, there is agreement that standardizing the definition of value in HIV care is key to their incorporation. This study aims to address the lack of routine, standardized data in HIV care. Methods: An international working group (WG) of 37 experts and patients, and a steering group (SG) of 18 experts were convened from 14 countries. The project team (PT) identified outcomes by conducting a literature review, screening 1979 articles and reviewing the full texts of 547 of these articles. Semi-structured interviews and advisory groups were performed with the WG, SG and people living with HIV to add to the list of potentially relevant outcomes. The WG voted via a modified Delphi process - informed by six Zoom calls - to establish a core set of outcomes for use in clinical practice. Results: From 156 identified outcomes, consensus was reached to include three patient-reported outcomes, four clinician-reported measures and one administratively reported outcome; standardized measures were included. The WG also reached agreement to measure 22 risk-adjustment variables. This outcome set can be applied to any person living with HIV aged > 18 years. Conclusions: Adoption of the HIV360 outcome set will enable healthcare providers to record, compare and integrate standardized metrics across treatment sites to drive quality improvement in HIV care.
- Published
- 2021
- Full Text
- View/download PDF
10. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
- Author
-
Byonanebye D. M., Polizzotto M. N., Begovac J., Grabmeier-Pfistershammer K., Abela I., Castagna A., de Wit S., Mussini C., Vehreschild J. J., d'Arminio Monforte A., Wit F. W. N. M., Pradier C., Chkhartishvili N., Sonnerborg A., Hoy J., Lundgren J., Neesgaard B., Bansi-Matharu L., Greenberg L., Llibre J. M., Vannappagari V., Gallant J., Necsoi C., Cichon P., Reiss P., Aho I., Tsertsvadze T., Mennozzi M., Rauch A., Muccini C., Law M., Mocroft A., Ryom L., Petoumenos K., Hillebregt M., Rose N., Zangerle R., Appoyer H., Delforge M., Wandeler G., Stephan C., Bucht M., Chokoshvili O., Rodano A., Tavelli A., Fanti I., Borghi V., Fontas E., Dollet K., Caissotti C., Casabona J., Miro J. M., Smith C., Lampe F., Johnson M., Burns F., Chaloner C., Lazzarin A., Poli A., Falconer K., Svedhem V., Gunthard H., Ledergerber B., Bucher H., Scherrer A., Wasmuth J. C., Rockstroh J., Fatkenheuer G., Stecher M., Schulze N., Franke B., Rooney J., Rogatto F., Garges H., Kowalska J., Raben D., Peters L., Anne A. V., Dedes N., Williams E. D., Bruguera A., Haubrich R., Svedhem-Johansson V., Bloch M., Braun D., Calmy A., Schuttfort G., Youle M., Zona S., Antinori A., Bolokadze N., Schwarze-Zander C., Duvivier C., Dragovic G., Radoi R., Oprea C., Vasylyev M., Matulionyte R., Mulabdic V., Marchetti G., Kuzovatova E., Coppola N., Martini S., Harxhi A., Waehre T., Pharris A., Vassilenko A., Bogner J., Maagaard A., Jablonowska E., Elbirt D., Marrone G., Leen C., Wyen C., Kundro M., Thorpe D., Volny-Anne A., Mendao L., Larsen J. F., Jakobsen M. L., Bruun T., Bojesen A., Hansen E. V., Elsing T. W., Kristensen D., Thomsen S., Weide T., Pelchen-Matthews A., Byonanebye, D. M., Polizzotto, M. N., Begovac, J., Grabmeier-Pfistershammer, K., Abela, I., Castagna, A., de Wit, S., Mussini, C., Vehreschild, J. J., d'Arminio Monforte, A., Wit, F. W. N. M., Pradier, C., Chkhartishvili, N., Sonnerborg, A., Hoy, J., Lundgren, J., Neesgaard, B., Bansi-Matharu, L., Greenberg, L., Llibre, J. M., Vannappagari, V., Gallant, J., Necsoi, C., Cichon, P., Reiss, P., Aho, I., Tsertsvadze, T., Mennozzi, M., Rauch, A., Muccini, C., Law, M., Mocroft, A., Ryom, L., Petoumenos, K., Hillebregt, M., Rose, N., Zangerle, R., Appoyer, H., Delforge, M., Wandeler, G., Stephan, C., Bucht, M., Chokoshvili, O., Rodano, A., Tavelli, A., Fanti, I., Borghi, V., Fontas, E., Dollet, K., Caissotti, C., Casabona, J., Miro, J. M., Smith, C., Lampe, F., Johnson, M., Burns, F., Chaloner, C., Lazzarin, A., Poli, A., Falconer, K., Svedhem, V., Gunthard, H., Ledergerber, B., Bucher, H., Scherrer, A., Wasmuth, J. C., Rockstroh, J., Fatkenheuer, G., Stecher, M., Schulze, N., Franke, B., Rooney, J., Rogatto, F., Garges, H., Kowalska, J., Raben, D., Peters, L., Anne, A. V., Dedes, N., Williams, E. D., Bruguera, A., Haubrich, R., Svedhem-Johansson, V., Bloch, M., Braun, D., Calmy, A., Schuttfort, G., Youle, M., Zona, S., Antinori, A., Bolokadze, N., Schwarze-Zander, C., Duvivier, C., Dragovic, G., Radoi, R., Oprea, C., Vasylyev, M., Matulionyte, R., Mulabdic, V., Marchetti, G., Kuzovatova, E., Coppola, N., Martini, S., Harxhi, A., Waehre, T., Pharris, A., Vassilenko, A., Bogner, J., Maagaard, A., Jablonowska, E., Elbirt, D., Marrone, G., Leen, C., Wyen, C., Kundro, M., Thorpe, D., Volny-Anne, A., Mendao, L., Larsen, J. F., Jakobsen, M. L., Bruun, T., Bojesen, A., Hansen, E. V., Elsing, T. W., Kristensen, D., Thomsen, S., Weide, T., and Pelchen-Matthews, A.
- Subjects
0301 basic medicine ,Anti-HIV Agents ,Immunology ,Integrase inhibitor ,Blood lipids ,HIV Infections ,Tenofovir alafenamide ,03 medical and health sciences ,0302 clinical medicine ,ANTIRETROVIRAL AGENTS ,medicine ,Humans ,Immunology and Allergy ,Protease inhibitor (pharmacology) ,Prospective Studies ,HIV Integrase Inhibitors ,030212 general & internal medicine ,Myocardial infarction ,Dyslipidemias ,business.industry ,Incidence ,Incidence (epidemiology) ,dyslipidemia ,HIV ,medicine.disease ,Virology ,antiretroviral agents ,integrase inhibitors ,030104 developmental biology ,Infectious Diseases ,Anti-Retroviral Agents ,Reverse Transcriptase Inhibitors ,business ,Dyslipidemia - Abstract
Objective: To compare the incidence of dyslipidemia in people with HIV receiving integrase inhibitors (INSTI) versus boosted protease inhibitors (PI/b) and nonnucleoside reverse transcriptase inhibitors (NNRTI) within RESPOND consortium of prospective cohorts. Methods: Participants were eligible if they were at least 18 years, without dyslipidemia and initiated or switched to a three-drug antiretroviral therapy (ART)-regimen consisting of either INSTI, NNRTI, or PI/b for the first time, between 1 January 2012 and 31 December 2018. Dyslipidemia was defined as random total cholesterol more than 240 mg/dl, HDL less than 35 mg/dl, triglyceride more than 200 mg/dl, or initiation of lipid-lowering therapy. Poisson regression was used to determine the adjusted incidence rate ratios. Follow-up was censored after 3 years or upon ART-regimen discontinuation or last lipid measurement or 31 December 2019, whichever occurred first. Results: Overall, 4577 people with HIV were eligible (INSTI = 66.9%, PI/b = 12.5%, and NNRTI = 20.6%), 1938 (42.3%) of whom were ART-naive. During 1.7 (interquartile range, 0.6 - 3.0) median years of follow-up, 1460 participants developed dyslipidemia [incidence rate: 191.6 per 1000 person-years, 95% confidence interval (CI) 182.0 - 201.7]. Participants taking INSTI had a lower incidence of dyslipidemia compared with those on PI/b (adjusted incidence rate ratio 0.71; CI 0.59 - 0.85), but higher rate compared with those on NNRTI (1.35; CI 1.15 - 1.58). Compared with dolutegravir, the incidence of dyslipidemia was higher with elvitegravir/cobicistat (1.20; CI 1.00 - 1.43) and raltegravir (1.24; CI 1.02 - 1.51), but lower with rilpivirine (0.77; CI 0.63 - 0.94). Conclusion: In this large consortium of heterogeneous cohorts, dyslipidemia was less common with INSTI than with PI/b. Compared with dolutegravir, dyslipidemia was more common with elvitegravir/cobicistat and raltegravir, but less common with rilpivirine.
- Published
- 2021
- Full Text
- View/download PDF
11. Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE
- Author
-
Atkinson A., Zwahlen M., Barger D., D'arminio Monforte A., De Wit S., Ghosn J., Girardi E., Svedhem V., Morlat P., Mussini C., Noguera-Julian A., Stephan C., Touloumi G., Kirk O., Mocroft A., Reiss P., Miro J. M., Carpenter J. R., Furrer H., Judd A., Zangerle R., Warszawski J., Meyer L., Dabis F., Krause M. M., Leport C., Wittkop L., Wit F., Prins M., Bucher H., Gibb D., Fatkenheuer G., Del Amo J., Obel N., Thorne C., Perez-Hoyos S., Hamouda O., Bartmeyer B., Chkhartishvili N., Antinori A., Brockmeyer N., Prieto L., Rojo Conejo P., Soriano-Arandes A., Battegay M., Kouyos R., Casabona J., M. Miro J., Castagna A., Konopnick D., Goetghebuer T., Sonnerborg A., Torti C., Sabin C., Teira R., Garrido M., Haerry D., Costagliola D., D'arminio-Monforte A., Raben D., Chene G., Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Agence Nationale de Recherches sur le Sida et les Hépatites Virales, European Project: 260694,EC:FP7:HEALTH,FP7-HEALTH-2010-single-stage,EUROCOORD(2011), Atkinson, A., Zwahlen, M., Barger, D., D'arminio Monforte, A., De Wit, S., Ghosn, J., Girardi, E., Svedhem, V., Morlat, P., Mussini, C., Noguera-Julian, A., Stephan, C., Touloumi, G., Kirk, O., Mocroft, A., Reiss, P., Miro, J. M., Carpenter, J. R., Furrer, H., Judd, A., Zangerle, R., Warszawski, J., Meyer, L., Dabis, F., Krause, M. M., Leport, C., Wittkop, L., Wit, F., Prins, M., Bucher, H., Gibb, D., Fatkenheuer, G., Del Amo, J., Obel, N., Thorne, C., Perez-Hoyos, S., Hamouda, O., Bartmeyer, B., Chkhartishvili, N., Antinori, A., Brockmeyer, N., Prieto, L., Rojo Conejo, P., Soriano-Arandes, A., Battegay, M., Kouyos, R., Casabona, J., M. Miro, J., Castagna, A., Konopnick, D., Goetghebuer, T., Sonnerborg, A., Torti, C., Sabin, C., Teira, R., Garrido, M., Haerry, D., Costagliola, D., D'arminio-Monforte, A., Raben, D., Chene, G., Global Health, Infectious diseases, AII - Infectious diseases, and APH - Aging & Later Life
- Subjects
Microbiology (medical) ,Microbiologie et protistologie [parasitologie hum. et anim.] ,medicine.medical_specialty ,Human immunodeficiency virus (HIV) ,HIV Infections ,Logistic regression ,Pneumocystis pneumonia ,medicine.disease_cause ,01 natural sciences ,law.invention ,010104 statistics & probability ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Pragmatic Clinical Trials as Topic ,medicine ,Humans ,030212 general & internal medicine ,0101 mathematics ,Pathologie maladies infectieuses ,AIDS-Related Opportunistic Infections ,human immunodeficiency virus ,business.industry ,Pneumonia, Pneumocystis ,pneumocystis pneumonia ,Hazard ratio ,HIV ,medicine.disease ,Confidence interval ,3. Good health ,CD4 Lymphocyte Count ,Microbiologie et protistologie [entomologie,phytoparasitolog.] ,Major Articles and Commentaries ,Infectious Diseases ,AcademicSubjects/MED00290 ,HIV-RNA ,Censoring (clinical trials) ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Observational study ,prophylaxis ,business ,Microbiologie et protistologie [bacteriol.virolog.mycolog.] - Abstract
BACKGROUND: Using data from the COHERE collaboration, we investigated whether primary prophylaxis for pneumocystis pneumonia (PcP) might be withheld in all patients on antiretroviral therapy (ART) with suppressed plasma human immunodeficiency virus (HIV) RNA (≤400 copies/mL), irrespective of CD4 count. METHODS: We implemented an established causal inference approach whereby observational data are used to emulate a randomized trial. Patients taking PcP prophylaxis were eligible for the emulated trial if their CD4 count was ≤200 cells/µL in line with existing recommendations. We compared the following 2 strategies for stopping prophylaxis: (1) when CD4 count was >200 cells/µL for >3 months or (2) when the patient was virologically suppressed (2 consecutive HIV RNA ≤400 copies/mL). Patients were artificially censored if they did not comply with these stopping rules. We estimated the risk of primary PcP in patients on ART, using the hazard ratio (HR) to compare the stopping strategies by fitting a pooled logistic model, including inverse probability weights to adjust for the selection bias introduced by the artificial censoring. RESULTS: A total of 4813 patients (10 324 person-years) complied with eligibility conditions for the emulated trial. With primary PcP diagnosis as an endpoint, the adjusted HR (aHR) indicated a slightly lower, but not statistically significant, different risk for the strategy based on viral suppression alone compared with the existing guidelines (aHR, 8; 95% confidence interval, 6-1.1; P = .2). CONCLUSIONS: This study suggests that primary PcP prophylaxis might be safely withheld in confirmed virologically suppressed patients on ART, regardless of their CD4 count., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2020
- Full Text
- View/download PDF
12. An explainable model of host genetic interactions linked to COVID-19 severity
- Author
-
Onoja, Anthony, Picchiotti, Nicola, Fallerini, Chiara, Baldassarri, Margherita, Fava, Francesca, Colombo, Francesca, Chiaromonte, Francesca, Renieri, Alessandra, Furini, Simone, Raimondi, Francesco GEN-COVID Multicenter Study: Francesca Mari, Sergio, Daga, Elisa, Benetti, Mirella, Bruttini, Maria, Palmieri, Susanna, Croci, Sara, Amitrano, Ilaria, Meloni, Elisa, Frullanti, Gabriella, Doddato, Mirjam, Lista, Giada, Beligni, Floriana, Valentino, Kristina, Zguro, Rossella, Tita, Annarita, Giliberti, Maria Antonietta Mencarelli, Caterina Lo Rizzo, Anna Maria Pinto, Francesca, Ariani, Laura Di Sarno, Francesca, Montagnani, Mario, Tumbarello, Ilaria, Rancan, Massimiliano, Fabbiani, Barbara, Rossetti, Laura, Bergantini, Miriana, D'Alessandro, Paolo, Cameli, David, Bennett, Federico, Anedda, Simona, Marcantonio, Sabino, Scolletta, Federico, Franchi, Maria Antonietta Mazzei, Susanna, Guerrini, Edoardo, Conticini, Luca, Cantarini, Bruno, Frediani, Danilo, Tacconi, Chiara Spertilli Raffaelli, Marco, Feri, Alice, Donati, Raffaele, Scala, Luca, Guidelli, Genni, Spargi, Marta, Corridi, Cesira, Nencioni, Leonardo, Croci, Gian Piero Caldarelli, Davide, Romani, Paolo, Piacentini, Maria, Bandini, Elena, Desanctis, Silvia, Cappelli, Anna, Canaccini, Agnese, Verzuri, Valentina, Anemoli, Manola, Pisani, Agostino, Ognibene, Alessandro, Pancrazzi, Maria, Lorubbio, Massimo, Vaghi, Antonella D'Arminio Monforte, Federica Gaia Miraglia, Raffaele, Bruno, Marco, Vecchia, Massimo, Girardis, Sophie, Venturelli, Stefano, Busani, Andrea, Cossarizza, Andrea, Antinori, Alessandra, Vergori, Arianna, Emiliozzi, Stefano, Rusconi, Matteo, Siano, Arianna, Gabrieli, Agostino, Riva, Daniela, Francisci, Elisabetta, Schiaroli, Francesco, Paciosi, Andrea, Tommasi, Umberto, Zuccon, Lucia, Vietri, Pier Giorgio Scotton, Francesca, Andretta, Sandro, Panese, Stefano, Baratti, Renzo, Scaggiante, Francesca, Gatti, Saverio Giuseppe Parisi, Francesco, Castelli, Eugenia, Quiros-Roldan, Melania Degli Antoni, Isabella, Zanella, Matteo Della Monica, Carmelo, Piscopo, Mario, Capasso, Roberta, Russo, Immacolata, Andolfo, Achille, Iolascon, Giuseppe, Fiorentino, Massimo, Carella, Marco, Castori, Filippo, Aucella, Pamela, Raggi, Rita, Perna, Matteo, Bassetti, Antonio Di Biagio, Maurizio, Sanguinetti, Luca, Masucci, Alessandra, Guarnaccia, Serafina, Valente, Oreste De Vivo, Elena, Bargagli, Marco, Mandalà, Alessia, Giorli, Lorenzo, Salerni, Patrizia, Zucchi, Pierpaolo, Parravicini, Elisabetta, Menatti, Tullio, Trotta, Ferdinando, Giannattasio, Gabriella, Coiro, Fabio, Lena, Gianluca, Lacerenza, Domenico, A Coviello, Cristina, Mussini, Enrico, Martinelli, Luisa, Tavecchia, Mary Ann Belli, Lia, Crotti, Gianfranco, Parati, Maurizio, Sanarico, Filippo, Biscarini, Alessandra, Stella, Marco, Rizzi, Franco, Maggiolo, Diego, Ripamonti, Claudia, Suardi, Tiziana, Bachetti, Maria Teresa La Rovere, Simona, Sarzi-Braga, Maurizio, Bussotti, Katia, Capitani, Simona, Dei, Sabrina, Ravaglia, Rosangela, Artuso, Elena, Andreucci, Giulia, Gori, Angelica, Pagliazzi, Erika, Fiorentini, Antonio, Perrella, Francesco, Bianchi, Paola, Bergomi, Emanuele, Catena, Riccardo, Colombo, Sauro, Luchi, Giovanna, Morelli, Paola, Petrocelli, Sarah, Iacopini, Sara, Modica, Silvia, Baroni, Francesco Vladimiro Segala, Francesco, Menichetti, Marco, Falcone, Giusy, Tiseo, Chiara, Barbieri, Tommaso, Matucci, Grassi, Davide, Ferri, Claudio, Marinangeli, Franco, Brancati, Francesco, Antonella, Vincenti, Valentina, Borgo, Lombardi, Stefania, Mirco, Lenzi, Massimo Antonio Di Pietro, Francesca, Vichi, Benedetta, Romanin, Letizia, Attala, Cecilia, Costa, Andrea, Gabbuti, Roberto, Menè, Marta, Colaneri, Patrizia, Casprini, Giuseppe, Merla, Gabriella Maria Squeo, Marcello, Maffezzoni, Stefania, Mantovani, Mario, U Mondelli, Serena, Ludovisi, Onoja, Anthony, Picchiotti, Nicola, Fallerini, Chiara, Baldassarri, Margherita, Fava, Francesca, nbsp, Multicenter Study, GEN-COVID, Colombo, Francesca, Chiaromonte, Francesca, Renieri, Alessandra, Furini, Simone, Raimondi, Francesco, Anthony, O, Nicola, P, Chiara, F, Margherita, B, Francesca, F, Francesca, C, Alessandra, R, Simone, F, Francesco, R, Mari, F, Daga, S, Benetti, E, Bruttini, M, Palmieri, M, Croci, S, Amitrano, S, Meloni, I, Frullanti, E, Doddato, G, Lista, M, Beligni, G, Valentino, F, Zguro, K, Tita, R, Giliberti, A, Antonietta Mencarelli, M, Lo Rizzo, C, Maria Pinto, A, Ariani, F, Di Sarno, L, Montagnani, F, Tumbarello, M, Rancan, I, Fabbiani, M, Rossetti, B, Bergantini, L, D’Alessandro, M, Cameli, P, Bennett, D, Anedda, F, Marcantonio, S, Scolletta, S, Franchi, F, Antonietta Mazzei, M, Guerrini, S, Conticini, E, Cantarini, L, Frediani, B, Tacconi, D, Spertilli Raffaelli, C, Feri, M, Donati, A, Scala, R, Guidelli, L, Spargi, G, Corridi, M, Nencioni, C, Croci, L, Piero Caldarelli, G, Romani, D, Piacentini, P, Bandini, M, Desanctis, E, Cappelli, S, Canaccini, A, Verzuri, A, Anemoli, V, Pisani, M, Ognibene, A, Pancrazzi, A, Lorubbio, M, Vaghi, M, D’Arminio Monforte, A, Gaia Miraglia, F, Bruno, R, Vecchia, M, Girardis, M, Venturelli, S, Busani, S, Cossarizza, A, Antinori, A, Vergori, A, Emiliozzi, A, Rusconi, S, Siano, M, Gabrieli, A, Riva, A, Francisci, D, Schiaroli, E, Paciosi, F, Tommasi, A, Zuccon, U, Vietri, L, Giorgio Scotton, P, Andretta, F, Panese, S, Baratti, S, Scaggiante, R, Gatti, F, Giuseppe Parisi, S, Castelli, F, Quiros-Roldan, E, Degli Antoni, M, Zanella, I, Della Monica, M, Piscopo, C, Capasso, M, Russo, R, Andolfo, I, Iolascon, A, Fiorentino, G, Carella, M, Castori, M, Aucella, F, Raggi, P, Perna, R, Bassetti, M, Di Biagio, A, Sanguinetti, M, Masucci, L, Guarnaccia, A, Valente, S, De Vivo, O, Bargagli, E, Mandalà, M, Giorli, A, Salerni, L, Zucchi, P, Parravicini, P, Menatti, E, Trotta, T, Giannattasio, F, Coiro, G, Lena, F, Lacerenza, G, Coviello, D, Mussini, C, Martinelli, E, Tavecchia, L, Ann Belli, M, Crotti, L, Parati, G, Sanarico, M, Biscarini, F, Stella, A, Rizzi, M, Maggiolo, F, Ripamonti, D, Suardi, C, Bachetti, T, Teresa La Rovere, M, Sarzi-Braga, S, Bussotti, M, Capitani, K, Dei, S, Ravaglia, S, Artuso, R, Andreucci, E, Gori, G, Pagliazzi, A, Fiorentini, E, Perrella, A, Bianchi, F, Bergomi, P, Catena, E, Colombo, R, Luchi, S, Morelli, G, Petrocelli, P, Iacopini, S, Modica, S, Baroni, S, Vladimiro Segala, F, Menichetti, F, Falcone, M, Tiseo, G, Barbieri, C, Matucci, T, Grassi, D, Ferri, C, Marinangeli, F, Brancati, F, Vincenti, A, Borgo, V, Lombardi, S, Lenzi, M, Antonio Di Pietro, M, Vichi, F, Romanin, B, Attala, L, Costa, C, Gabbuti, A, Menè, R, Colaneri, M, Casprini, P, Merla, G, Maria Squeo, G, Maffezzoni, M, Mantovani, S, Mondelli &, M, and Ludovisi, S
- Subjects
Genetics ,Coronavirus disease 2019 (COVID-19) ,Host (biology) ,COVID-19 ,Medicine (miscellaneous) ,Settore BIO/11 - Biologia Molecolare ,Biology ,Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA ,Whole Exome Sequencing ,General Biochemistry, Genetics and Molecular Biology ,machine learning ,Phenotype ,Exome Sequencing ,Humans ,Genetic Predisposition to Disease ,Genome-Wide Association Study ,General Agricultural and Biological Sciences ,COVID ,Human - Abstract
We employed a multifaceted computational strategy to identify the genetic factors contributing to increased risk of severe COVID-19 infection from a Whole Exome Sequencing (WES) dataset of a cohort of 2000 Italian patients. We coupled a stratified k-fold screening, to rank variants more associated with severity, with training of multiple supervised classifiers, to predict severity on the basis of screened features. Feature importance analysis from tree-based models allowed to identify a handful of 16 variants with highest support which, together with age and gender covariates, were found to be most predictive of COVID-19 severity. When tested on a follow-up cohort, our ensemble of models predicted severity with good accuracy (ACC=81.88%; ROC_AUC=96%; MCC=61.55%). Principal Component Analysis (PCA) and clustering of patients on important variants orthogonally identified two groups of individuals with a higher fraction of severe cases. Our model recapitulated a vast literature of emerging molecular mechanisms and genetic factors linked to COVID-19 response and extends previous landmark Genome Wide Association Studies (GWAS). It revealed a network of interplaying genetic signatures converging on established immune system and inflammatory processes linked to viral infection response, such as JAK-STAT, Cytokine, Interleukin, and C-type lectin receptor signaling. It also identified additional processes cross-talking with immune pathways, such as GPCR signalling, which might offer additional opportunities for therapeutic intervention and patient stratification. Publicly available PheWAS datasets revealed that several variants were significantly associated with phenotypic traits such as “Respiratory or thoracic disease”, confirming their link with COVID-19 severity outcome. Taken together, our analysis suggests that curated genetic information can be effectively integrated along with other patient clinical covariates to forecast COVID-19 disease severity and dissect the underlying host genetic mechanisms for personalized medicine treatments.
- Published
- 2022
- Full Text
- View/download PDF
13. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort
- Author
-
Pelchen-Matthews, A., Borges, A. H., Reekie, J., Rasmussen, L. D., Wiese, L., Weber, J., Pradier, C., Degen, O., Paredes, R., Tau, L., Flamholc, L., Gottfredsson, M., Kowalska, J. D., Jablonowska, E., Mozer-Lisewska, I., Radoi, R., Vasylyev, M., Kuznetsova, A., Begovac, J., Svedhem, V., Clark, A., Cozzi-Lepri, A., Harxhi, A., Losso, M., Kundro, M., Schmied, B., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Paduto, D., Clumeck, N., De Wit, S., Delforge, M., Florence, E., Vandekerckhove, L., Hadziosmanovic, V., Machala, L., Jilich, D., Sedlacek, D., Kronborg, G., Benfield, T., Gerstoft, J., Katzenstein, T., Pedersen, C., Johansen, I. S., Ostergaard, L., Moller, N. F., Nielsen, L. N., Zilmer, K., Smidt, J., Aho, I., Viard, J. -P., Girard, P. -M., Fontas, E., Duvivier, C., Rockstroh, J., Behrens, G., Stellbrink, H. J., Stephan, C., Goethe, J. W., Bogner, J., Fatkenheuer, G., Chkhartishvili, N., Sambatakou, H., Adamis, G., Paissios, N., Szlavik, J., Kelly, C., Turner, D., Burke, M., Shahar, E., Hassoun, G., Elinav, H., Haouzi, M., Elbirt, D., D'Arminio Monforte, A., Esposito, R., Mazeu, I., Mussini, C., Mazzotta, F., Gabbuti, A., Lazzarin, A., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Uzdaviniene, V., Matulionyte, R., Staub, T., Hemmer, R., Dragas, S., Stevanovic, M., Reiss, P., Trajanovska, J., Reikvam, D. H., Maeland, A., Bruun, J., Knysz, B., Gasiorowski, J., Inglot, M., Bakowska, E., Flisiak, R., Grzeszczuk, A., Parczewski, M., Maciejewska, K., Aksak-Was, B., Beniowski, M., Mularska, E., Kamerys, J., Wojcik, K., Rozplochowski, B., Zagalo, A., Mansinho, K., Maltez, F., Oprea, C., Yakovlev, A., Trofimora, T., Khromova, I., Kuzovatova, E., Borodulina, E., Vdoushkina, E., Ranin, J., Tomazic, J., Miro, J. M., Laguno, M., Martinez, E., Garcia, F., Blanco, J. L., Martinez-Rebollar, M., Mallolas, J., Callau, P., Rojas, J., Inciarta, A., Moreno, S., del Campo, S., Clotet, B., Jou, A., Puig, J., Llibre, J. M., Santos, J. R., Domingo, P., Gutierrez, M., Mateo, G., Sambeat, M. A., Laporte, J. M., Falconer, K., Thalme, A., Sonnerborg, A., Treutiger, C. J., Scherrer, A., Weber, R., Cavassini, M., Calmy, A., Furrer, H., Battegay, M., Schmid, P., Mikhalik, J., Sluzhynska, M., Milinkovic, A., Johnson, A. M., Simons, E., Edwards, S., Phillips, A., Johnson, M. A., Mocroft, A., Orkin, C., Winston, A., Leen, C., Wandeler, G., Lundgren, J., Guaraldi, G., Kirk, O., Peters, L., Bojesen, A., Raben, D., Hansen, E. V., Kristensen, D., Larsen, J. F., Fischer, A. H., Amele, S., and Roen, A.
- Subjects
Adult ,Male ,antiretroviral treatment ,medicine.medical_specialty ,Anti-HIV Agents ,Human immunodeficiency virus (HIV) ,non-AIDS-defining clinical conditions ,Comorbidity ,Rate ratio ,medicine.disease_cause ,symbols.namesake ,heavily treatment experienced ,Acquired immunodeficiency syndrome (AIDS) ,Antiretroviral Therapy, Highly Active ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Prospective Studies ,Poisson regression ,Prospective cohort study ,Acquired Immunodeficiency Syndrome ,business.industry ,Confounding ,HIV resistance ,acquired immunodeficiency syndrome ,Middle Aged ,Viral Load ,prevalence ,outcomes ,heavily ,treatment-experienced ,individuals ,HIV ,medicine.disease ,Europe ,AIDS ,Treatment Outcome ,Infectious Diseases ,Cohort ,symbols ,Female ,business ,Viral load - Abstract
Background: Although antiretroviral treatments have improved survival of persons living with HIV, their long-term use may limit available drug options. We estimated the prevalence of heavily treatment-experienced (HTE) status and the potential clinical consequences of becoming HTE. Setting: EuroSIDA, a European multicenter prospective cohort study. Methods: A composite definition for HTE was developed, based on estimates of antiretroviral resistance and prior exposure to specific antiretroviral regimens. Risks of progressing to clinical outcomes were assessed by Poisson regression, comparing every HTE individual with 3 randomly selected controls who never became HTE. Results: Of 15,570 individuals under follow-up in 2010-2016, 1617 (10.4%, 95% CI: 9.9% to 10.9%) were classified as HTE. 1093 individuals became HTE during prospective follow-up (HTE incidence rate 1.76, CI: 1.66 to 1.87 per 100 person-years of follow-up). The number of HTE individuals was highest in West/Central Europe (636/4019 persons, 15.7%) and lowest in East Europe (26/2279 persons, 1.1%). Although most HTE individuals maintained controlled viral loads (
- Published
- 2021
- Full Text
- View/download PDF
14. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study
- Author
-
Fallerini, C., Daga, S., Mantovani, S., Benetti, E., Picchiotti, N., Francisci, D., Paciosi, F., Schiaroli, E., Baldassarri, M., Fava, F., Palmieri, M., Ludovisi, S., Castelli, F., Quiros-Roldan, E., Vaghi, M., Rusconi, S., Siano, M., Bandini, M., Spiga, O., Capitani, K., Furini, S., Mari, F., Renieri, A., Mondelli, M. U., Frullanti, E., Valentino, F., Doddato, G., Giliberti, A., Tita, R., Amitrano, S., Bruttini, M., Croci, S., Meloni, I., Mencarelli, M. A., Rizzo, C. L., Pinto, A. M., Sarno, L. D., Beligni, G., Tommasi, A., Iuso, N., Montagnani, F., Fabbiani, M., Rossetti, B., Zanelli, G., Bargagli, E., Bergantini, L., D'Alessandro, M., Cameli, P., Bennett, D., Anedda, F., Marcantonio, S., Scolletta, S., Franchi, F., Mazzei, M. A., Guerrini, S., Conticini, E., Cantarini, L., Frediani, B., Tacconi, D., Spertilli, C., Feri, M., Donati, A., Scala, R., Guidelli, L., Spargi, G., Corridi, M., Nencioni, C., Croci, L., Caldarelli, G. P., Spagnesi, M., Romani, D., Piacentini, P., Desanctis, E., Cappelli, S., Canaccini, A., Verzuri, A., Anemoli, V., Ognibene, A., D'Arminio Monforte, A., Miraglia, F. G., Girardis, M., Venturelli, S., Busani, S., Cossarizza, A., Antinori, A., Vergori, A., Emiliozzi, A., Gabrieli, A., Riva, A., Scotton, P. G., Andretta, F., Panese, S., Scaggiante, R., Gatti, F., Parisi, S. G., Baratti, S., Antoni, M. D., Monica, M. D., Piscopo, C., Capasso, M., Russo, R., Andolfo, I., Iolascon, A., Fiorentino, G., Carella, M., Castori, M., Merla, G., Squeo, G. M., Aucella, F., Raggi, P., Marciano, C., Perna, R., Bassetti, M., Biagio, A. D., Sanguinetti, M., Masucci, L., Valente, S., Mandala, M., Giorli, A., Salerni, L., Zucchi, P., Parravicini, P., Menatti, E., Trotta, T., Giannattasio, F., Coiro, G., Lena, F., Coviello, D. A., Mussini, C., Bosio, G., Martinelli, E., Mancarella, S., Tavecchia, L., Gori, M., Crotti, L., Parati, G., Gabbi, C., Zanella, I., Rizzi, M., Maggiolo, F., Ripamonti, D., Bachetti, T., Rovere, M. T. L., Sarzi-Braga, S., Bussotti, M., Chiariello, M., Belli, M. A., Dei, S., Fallerini, C., Daga, S., Mantovani, S., Benetti, E., Picchiotti, N., Francisci, D., Paciosi, F., Schiaroli, E., Baldassarri, M., Fava, F., Palmieri, M., Ludovisi, S., Castelli, F., Quiros-Roldan, E., Vaghi, M., Rusconi, S., Siano, M., Bandini, M., Spiga, O., Capitani, K., Furini, S., Mari, F., Renieri, A., Mondelli, M. U., Frullanti, E., Valentino, F., Doddato, G., Giliberti, A., Tita, R., Amitrano, S., Bruttini, M., Croci, S., Meloni, I., Mencarelli, M. A., Rizzo, C. L., Pinto, A. M., Sarno, L. D., Beligni, G., Tommasi, A., Iuso, N., Montagnani, F., Fabbiani, M., Rossetti, B., Zanelli, G., Bargagli, E., Bergantini, L., D'Alessandro, M., Cameli, P., Bennett, D., Anedda, F., Marcantonio, S., Scolletta, S., Franchi, F., Mazzei, M. A., Guerrini, S., Conticini, E., Cantarini, L., Frediani, B., Tacconi, D., Spertilli, C., Feri, M., Donati, A., Scala, R., Guidelli, L., Spargi, G., Corridi, M., Nencioni, C., Croci, L., Caldarelli, G. P., Spagnesi, M., Romani, D., Piacentini, P., Desanctis, E., Cappelli, S., Canaccini, A., Verzuri, A., Anemoli, V., Ognibene, A., D'Arminio Monforte, A., Miraglia, F. G., Girardis, M., Venturelli, S., Busani, S., Cossarizza, A., Antinori, A., Vergori, A., Emiliozzi, A., Gabrieli, A., Riva, A., Scotton, P. G., Andretta, F., Panese, S., Scaggiante, R., Gatti, F., Parisi, S. G., Baratti, S., Antoni, M. D., Monica, M. D., Piscopo, C., Capasso, M., Russo, R., Andolfo, I., Iolascon, A., Fiorentino, G., Carella, M., Castori, M., Merla, G., Squeo, G. M., Aucella, F., Raggi, P., Marciano, C., Perna, R., Bassetti, M., Biagio, A. D., Sanguinetti, M., Masucci, L., Valente, S., Mandala, M., Giorli, A., Salerni, L., Zucchi, P., Parravicini, P., Menatti, E., Trotta, T., Giannattasio, F., Coiro, G., Lena, F., Coviello, D. A., Mussini, C., Bosio, G., Martinelli, E., Mancarella, S., Tavecchia, L., Gori, M., Crotti, L., Parati, G., Gabbi, C., Zanella, I., Rizzi, M., Maggiolo, F., Ripamonti, D., Bachetti, T., Rovere, M. T. L., Sarzi-Braga, S., Bussotti, M., Chiariello, M., Belli, M. A., Dei, S., Fallerini, C, Daga, S, Mantovani, S, Benetti, E, Picchiotti, N, Francisci, D, Paciosi, F, Schiaroli, E, Baldassarri, M, Fava, F, Palmieri, M, Ludovisi, S, Castelli, F, Quiros-Roldan, E, Rusconi, S, Siano, M, Bandini, M, Spiga, O, Capitani, K, Furini, S, Mari, F, Renieri, A, Mondelli, M, Frullanti, E, Valentino, F, Doddato, G, Giliberti, A, Tita, R, Amitrano, S, Bruttini, M, Croci, S, Meloni, I, Mencarelli, M, Rizzo, C, Pinto, A, Sarno, L, Beligni, G, Tommasi, A, Iuso, N, Montagnani, F, Fabbiani, M, Rossetti, B, Zanelli, G, Bargagli, E, Bergantini, L, D'Alessandro, M, Cameli, P, Bennett, D, Anedda, F, Marcantonio, S, Scolletta, S, Franchi, F, Mazzei, M, Guerrini, S, Conticini, E, Cantarini, L, Frediani, B, Tacconi, D, Spertilli, C, Feri, M, Donati, A, Scala, R, Guidelli, L, Spargi, G, Corridi, M, Nencioni, C, Croci, L, Caldarelli, G, Spagnesi, M, Romani, D, Piacentini, P, Desanctis, E, Cappelli, S, Canaccini, A, Verzuri, A, Anemoli, V, Ognibene, A, D'Arminio Monforte, A, Miraglia, F, Girardis, M, Venturelli, S, Busani, S, Cossarizza, A, Antinori, A, Vergori, A, Emiliozzi, A, Gabrieli, A, Riva, A, Scotton, P, Andretta, F, Panese, S, Scaggiante, R, Gatti, F, Parisi, S, Baratti, S, Antoni, M, Monica, M, Piscopo, C, Capasso, M, Russo, R, Andolfo, I, Iolascon, A, Fiorentino, G, Carella, M, Castori, M, Merla, G, Squeo, G, Aucella, F, Raggi, P, Marciano, C, Perna, R, Bassetti, M, Biagio, A, Sanguinetti, M, Masucci, L, Valente, S, Mandala, M, Giorli, A, Salerni, L, Zucchi, P, Parravicini, P, Menatti, E, Trotta, T, Giannattasio, F, Coiro, G, Lena, F, Coviello, D, Mussini, C, Bosio, G, Martinelli, E, Mancarella, S, Tavecchia, L, Gori, M, Crotti, L, Parati, G, Gabbi, C, Zanella, I, Rizzi, M, Maggiolo, F, Ripamonti, D, Bachetti, T, Rovere, M, Sarzi-Braga, S, Bussotti, M, Chiariello, M, Belli, M, Dei, S, and Vaghi, M
- Subjects
0301 basic medicine ,Male ,medicine ,Disease ,Severity of Illness Index ,genomic ,0302 clinical medicine ,HEK293 Cell ,Epidemiology ,genetics ,030212 general & internal medicine ,Biology (General) ,COVID ,TLR7 ,General Neuroscience ,virus diseases ,General Medicine ,Single Nucleotide ,Middle Aged ,Italy ,Cohort ,Medicine ,COVID-19 ,LASSO Logistic Regression Analysis ,genomics ,human ,Adult ,Case-Control Studies ,Genetic Predisposition to Disease ,HEK293 Cells ,Humans ,SARS-CoV-2 ,Toll-Like Receptor 7 ,Polymorphism, Single Nucleotide ,medicine.symptom ,Case-Control Studie ,Insight ,Human ,medicine.medical_specialty ,QH301-705.5 ,Science ,Short Report ,macromolecular substances ,Asymptomatic ,Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA ,General Biochemistry, Genetics and Molecular Biology ,LASSO Logistic Regression Analysi ,03 medical and health sciences ,Internal medicine ,Severity of illness ,Polymorphism ,General Immunology and Microbiology ,business.industry ,Case-control study ,Genetics and Genomics ,LASSO logistic regression analysis ,Clinical trial ,030104 developmental biology ,Nested case-control study ,genetic ,business - Abstract
Background:Recently, loss-of-function variants in TLR7 were identified in two families in which COVID-19 segregates like an X-linked recessive disorder environmentally conditioned by SARS-CoV-2. We investigated whether the two families represent the tip of the iceberg of a subset of COVID-19 male patients.Methods:This is a nested case-control study in which we compared male participants with extreme phenotype selected from the Italian GEN-COVID cohort of SARS-CoV-2-infected participants (Results:Overall, we found TLR7 deleterious variants in 2.1% of severely affected males and in none of the asymptomatic participants. The functional gene expression profile analysis demonstrated a reduction in TLR7-related gene expression in patients compared with controls demonstrating an impairment in type I and II IFN responses.Conclusions:Young males with TLR7 loss-of-function variants and severe COVID-19 represent a subset of male patients contributing to disease susceptibility in up to 2% of severe COVID-19.Funding:Funded by private donors for the Host Genetics Research Project, the Intesa San Paolo for 2020 charity fund, and the Host Genetics Initiative.Clinical trial number:NCT04549831.
- Published
- 2021
15. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period
- Author
-
Lars Oestergaard, Santiago Moreno, Dorthe Raben, Pere Domingo, Christian Pradier, Elzbieta Bakowska, Lene Ryom, Marcelo H. Losso, Annegret Pelchen-Matthews, Dzmitry Paduta, Tatiana Trofimova, Marta Vasylyev, Anastasiia Kuznetsova, Christoph Stephan, Manuel Battegay, Antonella d'Arminio Monforte, Elżbieta Jabłonowska, Irina Khromova, Justyna D. Kowalska, Amanda Mocroft, Viktar Mitsura, Antonella Castagna, Linos Vandekerckhove, Kowalska, Justyna D, Pelchen-Matthews, Annegret, Ryom, Lene, Losso, Marcelo H, Trofimova, Tatiana, Mitsura, Viktar M, Khromova, Irina, Paduta, Dzmitry, Stephan, Christoph, Domingo, Pere, Bakowska, Elzbieta, Monforte, Antonella d'Arminio, Oestergaard, Lar, Jablonowska, Elzbieta, Kuznetsova, Anastasiia, Moreno, Santiago, Vasylyev, Marta, Pradier, Christian, Battegay, Manuel, Vandekerckhove, Lino, Castagna, Antonella, Raben, Dorthe, and Mocroft, Amanda
- Subjects
medicine.medical_specialty ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,Logistic regression ,medicine.disease_cause ,Odds ,Acquired immunodeficiency syndrome (AIDS) ,Pregnancy ,Prevalence ,Humans ,Immunology and Allergy ,Medicine ,Prospective Studies ,Prospective cohort study ,Generalized estimating equation ,Aged ,business.industry ,Obstetrics ,Confounding ,Abortion, Induced ,medicine.disease ,Cross-Sectional Studies ,Infectious Diseases ,Female ,business - Abstract
OBJECTIVE: To evaluate time trends in pregnancies and pregnancy outcomes among women with HIV in Europe. DESIGN: European multicentre prospective cohort study. METHODS: EuroSIDA has collected annual cross-sectional audits of pregnancies between 1996 and 2015. Pregnancy data were extracted and described. Odds of pregnancy were modelled, adjusting for potential confounders using logistic regression with generalized estimating equations. RESULTS: Of 5535 women aged 16 to
- Published
- 2021
- Full Text
- View/download PDF
16. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study
- Author
-
Mocroft, Amanda, Miro, Jose M., Wandeler, Gilles, Llibre, Josep M., Boyd, Anders, van Bremen, Kathrin, Beniowski, Marek, Mikhalik, Julia, Cavassini, Matthias, Maltez, Fernando, Duvivier, Claudine, Uberti Foppa, Caterina, Knysz, Brygida, Bakowska, Elzbieta, Kuzovatova, Elena, Domingo, Pere, Zagalo, Alexandra, Viard, Jean Paul, Degen, Olaf, Milinkovic, Ana, Benfield, Thomas, Peters, Lars, Harxhi, A., Losso, M., Kundro, M., Schmied, B., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Paduto, D., Clumeck, N., De Wit, S., Delforge, M., Florence, E., Vandekerckhove, L., Hadziosmanovic, V., Begovac, J., Machala, L., Sedlacek, D., Kronborg, G., Gerstoft, J., Katzenstein, T., Pedersen, C., Johansen, I. S., Ostergaard, L., Wiese, L., Moller, N. F., Nielsen, L. N., Zilmer, K., Smidt, J., Aho, I., Lacombe, K., Pradier, C., Fontas, E., Rockstroh, J., Behrens, G., Hoffmann, C., Stellbrink, H. J., Stefan, C., Bogner, J., Fätkenheuer, G., Chkhartishvili, N., Sambatakou, H., Adamis, G., Paissios, N., Szlávik, J., Gottfredsson, M., Devitt, E., Tau, L., Turner, D., Burke, M., Shahar, E., Wattad, L. M., Elinav, H., Haouzi, M., Elbirt, D., D’Arminio Monforte, A., Esposito, R., Mazeu, I., Mussini, C., Mazzotta, F., Gabbuti, A., Lazzarin, A., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Uzdaviniene, V., Matulionyte, R., Staub, T., Hemmer, R., Dragas, S., Stevanovic, M., vd Valk, M., Trajanovska, J., Reikvam, D. H., Maeland, A., Bruun, J., Szetela, B., Inglot, M., Flisiak, R., Grzeszczuk, A., Parczewski, M., Maciejewska, K., Aksak-Was, B., Mularska, E., Jablonowska, E., Kamerys, J., Wojcik, K., Mozer-Lisewska, I., Rozplochowski, B., Mansinho, K., Radoi, R., Oprea, C., Gusev, D., Trofimova, T., Khromova, I., Borodulina, E., Ranin, J., Tomazic, J., Miró, J. M., Laguno, M., Martinez, E., Garcia, F., Blanco, J. L., Martinez-Rebollar, M., Mallolas, J., Callau, P., Rojas, J., Inciarta, A., Moreno, S., del Campo, S., Clotet, B., Jou, A., Paredes, R., Puig, J., Santos, J. R., Gutierrez, M., Mateo, G., Sambeat, M. A., Laporte, J. M., Svedhem, V., Thalme, A., Sönnerborg, A., Brännström, J., Flamholc, L., Kusejko, K., Braun, D., Calmy, A., Furrer, H., Battegay, M., Schmid, P., Kuznetsova, A., Sluzhynska, M., Johnson, M. A., Simons, E., Edwards, S., Phillips, A., Orkin, C., Winston, A., Clarke, A., Leen, C., Lundgren, J., Rasmussen, L. D., Kowalska, J. D., Guaraldi, G., Larsen, J. F., Bojesen, A., Neesgaard, B., Jaschinski, N., Fursa, O., Sather, M., Raben, D., Hansen, E. V., Kristensen, D., Fischer, A. H., Jensen, S. K., Elsing, T. W., Reekie, J., Cozzi-Lepri, A., Amele, S., Pelchen-Matthews, A., Roen, A., Tusch, E. S., Bannister, W., Mocroft, A., Miro, J. M., Wandeler, G., Llibre, J. M., Boyd, A., van Bremen, K., Beniowski, M., Mikhalik, J., Cavassini, M., Maltez, F., Duvivier, C., Uberti Foppa, C., Knysz, B., Bakowska, E., Kuzovatova, E., Domingo, P., Zagalo, A., Viard, J. -P., Degen, O., Milinkovic, A., Benfield, T., Peters, L., Harxhi, A., Losso, M., Kundro, M., Schmied, B., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Paduto, D., Clumeck, N., De Wit, S., Delforge, M., Florence, E., Vandekerckhove, L., Hadziosmanovic, V., Begovac, J., Machala, L., Sedlacek, D., Kronborg, G., Gerstoft, J., Katzenstein, T., Pedersen, C., Johansen, I. S., Ostergaard, L., Wiese, L., Moller, N. F., Nielsen, L. N., Zilmer, K., Smidt, J., Aho, I., Lacombe, K., Pradier, C., Fontas, E., Rockstroh, J., Behrens, G., Hoffmann, C., Stellbrink, H. J., Stefan, C., Bogner, J., Fatkenheuer, G., Chkhartishvili, N., Sambatakou, H., Adamis, G., Paissios, N., Szlavik, J., Gottfredsson, M., Devitt, E., Tau, L., Turner, D., Burke, M., Shahar, E., Wattad, L. M., Elinav, H., Haouzi, M., Elbirt, D., D'Arminio Monforte, A., Esposito, R., Mazeu, I., Mussini, C., Mazzotta, F., Gabbuti, A., Lazzarin, A., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Uzdaviniene, V., Matulionyte, R., Staub, T., Hemmer, R., Dragas, S., Stevanovic, M., vd Valk, M., Trajanovska, J., Reikvam, D. H., Maeland, A., Bruun, J., Szetela, B., Inglot, M., Flisiak, R., Grzeszczuk, A., Parczewski, M., Maciejewska, K., Aksak-Was, B., Mularska, E., Jablonowska, E., Kamerys, J., Wojcik, K., Mozer-Lisewska, I., Rozplochowski, B., Mansinho, K., Radoi, R., Oprea, C., Gusev, D., Trofimova, T., Khromova, I., Borodulina, E., Ranin, J., Tomazic, J., Laguno, M., Martinez, E., Garcia, F., Blanco, J. L., Martinez-Rebollar, M., Mallolas, J., Callau, P., Rojas, J., Inciarta, A., Moreno, S., del Campo, S., Clotet, B., Jou, A., Paredes, R., Puig, J., Santos, J. R., Gutierrez, M., Mateo, G., Sambeat, M. A., Laporte, J. M., Svedhem, V., Thalme, A., Sonnerborg, A., Brannstrom, J., Flamholc, L., Kusejko, K., Braun, D., Calmy, A., Furrer, H., Battegay, M., Schmid, P., Kuznetsova, A., Sluzhynska, M., Johnson, A. M., Simons, E., Edwards, S., Phillips, A., Johnson, M. A., Orkin, C., Winston, A., Clarke, A., Leen, C., Lundgren, J., Rasmussen, L. D., Kowalska, J. D., Guaraldi, G., Larsen, J. F., Bojesen, A., Neesgaard, B., Jaschinski, N., Fursa, O., Sather, M., Raben, D., Hansen, E. V., Kristensen, D., Fischer, A. H., Jensen, S. K., Elsing, T. W., Reekie, J., Cozzi-Lepri, A., Amele, S., Pelchen-Matthews, A., Roen, A., Tusch, E. S., Bannister, W., and Infectious diseases
- Subjects
Hepatitis B virus ,Hepatitis B Surface Antigens ,Health Policy ,virus diseases ,HIV Infections ,Hepatitis B ,digestive system diseases ,HBV DNA ,hepatitis B ,nonliver cancer ,Infectious Diseases ,Hepatitis B, Chronic ,Neoplasms ,DNA, Viral ,Humans ,Pharmacology (medical) ,610 Medicine & health - Abstract
Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH). Methods: All persons aged ≥18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results: Of 17485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR)8.42/1000 PYFU; 95% confidence interval (CI) 7.94–8.90/1000 PYFU] and 99 in those HBV positive (IR10.54/1000 PYFU; 95% CI8.47–12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR)1.23; 95% CI 1.00–1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00–1.89) and NHL (aIRR 2.57; 95% CI 1.16–5.68). There was no significant association between HBV and lung or anal cancer. Conclusions: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
- Published
- 2021
- Full Text
- View/download PDF
17. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study
- Author
-
Gianpaolo Lorini, Roberta D'Ambrosio, Monia Mendeni, Angelo Pan, Valentina Zuccaro, Canio Carriero, Massimo Colombo, Gianpiero Aimo, Natalia Terreni, Barbara Menzaghi, Massimo Memoli, Alessandro Soria, Aldo Autolitano, Elisabetta Degasperi, Serena Pelusi, M. Puoti, Luca Valenti, Cristiana Bianco, Ombretta Spinelli, Elisabetta Buscarini, Antonella d'Arminio Monforte, Sara Gritti, Paolo Del Poggio, Alessia Giorgini, Tiziana Quirino, T. Re, Marie Graciella Pigozzi, Maria Grazia Rumi, Maria Chiara Colombo, Giuliana Cologni, Daniele Prati, Angiola Spinetti, Stefano Fagiuoli, Mauro Viganò, Isabella Carderi, Luisa Pasulo, Pietro Lampertico, Alessio Aghemo, Paolo Bonfanti, C. Iegri, Valenti, L, Pelusi, S, Aghemo, A, Gritti, S, Pasulo, L, Bianco, C, Iegri, C, Cologni, G, Degasperi, E, D'Ambrosio, R, del Poggio, P, Soria, A, Puoti, M, Carderi, I, Pigozzi, M, Carriero, C, Spinetti, A, Zuccaro, V, Memoli, M, Giorgini, A, Vigano, M, Rumi, M, Re, T, Spinelli, O, Colombo, M, Quirino, T, Menzaghi, B, Lorini, G, Pan, A, D'Arminio Monforte, A, Buscarini, E, Autolitano, A, Bonfanti, P, Terreni, N, Aimo, G, Mendeni, M, Prati, D, Lampertico, P, and Fagiuoli, S
- Subjects
Liver Cirrhosis ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Sustained Virologic Response ,Chronic liver disease ,Gastroenterology ,Antiviral Agents ,Cohort Studies ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Internal medicine ,Diabetes mellitus ,Diabetes Mellitus ,Medicine ,Humans ,2. Zero hunger ,Hepatology ,business.industry ,Hazard ratio ,Liver Neoplasms ,Odds ratio ,Hepatitis C, Chronic ,medicine.disease ,3. Good health ,Metformin ,Cardiovascular Diseases ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,HCV ,030211 gastroenterology & hepatology ,business ,Body mass index ,medicine.drug - Abstract
The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real-life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.7% achieved viral eradication (NAVIGATORE-Lombardia registry). In a subset (n=748), liver stiffness measurement (LSM) was available at baseline and follow-up. Higher body mass index (BMI; odds ratio [OR] 1.06 per kg/m2, 1.03-1.09) and diabetes (OR 2.01 [1.65-2.46]) were independently associated with advanced fibrosis at baseline, whereas statin use was protective (OR 0.46 [0.35-0.60]; P 
- Published
- 2021
18. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)
- Author
-
Ilaria Mastrorosa, Roberta Gagliardini, Francesco Vladimiro Segala, Annalisa Mondi, Patrizia Lorenzini, Carlotta Cerva, Eleonora Taddei, Francesca Bai, Alessandra Vergori, Marcantonio Negri, Carmela Pinnetti, Stefania Cicalini, Rita Murri, Valentina Mazzotta, Marta Camici, Silvia Mosti, Teresa Bini, Gaetano Maffongelli, Alessia Beccacece, Eugenia Milozzi, Marco Iannetta, Silvia Lamonica, Marisa Fusto, Maria Maddalena Plazzi, Sandrine Ottou, Miriam Lichtner, Massimo Fantoni, Massimo Andreoni, Loredana Sarmati, Roberto Cauda, Enrico Girardi, Emanuele Nicastri, Antonella D'Arminio Monforte, Fabrizio Palmieri, Antonella Cingolani, Francesco Vaia, Andrea Antinori, Chiara Agrati, Filippo Barreca, Maria Paola Bertuccio, Evangelo Boumis, Angela D'Urso, Margherita De Masi, Federico De Zottis, Cosmo Del Borgo, Francesco Di Gennaro, Arianna Emiliozzi, Laura Fondaco, Francesca Giovannenze, Elisabetta Grilli, Daniele Iodice, Erminia Masone, Barbara Massa, Paola Mencarini, Gian Piero Oliva, Giovanna Onnelli, Pier Giorgio Pace, Jessica Paulicelli, Chiara Sorace, and Pietro Vitale
- Subjects
General Medicine - Published
- 2023
- Full Text
- View/download PDF
19. Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era
- Author
-
Carlo Federico Perno, Franco Maggiolo, Giordano Madeddu, Enrico Girardi, Alessandro Cozzi-Lepri, Roberta Gagliardini, Antonella Cingolani, Andrea Antinori, Antonella d'Arminio Monforte, Giulia Marchetti, Andrea De Vito, and Annalisa Saracino
- Subjects
Male ,0301 basic medicine ,Anti-HIV Agents ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,Logistic regression ,medicine.disease_cause ,Time ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,business.industry ,Viral Load ,030104 developmental biology ,Infectious Diseases ,Serodiscordant ,Cohort ,RNA ,Population study ,Female ,Observational study ,business ,Viral load ,Demography ,Cohort study - Abstract
Objective Zero risk of linked HIV transmission in serodiscordant couples when the HIV-infected partner had viral load less than 200 copies/ml ('U status') was found in observational studies. We aimed at estimating the proportion of time in which 'U status' was maintained and identifying factors associated with the risk of losing it. Design Observational cohort study. Methods We included participants in the ICONA cohort who had reached an established 'U status' (viral load ≤200 copies/ml for >6 months) as of December 2010. The outcome was the number of person-days of follow-up (PDFU) above a viral load greater than 200 copies/ml, relative to the total number of PDFU observed. A logistic regression model was used to identify factors independently associated with the risk of losing 'U status'. Results Eight thousand, two hundred and forty-one persons living with HIV were included in the analysis who contributed 2 670 888 PDFU. Of these, 1648 (20%) were women, 768 (9%) were people who inject drugs (PWID), and 2066 (25%) were foreign-born. The median of viral load measurements was 9 (IQR: 4-15). Overall, only 3.1% of PDFU were observed when viral load was above 200 copies/ml. The proportion of PDFU with viral load more than 200 copies/ml was higher than average in women (5.3%), unemployed (5.4%), PWID (4.7%), and in people with more than three previous virologic failures (6.3%). These variables were significant predictors of losing 'U status' in the multivariable logistic regression. Conclusion Our results reinforce the validity of the U=U message in real-world setting. However, we identified subsets of our study population at higher risk of losing the 'U status' for whom additional efforts are needed.
- Published
- 2021
- Full Text
- View/download PDF
20. Long-term positive effect of an educational antimicrobial stewardship program implemented in an Internal Medicine Department: a prospective analysis and a point prevalence survey on long-term effect
- Author
-
Andrea Cona, Antonella d'Arminio Monforte, Chiara Aldieri, Nathalie Iannotti, Ottavia Viganò, Lidia Gazzola, Teresa Bini, and Giulia Marchetti
- Subjects
0301 basic medicine ,Point prevalence survey ,medicine.medical_specialty ,Inservice Training ,education ,030106 microbiology ,Antimicrobial Stewardship ,03 medical and health sciences ,Prospective analysis ,0302 clinical medicine ,Antibiotic resistance ,Anti-Infective Agents ,Internal medicine ,Internal Medicine ,Humans ,Medicine ,Antimicrobial stewardship ,Pharmacology (medical) ,Term effect ,Hospital Mortality ,Prospective Studies ,Pharmacology ,business.industry ,Length of Stay ,Antimicrobial ,Drug Utilization ,humanities ,Term (time) ,Infectious diseases consultation ,Infectious Diseases ,Oncology ,030220 oncology & carcinogenesis ,business - Abstract
The study aims to evaluate antimicrobial consumption and appropriateness one year after the implementation of an antimicrobial stewardship (AMS) program in an Internal Medicine Department in Milan. AMS program structured in two phases: "AMS phase", 5 months AMS-program based on an "audit-and-feedback model"; the "follow-up phase", 5 months long point prevalence survey conducted one year later. Outcomes of the study: antimicrobial consumption and appropriateness of antimicrobial therapy. Secondary outcomes: in-hospital mortality and length of stay (LOS). During the "AMS phase", we obtained a mean decrease of -11.4% of total antibiotic consumption as compared to the previous year (67.9 defined daily dose (DDD)/100 bed-days (bd) vs. 79.4 DDD/100bd
- Published
- 2020
- Full Text
- View/download PDF
21. A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
- Author
-
Giovanni Landoni, Lorenzo Piemonti, Antonella d’Arminio Monforte, Paolo Grossi, Alberto Zangrillo, Enrico Bucci, Marcello Allegretti, Giovanni Goisis, Elizabeth M. Gavioli, Neal Patel, Maria De Pizzol, Georgea Pasedis, Flavio Mantelli, Landoni, Giovanni, Piemonti, Lorenzo, Monforte, Antonella d'Arminio, Grossi, Paolo, Zangrillo, Alberto, Bucci, Enrico, Allegretti, Marcello, Goisis, Giovanni, Gavioli, Elizabeth M, Patel, Neal, De Pizzol, Maria, Pasedis, Georgea, and Mantelli, Flavio
- Subjects
Microbiology (medical) ,Infectious Diseases ,Settore MED/17 - Malattie Infettive ,CXCR1/2 ,IL-8 ,Reparixin ,COVID-19 ,SARS-COV-2 - Abstract
Introduction: Acute lung injury and acute respiratory distress syndrome are common complications in patients with coronavirus disease 2019 (COVID-19). Poor outcomes in patients with COVID-19 are associated with cytokine release syndrome. Binding of interleukin-8 (CXCL8/IL-8) to its chemokine receptors, CXCR1/2, may mediate this inflammatory process. The aim of this clinical trial was to determine if CXCR1/2 blockade with reparixin can improve clinical outcomes in hospitalized patients with severe COVID-19 pneumonia. The dose and safety of reparixin have been investigated in clinical trials of patients with metastatic breast cancer. Methods: This was a phase 2,open-label, multicenter, randomized study in hospitalized adult patients with severe COVID-19 pneumonia from May5, 2020 until November27, 2020. Patients were randomized 2:1 to receive 1200mg reparixin orally three times daily or standard of care (SOC) for up to 21days. The primary endpoint was defined as a composite of clinical events: use of supplemental oxygen, need for mechanical ventilation, intensive care unit admission, and/or use of rescue medication. Results: Fifty-five patients were enrolled between reparixin (n = 36) and SOC (n = 19). The rate of clinical events was statistically significantly lower in the reparixin group compared with the SOC group (16.7% [95%CI 6.4-32.8%] vs. 42.1% [95%CI 20.3-66.5%], P = 0.02). The sensitivity analysis based on the Cox regression model provided an adjusted hazard ratio of 0.33 with statistical significance lower than 0.05 (95%CI 0.11-0.99; P = 0.047). Reparixin treatment appeared to be well tolerated. Conclusion: In patients with severe COVID-19, reparixin led to an improvement in clinical outcomes when compared with the SOC. A larger phase3 clinical study is needed to confirm these results. Trial registration: EudraCT identifier, 2020-001645-40; registered May6, 2020 (retrospectively registered), and clinicaltrials.gov (NCT04794803) on March 8, 2021.
- Published
- 2022
- Full Text
- View/download PDF
22. HIV-NAAT use for early detection of HIV infection among high-risk men who have sex with men in Italy
- Author
-
Angelo Roberto Raccagni, Elena Bruzzesi, Daniele Calzavara, Pietro Vinti, Massimo Cernuschi, Simona Bossolasco, Anna De Bona, Roberto Rossotti, Antonella D'Arminio Monforte, Antonella Castagna, and Silvia Nozza
- Subjects
Infectious Diseases ,Health Policy ,Pharmacology (medical) - Published
- 2022
23. Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients
- Author
-
Rovito, R., Bono, V., Augello, M., Tincati, C., Mainoldi, F., Beaudoin-Bussières, G., Tauzin, A., Bianchi, S., Hadla, M., Yellenki, V., d'Arminio Monforte, A., Casola, S., Borghi, E., Finzi, A., and Marchetti, G.
- Subjects
Settore MED/17 - Malattie Infettive ,Immunoglobulin M ,SARS-CoV-2 ,Tumor Necrosis Factor-alpha ,Immunoglobulin G ,Humans ,COVID-19 ,Interleukin-2 ,Cytokines ,Interleukin-4 ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Immunologic Memory - Abstract
Severe/critical COVID-19 is associated with immune dysregulation and plasmatic SARS-CoV-2 detection (i.e. RNAemia). We detailed the association of SARS-CoV-2 RNAemia with immune responses in COVID-19 patients at the end of the first week of disease. We enrolled patients hospitalized in acute phase of ascertained SARS-CoV-2 pneumonia, and evaluated SARS-CoV-2 RNAemia, plasmatic cytokines, activated/pro-cytolytic T-cells phenotypes, SARS-CoV-2-specific cytokine-producing T-cells (IL-2, IFN-γ, TNF-α, IL-4, IL-17A), simultaneous Th1-cytokines production (polyfunctionality) and amount (iMFI). The humoral responses were assessed with anti-S1/S2 IgG, anti-RBD total-Ig, IgM, IgA, IgG1 and IgG3, neutralization and antibody-dependent cellular cytotoxicity (ADCC). Out of 54 patients, 27 had detectable viremia (viremic). Albeit comparable age and co-morbidities, viremic more frequently required ventilatory support, with a trend to higher death. Viremic displayed higher pro-inflammatory cytokines (IFN-α, IL-6), lower activated T-cells (HLA-DR+CD38+), lower functional SARS-CoV-2-specific T-cells (IFN-γ+CD4+, TNF-α+CD8+, IL-4+CD8+, IL-2+TNF-α+CD4+, and IL-2+TNF-α+CD4+ iMFI) and SARS-CoV-2-specific Abs (anti-S IgG, anti-RBD total-Ig, IgM, IgG1, IgG3; ID
- Published
- 2022
24. MO409: GDF-15 is a Predictor of Mortality in Chronic Kidney Disease Patients With Covid-19 Infection
- Author
-
Paola Ciceri, Valeria Bono, Lorenza Magagnoli, Matteo Sala, Luisa Artioli, Roberta Rovito, Mohamad Hadla, Vaibhav Yellenki, Antonella D'arminio Monforte, Andrea Galassi, Camilla Tincati, Giulia Marchetti, and Mario Gennaro Cozzolino
- Subjects
Transplantation ,Nephrology - Abstract
BACKGROUND AND AIMS A cytokine storm drives the pathogenesis of severe coronavirus disease (COVID-19) and several biomarkers with different mechanisms of action have been linked to mortality. Chronic kidney disease (CKD) emerged as a very common risk factor for severe COVID-19. Indeed, CKD patients are at increased risk of premature death from many causes, including, but not limited to, cardiovascular disease (CVD) and infections. In this study, we aimed to investigate the associations between the growth differentiation factor 15 (GDF-15), an established cardiovascular and inflammatory biomarker and outcomes in CKD patients hospitalized for COVID-19. METHOD A retrospective study on COVID-19 hospitalized subjects in the acute phase of the disease. A broad range of cytokines (CD25, IL-18, TNF-α, TNF RI, TNF RII, GDF-15, IL-7, LIF, IL-6, CHITINASE3_LIKE1, RAGE and Pentraxin-3) were assessed in plasma (Luminex, ELISA) collected upon hospitalization. A total of 77 subjects were divided into two groups according to their estimated glomerular filtration rate (eGFR, by CKD-EPI formula), ≥45 mL/min (n = 44), or ˂45 mL/min (n = 33). RESULTS We found no statistical differences between the two groups in terms of demographic features. Among comorbidities, we found a higher percentage of patients with diabetes in the eGFR < 45 group. Likewise, the serum tests upon admission showed in the eGFR < 45 group a higher value of neutrophilic count. Upon hospital admission, the patient groups were comparable in terms of symptoms, time from symptom onset to admission and death or discharge, radiological evidence of pneumonia and respiratory parameters and time of hospitalization. Furthermore, there were no statistical differences between medical therapy during hospitalization, need for respiratory support with Continuous Positive Airways Pressure or Non-Invasive Mechanical Ventilation, or death rather than discharge as the clinical outcome. Serum levels of 20 different compounds were measured in COVID-19 patients admitted to the hospital 4–5 days after the onset of symptoms. Interestingly, we found that patients with lower renal function (eGFR < 45 mL/min) had a significant increase of GDF-15, CD-25 and RAGE and, furthermore, higher serum levels of these molecules were detected in non-survivor patients and in those who needed ventilation. Also, TNFα, TNFR I, TNFR II, IL-7 and LIF had a significant increase in patients with eGFR < 45 mL/min with more elevated levels in non-survivor patients. In univariate analysis low and mid-low GDF-15 quartiles (4.45 ng/mL) were associated with higher mortality risk (Figure 1). Independent association between GDF-15 quartiles and mortality risk was confirmed in Cox model adjusted for eGFR, age, fever, dyspnoea and P/F [hazard ratio (HR) 2.28, 95% confidence interval (CI) 1.53–3.39, P < 0.0001) The strength of association between GDF-15 quartiles and mortality risk was increased in patients with eGFR < 45 mL/min/1.73 m2 (HR 2.53, CI 1.34–4.79) compared with the other eGFR group (HR 1.99, CI 1.17–3.39) (Table 1). CONCLUSION Our results demonstrate that GDF-15 is an independent predictor of COVID-19 mortality in CKD patients. Given the reported increase of this cytokine with age and its possible mechanistic role in various pathological conditions, our findings suggest that GDF-15 signalling pathway inhibitors may be included as possible therapeutic candidates for COVID-19 in CKD.
- Published
- 2022
- Full Text
- View/download PDF
25. Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19
- Author
-
Antonella, d'Arminio Monforte, Alessandro, Tavelli, Sara, De Benedittis, Francesca, Bai, Camilla, Tincati, Lidia, Gazzola, Ottavia, Viganò, Marina, Allegrini, Debora, Mondatore, Daniele, Tesoro, Diletta, Barbanotti, Giovanni, Mulé, Roberto, Castoldi, Anna, De Bona, Teresa, Bini, Davide, Chiumello, Stefano, Centanni, Sabrina, Passarella, Nicola, Orfeo, Giulia, Marchetti, Alessandro, Cozzi-Lepri, and For The Spid Group
- Abstract
Whether vaccination confers a protective effect against progression after hospital admission for COVID-19 remains to be elucidated. Observational study including all the patients admitted to San Paolo Hospital in Milan for COVID-19 in 2021. Previous vaccination was categorized as: none, one dose, full vaccination (two or three dosesgt;14 days before symptoms onset). Data were collected at hospital admission, including demographic and clinical variables, age-unadjusted Charlson Comorbidity index (CCI). The highest intensity of ventilation during hospitalization was registered. The endpoints were in-hospital death (primary) and mechanical ventilation/death (secondary). Survival analysis was conducted by means of Kaplan-Meier curves and Cox regression models. Effect measure modification by age was formally tested. We included 956 patients: 151 (16%) fully vaccinated (18 also third dose), 62 (7%) one dose vaccinated, 743 (78%) unvaccinated. People fully vaccinated were older and suffering from more comorbidities than unvaccinated. By 28 days, the risk of death was of 35.9% (95%CI: 30.1-41.7) in unvaccinated, 41.5% (24.5-58.5) in one dose and 28.4% (18.2-38.5) in fully vaccinated (
- Published
- 2022
26. Compassionate Use of Remdesivir for Patients with Severe Covid-19
- Author
-
Jennifer Cunningham, Marta Mora-Rillo, Robert P. Myers, Gary M. Green, Polly Desai, Toshitaka Maeno, Antonella D’Arminio Monforte, Yoshikazu Mutoh, Emanuele Nicastri, Ilana Henne, Susanna K. Tan, Erika Asperges, Jonathan Grein, Saad Ismail, Alex Studemeister, Rentaro Oda, Anuj Gaggar, Anu Osinusi, Kikuo Yo, Erwan L’Her, Huyen Cao, Hideaki Kato, Duc Nguyen, Seema Ahmed, Daniel Shin, Marco Massari, John Redinski, Giuseppe Lapadula, Lijie Zhong, Shingo Chihara, Laura Telep, Alexander Zoufaly, Daniel Chelliah, Ewa Verweij, Timothy Flanigan, Lucinda Winterbourne, Robertino Mera, Eugenia Quiros-Roldan, Diana M. Brainard, Adam DeZure, Leighann Timbs, Norio Ohmagari, Stuart H. Cohen, Sumit Majumder, Richard Childs, François-Xavier Lescure, Jorge Bernett, Emon Elboudwarej, Yang Zhao, Anand Chokkalingam, Scott Sellers, George Diaz, Torsten Feldt, Margaret L. Green, Danny Chen, Antonella Castagna, Grein, J, Ohmagari, N, Shin, D, Diaz, G, Asperges, E, Castagna, A, Feldt, T, Green, G, Green, M, Lescure, F, Nicastri, E, Oda, R, Yo, K, Quiros-Roldan, E, Studemeister, A, Redinski, J, Ahmed, S, Bernett, J, Chelliah, D, Chen, D, Chihara, S, Cohen, S, Cunningham, J, D'Arminio Monforte, A, Ismail, S, Kato, H, Lapadula, G, L'Her, E, Maeno, T, Majumder, S, Massari, M, Mora-Rillo, M, Mutoh, Y, Nguyen, D, Verweij, E, Zoufaly, A, Osinusi, A, Dezure, A, Zhao, Y, Zhong, L, Chokkalingam, A, Elboudwarej, E, Telep, L, Timbs, L, Henne, I, Sellers, S, Cao, H, Tan, S, Winterbourne, L, Desai, P, Mera, R, Gaggar, A, Myers, R, Brainard, D, Childs, R, Flanigan, T, Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F. -X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., Chen, D., Chihara, S., Cohen, S. H., Cunningham, J., D'Arminio Monforte, A., Ismail, S., Kato, H., Lapadula, G., L'Her, E., Maeno, T., Majumder, S., Massari, M., Mora-Rillo, M., Mutoh, Y., Nguyen, D., Verweij, E., Zoufaly, A., Osinusi, A. O., Dezure, A., Zhao, Y., Zhong, L., Chokkalingam, A., Elboudwarej, E., Telep, L., Timbs, L., Henne, I., Sellers, S., Cao, H., Tan, S. K., Winterbourne, L., Desai, P., Mera, R., Gaggar, A., Myers, R. P., Brainard, D. M., Childs, R., and Flanigan, T.
- Subjects
Compassionate Use Trials ,Male ,viruses ,030204 cardiovascular system & hematology ,Pharmacology ,Medical and Health Sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Japan ,80 and over ,Medicine ,030212 general & internal medicine ,Viral ,Lung ,Polymerase ,Aged, 80 and over ,Alanine ,biology ,Respiration ,General Medicine ,Prodrug ,Middle Aged ,humanities ,Europe ,Infectious Diseases ,6.1 Pharmaceuticals ,Artificial ,Administration ,Original Article ,Administration, Intravenous ,Female ,Intravenous ,Coronavirus Infections ,Human ,Adenosine monophosphate ,United State ,Adult ,Canada ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Clinical Trials and Supportive Activities ,Pneumonia, Viral ,Administration, Intravenou ,Antiviral Agents ,03 medical and health sciences ,Betacoronavirus ,Young Adult ,Clinical Research ,General & Internal Medicine ,Humans ,Pandemics ,Aged ,Antiviral Agent ,Betacoronaviru ,Pandemic ,business.industry ,Coronavirus Infection ,SARS-CoV-2 ,Prevention ,Compassionate Use ,Evaluation of treatments and therapeutic interventions ,COVID-19 ,Pneumonia ,Respiration, Artificial ,In vitro ,Adenosine Monophosphate ,United States ,COVID-19 Drug Treatment ,Coronavirus ,Emerging Infectious Diseases ,Good Health and Well Being ,chemistry ,biology.protein ,business - Abstract
Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. Methods We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. Results Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. Conclusions In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)
- Published
- 2020
27. Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy
- Author
-
Silvia, Nozza, Laura, Timelli, Annalisa, Saracino, Nicola, Gianotti, Claudia, Lazzaretti, Alessandro, Tavelli, Massimo, Puoti, Sergio, Lo Caputo, Andrea, Antinori, Antonella d'Arminio, Monforte, Cristina, Mussini, Enrico, Girardi, On Behalf Of Icona Foundation Study Group, Nozza, S, Timelli, L, Saracino, A, Gianotti, N, Lazzaretti, C, Tavelli, A, Puoti, M, Caputo, S, Antinori, A, D'Arminio Monforte, A, Mussini, C, and Girardi, E
- Subjects
0301 basic medicine ,Cart ,medicine.medical_specialty ,030106 microbiology ,Population ,Disease ,Article ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,medicine ,030212 general & internal medicine ,Poisson regression ,Family history ,education ,hospitalizations ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,non-AIDS defining conditions ,PLWHIV ,General Medicine ,medicine.disease ,Hospitalization ,Cohort ,symbols ,Medicine ,business ,Non-AIDS defining condition - Abstract
Background: We aimed to describe the change in the incidence and causes of hospitalization between 2008 and 2018 among persons living with HIV (PLWHIV) who started antiretroviral therapy (ART) from 2008 onwards in Italy. Methods: We included participants in the ICONA (Italian Cohort Naïve Antiretrovirals) cohort who started ART in 2008. All the hospitalizations occurring during the first 30 days from the start of ART were excluded. Hospitalizations were classified as due to: AIDS-defining conditions (ADC), non-ADC infections and non-infections/non-ADC (i.e., cardiovascular, pulmonary, renal-genitourinary, cancers, gastrointestinal-liver, psychiatric and other diseases). Comparisons of rates across time were assessed using Poisson regression. The Poisson multivariable model evaluated risk factors for hospitalizations, including both demographic and clinical characteristics. Results: A total of 9524 PLWHIV were included, 6.8% were drug users, 48.9% men-who-have sex with men (MSM), 39.6% heterosexual contacts, 80.8% were males, 42.3% smokers, 16.6% coinfected with HCV and 6.8% with HBV (HBsAg-positive). During 36,157 person-years of follow-up (PYFU), there were 1058 hospitalizations in 747 (7.8%) persons, they had HIV-RNA >, 50 copies mL in 34.9% and CD4 <, 200/mmc in 27%. Causes of hospitalization were 23% ADC, 22% non-ADC infections, 55% non-infections/non-ADC (11% cancers, 9% gastrointestinal-liver, 6% cardiovascular, 5% renal-genitourinary, 5% psychiatric, 4% pulmonary, 15% other). Over the study period, the incidence rate (IR) decreased significantly (from 5.8 per 100 PYFU in 2008–2011 to 2.21 per 100 PYFU in 2016–2018). Age >, 50 years, intravenous drug use (IDU), family history of cardiovascular disease, HIV-RNA >, 50, CD4 <, 200, were associated with a higher hospitalization risk. Conclusions: In our population of PLWHIV, the rate of hospitalization decreased over time.
- Published
- 2021
28. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?
- Author
-
Vourli, G., Noori, T., Pharris, A., Porter, K., Axelsson, M., Begovac, J., Cazein, F., Costagliola, D., Cowan, S., Croxford, S., Monforte, A. D., Delpech, V., Diaz, A., Girardi, E., Gunsenheimer-Bartmeyer, B., Hernando, V., Leierer, G., Lot, F., Nunez, O., Obel, N., Op de Coul, E., Paraskeva, D., Patrinos, S., Reiss, P., Schmid, D., Sonnerborg, A., Suligoi, B., Supervie, V., van Sighem, A., Zangerle, R., Touloumi, G., Egle, A., Kanatschnig, M., Ollinger, A., Rieger, A., Schmied, B., Wallner, E., Dewasurendra, D., Gisinger, M., Kitchen, M., Plattner, A., Rieser, E., Sarcletti, M., Greil, R., Schachner, M., Skocic, M., Muller, M., Aichwalder, R., Chromy, D., Grabmeier-Pfstershammer, K., Skoll, M., Touzeau, V., Cichon, P., Wolf-Nussmuller, S., Laferl, H., Zoufaly, A., Genger-Hackl, C., Kapper, A., Schneeberger, T., Trattner, E., Schober, G., Atzl, M., Hartmann, B., Puchhammer-Stockl, E., Berg, J., Appoyer, H., Rappold, M., Strickner, S., Schindelwig, K., Ledergerber, B., Fatkenheuer, G., Gerstof, J., Kronborg, G., Pedersen, C., Larsen, C. S., Pedersen, G., Mohey, R., Nielsen, L., Weise, L., Kvinesdal, B., Jensen, J., Abgrall, S., Bernard, L., Billaud, E., Boue, F., Boyer, L., Cabie, A., Caby, F., Canestri, A., Cotte, L., de Truchis, P., Duval, X., Duvivier, C., Enel, P., Fischer, H., Gasnault, J., Gaud, C., Grabar, S., Khuong-Josses, M. A., Launay, O., Marchand, L., Mary-Krause, M., Matheron, S., Melica-Gregoire, G., Melliez, H., Meynard, J. L., Nacher, M., Pavie, J., Piroth, L., Poizot-Martin, I., Pradier, C., Reynes, J., Rouveix, E., Simon, A., Slama, L., Tattevin, P., Tissot-Dupont, H., Biga, J., Kurth, T., Jacquemet, N., Guiguet, M., Leclercq, S., Lievre, L., Marshall, E., Roul, H., Selinger-Leneman, H., Potard, V., Benveniste, O., Breton, G., Lupin, C., Bourzam, E., Girard, P. M., Fonquernie, L., Valin, N., Lefebvre, B., Sebire, M., Pialoux, G., Lebrette, M. G., Tibaut, P., Adda, A., Hamidi, M., Cadranel, J., Lavole, A., Parrot, A., Bouchaud, O., Vignier, N., Mechai, F., Makhlouf, S., Honore, P., Bergmann, J. F., Delcey, V., Lopes, A., Sellier, P., Parrinello, M., Oksenhendler, E., Gerard, L., Molina, J. M., Rozenbaum, W., Denis, B., De Castro, N., Lascoux, C., Yazdanpanah, Y., Lariven, S., Joly, V., Rioux, C., Poupard, M., Taverne, B., Sutton, L., Masse, V., Genet, P., Wifaq, B., Gerbe, J., Grefe, S., Dupont, C., Freire Maresca, A., Reimann, E., Bloch, M., Meier, F., Mortier, E., Zeng, F., Montoya, B., Perronne, C., Mathez, D., Marigot-Outtandy, D., Berthe, H., Greder Belan, A., Terby, A., Godin Collet, C., Marque Juillet, S., Ruquet, M., Roussin-Bretagne, S., Colardelle, P., Granier, F., Laurichesse, J. J., Perronne, V., Akpan, T., Marcou, M., Daneluzzi, V., Veyssier-Belot, C., Masson, H., Welker, Y., Brazille, P., Kahn, J. E., Zucman, D., Majerholc, C., Fourn, E., Bornarel, D., Chambrin, V., Kansau, I., Raho-Moussa, M., Lelievre, J. D., Saidani, M., Chesnel, C., Dumont, C., Vittecoq, D., Derradji, O., Bolliot, C., Goujard, C., Teicher, E., Mole, M., Bourdic, K., Salmon, D., Le Jeunne, C., Guet, P., Pietri, M. P., Pannier Metzger, E., Marcou, V., Loulergue, P., Dupin, N., Morini, J. P., Deleuze, J., Gerhardt, P., Chanal, J., Weiss, L., Lucas, M. L., Jung, C., Ptak, M., Viard, J. P., Ghosn, J., Gazalet, P., Cros, A., Maignan, A., Lortholary, O., Rouzaud, C., Touam, F., Benhadj, K., Consigny, P. H., Bossi, P., Gergely, A., Cessot, G., Durand, F., Beck-Wirth, G., Michel, C., Benomar, M., Rey, D., Partisani, M., Cheneau, C., Batard, M. L., Fischer, P., Leclercq, P., Blanc, M., Morand, P., Epaulard, O., Signori-Schmuck, A., Laurichesse, H., Jacomet, C., Vidal, M., Coban, D., Casanova, S., Fresard, A., Guglielminotti, C., Botelho-Nevers, E., Brunon-Gagneux, A., Ronat, V., Verdon, R., Dargere, S., Haustraete, E., Feret, P., Goubin, P., Chavanet, P., Fillion, A., Croisier, D., Gohier, S., Arvieux, C., Souala, F., Chapplain, J. M., Ratajczak, M., Rohan, J., Faller, J. P., Ruyer, O., Gendrin, V., Toko, L., Chirouze, C., Hustache-Mathieu, L., Faucher, J. F., Proust, A., Magy-Bertrand, N., Gil, H., Meaux-Ruault, N., Sotto, A., Rouanet, I., Mauboussin, J. M., Doncesco, R., Jacques, G., May, T., Rabaud, C., Andre, M., Delestan, M., Bouillon, M. P., Bani-Sadr, F., Rouger, C., Berger, J. L., Nguyen, Y., Marchou, B., Delobel, P., Martin Blondel, G., Cuzin, L., Biezunski, N., Alric, L., Bonnet, D., Guivarch, M., Palacin, A., Payssan, V., Ajana, F., Meybeck, A., Viget, N., Pugliese, P., Roger, P. M., Rosenthal, E., Durant, J., Cua, E., Naqvi, A., Perbost, I., Risso, K., Quinsat, D., Raphael, St., Del Giudice, P., Dides, P. Y., Sambuc, R., Antolini-Bouvenot, M. S., Druart, P., Meddeb, L., Ravaux, I., Menard, A., Tomei, C., Dhiver, C., Moreau, J., Mokhtari, S., Soavi, M. J., Tomas, V., Bregigeon, S., Faucher, O., Obry-Roguet, V., Ritleng, A. S., Petit, N., Bartoli, C., Ruiz, J. M., Blanc, D., Allegre, T., Sordage, M., Riou, J. M., Faudon, C., Slama, B., Zerazhi, H., Boulat, O., Chebrek, S., Beyrne, M., Granet Brunello, P., Pellissier, L., Bonnabel, D., Cohen Valensi, R., Mouchet, B., Mboungou, G., Lafeuillade, A., Hope-Rapp, E., Hittinger, G., Philip, G., Lambry, V., Raf, F., Allavena, C., Hall, N., Reliquet, V., Chidiac, C., Ferry, T., Perpoint, T., Miailhes, P., Boibieux, A., Livrozet, J. M., Makhlouf, D., Brunel, F., Chiarello, P., Hoen, B., Lamaury, I., Fabre, I., Samar, K., Duvallon, E., Clavel, C., Stegmann, S., Walter, V., Adriouch, L., Huber, F., Vanticlke, V., Couppie, P., Abel, S., Pierre-Francois, S., Ricaud, C., Rodet, R., Wartel, G., Sautron, C., Poubeau, P., Borgherini, G., Camuset, G., Arasteh, K., Kowohl Vivantes, S., Schurmann, D., Warncke Charite, M., Rockstroh, J., Wasmuth, J., Hass, S., Jensen, B. O., Feind, C., Esser, S., Schenk-Westkamp, P., Haberl, A., Stephan, C., Plettenberg, A., Kuhlendahl, F., Adam, A., Weitner, L., Schewe, K., Goey, H., Fenske, S., Buhk, T., Stellbrink, H. J., Hofmann, C., Hansen, S., Degen, O., Heuer, M., Stoll, M., Gerschmann, S., Horst, H., Trautmann, S., Gillor, D., Bogner, J., Sonntag, B., Salzberger, B., Fritzsche, C., Adamis, G., Antoniadou, A., Chini, M., Chrysos, G., Gikas, A., Gogos, H. A., Katsarou, O., Lazanas, M., Metallidis, S., Panagopoulos, P., Paparizos, V., Papastamopoulos, V., Paraskevis, D., Psychogiou, M., Sambatakou, H., Sipsas, N. V., Pantazis, N., Papadopoulos, A., Nitsotolis, T., Xylomenos, G., Marangos, M. N., Kouramba, A., Kontos, A., Lioni, A., Tsachouridou, O., Kourkounti, S., Ganitis, A., Barbounakis, E., d'Arminio Monforte, A., Antinori, A., Andreoni, M., Castagna, A., Castelli, F., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Marchetti, G. C., Rezza, G., von Schloesser, F., Viale, P., Ceccherini-Silberstein, F., Cozzi-Lepri, A., Lo Caputo, S., Mussini, C., Puoti, M., Perno, C. F., Bai, F., Balotta, C., Bandera, A., Bonora, S., Borderi, M., Calcagno, A., Capetti, A., Capobianchi, M. R., Cicalini, S., Cingolani, A., Cinque, P., Di Biagio, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Maggiolo, F., Marchetti, G., Monno, L., Nozza, S., Pinnetti, C., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M. M., Saracino, A., Sarmati, L., Fanti, I., Galli, L., Lorenzini, P., Rodano, A., Macchia, M., Tavelli, A., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petroni, F., Prota, G., Trufa, S., Giacometti, A., Costantini, A., Barocci, V., Angarano, G., Milano, E., Suardi, C., Donati, V., Verucchi, G., Castelnuovo, F., Minardi, C., Menzaghi, B., Abeli, C., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Pan, A., Lorenzotti, S., Sighinolf, L., Segala, D., Blanc, P., Vichi, F., Cassola, G., Viscoli, C., Alessandrini, A., Bobbio, N., Mazzarello, G., Fondaco, L., Bonfanti, P., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Cannizzo, E. S., Moioli, M. C., Piolini, R., Bernacchia, D., Salpietro, S., Tincati, C., Puzzolante, C., Migliorino, C., Sangiovanni, V., Borgia, G., Esposito, V., Di Flumeri, G., Gentile, I., Rizzo, V., Cattelan, A. M., Marinello, S., Cascio, A., Trizzino, M., Francisci, D., Schiaroli, E., Parruti, G., Sozio, F., Magnani, G., Ursitti, M. A., Cristaudo, A., Vullo, V., Acinapura, R., Moschese, D., Capozzi, M., Mondi, A., Rivano Capparuccia, M., Iaiani, G., Latini, A., Gagliardini, R., Plazzi, M. M., De Girolamo, G., Vergori, A., Cecchetto, M., Viviani, F., De Vito, A., Rossetti, B., Montagnani, F., Franco, A., Fontana Del Vecchio, R., Di Giuli, C., Caramello, P., Orofno, G. C., Sciandra, M., Bassetti, M., Londero, A., Manfrin, V., Battagin, G., Starnini, G., Ialungo, A., van der Valk, M., Geerlings, S. E., Goorhuis, A., Hovius, J. W., Lempkes, B., Nellen, F. J. B., van der Poll, T., Prins, J. M., van Vugt, M., Wiersinga, W. J., Wit, F. W. M. N., van Duinen, M., van Eden, J., Hazenberg, A., van Hes, A. M. H., Pijnappel, F. J. J., Smalhout, S. Y., Weijsenfeld, A. M., Jurriaans, S., Back, N. K. T., Zaaijer, H. L., Berkhout, B., Cornelissen, M. T. E., Schinkel, C. J., Wolthers, K. C., Peters, E. J. G., van Agtmael, M. A., Bomers, M., Sigalof, K. C. E., Heitmuller, M., Laan, L. M., Ang, C. W., van Houdt, R., Jonges, M., van Prehn, J., Kuijpers, T. W., Pajkrt, D., Scherpbier, H. J., de Boer, C., van der Plas, A., van den Berge, M., Stegeman, A., Baas, S., Hage de Loof, L., Wintermans, B., Veenemans, J., Pronk, M. J. H., Ammerlaan, H. S. M., de Munnik, E. S., Jansz, A. R., Tjhie, J., Wegdam, M. C. A., Deiman, B., Scharnhorst, V., van Eeden, A., Brokking, W., Elsenburg, L. J. M., Nobel, H., Damen, M., van Kasteren, M. E. E., Berrevoets, M. A. H., Brouwer, A. E., Adams, A., de Kruijf-Van de Wiel, B. A. F. M., Keelan-Pfaf, S., van der Ven, B., Buiting, A. G. M., Murck, J. L., Versteeg, D., de Vries-Sluijs, T. E. M. S., Bax, H. I., van Gorp, E. C. M., Nouwen, J. L., Rijnders, B. J. A., Schurink, C. A. M., Verbon, A., de Jong-Peltenburg, N. C., Bassant, N., van Beek, J. E. A., Vriesde, M., van Zonneveld, L. M., van den Berg-Cameron, H. J., de Groot, J., Boucher, C. A. B., Koopmans, M. P. G., van Kampen, J. J. A., Fraaij, P. L. A., van Rossum, A. M. C., Vermont, C. L., van der Knaap, L. C., Visser, E., Branger, J., Douma, R. A., Duijf-Van de Ven, C. J. H. M., Schippers, E. F., van Nieuwkoop, C., van IJperen, J. M., Geilings, J., van der Hut, G., van Burgel, N. D., Leyten, E. M. S., Gelinck, L. B. S., Mollema, F., Davids-Veldhuis, S., Wildenbeest, G. S., Heikens, E., Groeneveld, P. H. P., Bouwhuis, J. W., Lammers, A. J. J., Kraan, S., van Hulzen, A. G. W., Kruiper, M. S. M., van der Bliek, G. L., Bor, P. C. J., Bloembergen, P., Wolfagen, M. J. H. M., Ruijs, G. J. H. M., Kroon, F. P., de Boer, M. G. J., Scheper, H., Jolink, H., Dorama, W., van Holten, N., Claas, E. C. J., Wessels, E., den Hollander, J. G., El Moussaoui, R., Pogany, K., Kastelijns, M., Smit, J. V., Smit, E., Struik-Kalkman, D., Tearno, C., van Niekerk, T., Pontesilli, O., Lowe, S. H., Oude Lashof, A. M. L., Posthouwer, D., Ackens, R. P., Burgers, K., Schippers, J., Weijenberg-Maes, B., van Loo, I. H. M., Havenith, T. R. A., Weijer, S., van Vonderen, M. G. A., Kampschreur, L. M., Faber, S., Steeman-Bouma, R., Weel, J., Kootstra, G. J., Delsing, C. E., van der Burg-Van de Plas, M., Heins, H., Kortmann, W., van Twillert, G., Renckens, R., Ruiter-Pronk, D., van Truijen-Oud, F. A., Cohen Stuart, J. W. T., Jansen, E. R., Hoogewerf, M., Rozemeijer, W., van der Reijden, W. A., Sinnige, J. C., Brinkman, K., van den Berk, G. E. L., Blok, W. L., Frissen, P. H. J., Lettinga, K. D., Schouten, W. E. M., Veenstra, J., Vrouenraets, S. M. E., Brouwer, C. J., Geerders, G. F., Hoeksema, K., Kleene, M. J., Knapen, M., van der Meche, I. B., Mulder-Seeleman, E., Toonen, A. J. M., Wijnands, S., Kwa, D., van Crevel, R., van Aerde, K., Doferhof, A. S. M., Henriet, S. S. V., ter Hofstede, H. J. M., Hoogerwerf, J., Keuter, M., Richel, O., Albers, M., Grintjes-Huisman, K. J. T., de Haan, M., Marneef, M., Strik-Albers, R., Rahamat-Langendoen, J., Stelma, F. F., Burger, D., Gisolf, E. H., Hassing, R. J., Claassen, M., ter Beest, G., van Bentum, P. H. M., Langebeek, N., Tiemessen, R., Swanink, C. M. A., van Lelyveld, S. F. L., Soetekouw, R., van der Prijt, L. M. M., van der Swaluw, J., Bermon, N., Jansen, R., Herpers, B. L., Veenendaal, D., Verhagen, D. W. M., Lauw, F. N., van Broekhuizen, M. C., van Wijk, M., Bierman, W. F. W., Bakker, M., Kleinnijenhuis, J., Kloeze, E., Middel, A., Scholvinck, E. H., Stienstra, Y., Verhage, A. R., Wouthuyzen-Bakker, K. M., Boonstra, A., de Groot-De Jonge, H., van der Meulen, P. A., de Weerd, D. A., Niesters, H. G. M., van Leer-Buter, C. C., Knoester, M., Hoepelman, A. I. M., Arends, J. E., Barth, R. E., Bruns, A. H. W., Ellerbroek, P. M., Mudrikova, T., Oosterheert, J. J., de Regt, M. J. A., Schadd, E. M., van Zoelen, M. A. D., Aarsman, K., Grifoen-Van Santen, B. M. G., de Kroon, I., van Rooijen, C. S. A. M., van Berkel, M., Schuurman, R., Verduyn-Lunel, F., Wensing, A. M. J., Bont, L. J., Geelen, S. P. M., Loefen, Y. G. T., Wolfs, T. F. W., Nauta, N., Zaheri, S., Boyd, A. C., Bezemer, D. O., van Sighem, A. I., Smit, C., Hillebregt, M., de Jong, A., Woudstra, T., Bergsma, D., Meijering, R., van de Sande, L., Rutkens, T., van der Vliet, S., de Groot, L., van den Akker, M., Bakker, Y., El Berkaoui, A., Bezemer, M., Bretin, N., Djoechro, E., Geerlinks, J., Kruijne, E., Lodewijk, C., Lucas, E., van der Meer, R., Munjishvili, L., Paling, F., Peeck, B., Ree, C., Regtop, R., Ruijs, Y., Schoorl, M., Schnorr, P., Tuijn, E., Veenenberg, L., Witte, E. C., Tuk, B., Moreno, S., del Amo, J., Dalmau, D., Navarro, M. L., Gonzalez, M. I., Blanco, J. L., Garcia, F., Rubio, R., Iribarren, J. A., Gutierrez, F., Vidal, F., Berenguer, J., Gonzalez, J., Sobrino, P., Alejos, B., Alvarez, D., Jarrin, I., Moreno, C., Munoz-Fernandez, M. A., Garcia-Merino, I., Rico, C. G., de la Fuente, J. G., Torre, A. G., Portilla, J., Merino, E., Reus, S., Boix, V., Giner, L., Gadea, C., Portilla, I., Pampliega, M., Diez, M., Rodriguez, J. C., Sanchez-Paya, J., Podzamczer, D., Imaz, E. F. A., Van Den Eyncle, E., Di Yacovo, S., Sumoy, M., Gomez, J. L., Hernandez, J., Aleman, M. R., Alonso, M. D. M., Hernandez, M. I., Diaz-Flores, F., Garcia, D., Pelazas, R., Asensi, V., Valle, E., Carton, J. A., Perez, V. E., Molina, M. J. T., Garcia, J. V., Carrera, E. P. -C., Pulido, F., Bisbal, O., Matarranz, M., Lagarde, M., Rubio-Martin, R., Hernando, A., Bermejo, L., Dominguez, L., Arrizabalaga, J., Aramburu, M. J., Camino, X., Rodriguez-Arrondo, F., von Wichmann, M. A., Tome, L. P., Goenaga, M. A., Bustinduy, M. J., Galparsoro, H. A., Ibarguren, M., Aguado, M., Umerez, M., Masia, M., Lopez, C., Padilla, S., Navarro, A., Montolio, F., Robledano, C., Colome, J. G., Adsuar, A., Pascual, R., Carlos, F., Martinez, M., Garcia, J. L., Fernandez, M., Garcia, E., Muga, R., Tor, J., Sanvisens, A., Bernaldo de Quiros Lopez, J. C., Miralles, P., Gutierrez, I., Ramirez, M., Padilla, B., Gijon, P., Carrero, A., Aldamiz-Echevarria, T., Tejerina, F., Parras, F. J., Balsalobre, P., Diez, C., Peraire, J., Vilades, C., Veloso, S., Vargas, M., Lopez-Dupla, M., Olona, M., Aguilar, A., Sirvent, J. J., Alba, V., Calavia, O., Montero, M., Lacruz, J., Blanes, M., Calabuig, E., Cuellar, S., Lopez, J., Salavert, M., de la Serna, I. B., Arribas, J. R., Montes, M. L., Pena, J. M., Arribas, B., Castro, J. M., Zamora, J., Perez, I., Estebanez, M., Garcia, S., Diaz, M., Alcariz, N. S., Mingorance, J., Montero, D., Gonzalez, A., Isabel de Jose, M., de los Santos, I., Sanz, J., Salas, A., Sarria, C., Berrocal, A. G., Garcia-Fraile, L., Oteo, J. A., Blanco, J. R., Ibarra, V., Metola, L., Sanz, M., Perez-Martinez, L., Pascual, A., Ramos, C., Arazo, P., Gil, D., Jaen, A., Cairo, M., Irigoyen, D., Jordano, Q., Xercavins, M., Martinez-Lacasa, J., Velli, P., Font, R., Sanmarti, M., Ibanez, L., Rivero, M., Casado, M. I., Diaz, J. A., Uriz, J., Reparaz, J., Irigoyen, C., Arraiza, M. J., Segura, F., Amengual, M. J., Navarro, G., Sala, M., Cervantes, M., Pineda, V., Segura, V., Navarro, M., Anton, E., Nogueras, M. M., Casado, J. L., Dronda, F., Moreno, A., Elias, M. J. P., Lopez, D., Gutierrez, C., Madrid, N., Lamas, A., Marti, P., de Diaz, A., Serrrano, S., Donat, L., Cano, A., Bernal, E., Munoz, A., Pena, A., Munoz, L., Parra, J., Alvarez, M., Chueca, N., Guillot, V., Vinuesa, D., Fernandez, J. A., Del Romero, J., Rodriguez, C., Puerta, T., Carrio, J. C., Vera, M., Ballesteros, J., Domingo, P., Sambeat, M. A., Lamarca, K., Mateo, G., Gutierrez, M., Fernandez, I., Antela, A., Losada, E., Riera, M., Penaranda, M., Leyes, M., Ribas, M. A., Campins, A. A., Vidal, C., Gil, L., Fanjul, F., Marinescu, C., Ribera, E., Santos, J., Marquez, M., Viciana, I., Palacios, R., Gonzalez, C. M., Viciana, P., Leal, M., Lopez-Cortes, L. F., Espinosa, N., Munoz, J., Zubero, M. Z., Baraia-Etxaburu, J. M., Ibarra, S., Ferrero, O., Lopez de Munain, J., Camara, M. M., Lopez, I., de la Pena, M., Suarez-Garcia, I., Malmierca, E., Olalla, J., del Arco, A., de la Torre, J., Prada, J. L., Caracuel, Z., Lopez-Lirola, A. M., Lozano, A. B., Fernandez, E., Fernandez, J. M., Martinez, O. J., Vera, F. J., Martinez, L., Garcia, J., Alcaraz, B., Jimeno, A., Poveda, E., Pernas, B., Mena, A., Grandal, M., Castro, A., Pedreira, J. D., Galera, C., Albendin, H., Iborra, A., Campillo, M. A., Vidal, A., Amador, C., Pasquau, F., Ena, J., Benito, C., Fenoll, V., Mohamed-Balghata, M. O., Gomez, M. A., Alberto de Zarraga, M., Rivas, M. E., Gorgolas, M., Svedhem-Johansson, V., Flamholc, L., Gisslen, M., Hejdeman, B., Norgren, H., Wendahl, S., European Centre for Disease Prevention and Control (ECDC), Esser, Stefan (Beitragende*r), Schenk-Westkamp, Pia (Herausgeber*in), Vourli G., Noori T., Pharris A., Porter K., Axelsson M., Begovac J., Cazein F., Costagliola D., Cowan S., Croxford S., Monforte A.D., Delpech V., Diaz A., Girardi E., Gunsenheimer-Bartmeyer B., Hernando V., Leierer G., Lot F., Nunez O., Obel N., Op de Coul E., Paraskeva D., Patrinos S., Reiss P., Schmid D., Sonnerborg A., Suligoi B., Supervie V., van Sighem A., Zangerle R., Touloumi G., Egle A., Kanatschnig M., Ollinger A., Rieger A., Schmied B., Wallner E., Dewasurendra D., Gisinger M., Kitchen M., Plattner A., Rieser E., Sarcletti M., Greil R., Schachner M., Skocic M., Muller M., Aichwalder R., Chromy D., Grabmeier-Pfstershammer K., Skoll M., Touzeau V., Cichon P., Wolf-Nussmuller S., Laferl H., Zoufaly A., Genger-Hackl C., Kapper A., Schneeberger T., Trattner E., Schober G., Atzl M., Hartmann B., Puchhammer-Stockl E., Berg J., Appoyer H., Rappold M., Strickner S., Schindelwig K., Ledergerber B., Fatkenheuer G., Gerstof J., Kronborg G., Pedersen C., Larsen C.S., Pedersen G., Mohey R., Nielsen L., Weise L., Kvinesdal B., Jensen J., Abgrall S., Bernard L., Billaud E., Boue F., Boyer L., Cabie A., Caby F., Canestri A., Cotte L., de Truchis P., Duval X., Duvivier C., Enel P., Fischer H., Gasnault J., Gaud C., Grabar S., Khuong-Josses M.A., Launay O., Marchand L., Mary-Krause M., Matheron S., Melica-Gregoire G., Melliez H., Meynard J.L., Nacher M., Pavie J., Piroth L., Poizot-Martin I., Pradier C., Reynes J., Rouveix E., Simon A., Slama L., Tattevin P., Tissot-Dupont H., Biga J., Kurth T., Jacquemet N., Guiguet M., Leclercq S., Lievre L., Marshall E., Roul H., Selinger-Leneman H., Potard V., Benveniste O., Breton G., Lupin C., Bourzam E., Girard P.M., Fonquernie L., Valin N., Lefebvre B., Sebire M., Pialoux G., Lebrette M.G., Tibaut P., Adda A., Hamidi M., Cadranel J., Lavole A., Parrot A., Bouchaud O., Vignier N., Mechai F., Makhlouf S., Honore P., Bergmann J.F., Delcey V., Lopes A., Sellier P., Parrinello M., Oksenhendler E., Gerard L., Molina J.M., Rozenbaum W., Denis B., De Castro N., Lascoux C., Yazdanpanah Y., Lariven S., Joly V., Rioux C., Poupard M., Taverne B., Sutton L., Masse V., Genet P., Wifaq B., Gerbe J., Grefe S., Dupont C., Freire Maresca A., Reimann E., Bloch M., Meier F., Mortier E., Zeng F., Montoya B., Perronne C., Mathez D., Marigot-Outtandy D., Berthe H., Greder Belan A., Terby A., Godin Collet C., Marque Juillet S., Ruquet M., Roussin-Bretagne S., Colardelle P., Granier F., Laurichesse J.J., Perronne V., Akpan T., Marcou M., Daneluzzi V., Veyssier-Belot C., Masson H., Welker Y., Brazille P., Kahn J.E., Zucman D., Majerholc C., Fourn E., Bornarel D., Chambrin V., Kansau I., Raho-Moussa M., Lelievre J.D., Saidani M., Chesnel C., Dumont C., Vittecoq D., Derradji O., Bolliot C., Goujard C., Teicher E., Mole M., Bourdic K., Salmon D., Le Jeunne C., Guet P., Pietri M.P., Pannier Metzger E., Marcou V., Loulergue P., Dupin N., Morini J.P., Deleuze J., Gerhardt P., Chanal J., Weiss L., Lucas M.L., Jung C., Ptak M., Viard J.P., Ghosn J., Gazalet P., Cros A., Maignan A., Lortholary O., Rouzaud C., Touam F., Benhadj K., Consigny P.H., Bossi P., Gergely A., Cessot G., Durand F., Beck-Wirth G., Michel C., Benomar M., Rey D., Partisani M., Cheneau C., Batard M.L., Fischer P., Leclercq P., Blanc M., Morand P., Epaulard O., Signori-Schmuck A., Laurichesse H., Jacomet C., Vidal M., Coban D., Casanova S., Fresard A., Guglielminotti C., Botelho-Nevers E., Brunon-Gagneux A., Ronat V., Verdon R., Dargere S., Haustraete E., Feret P., Goubin P., Chavanet P., Fillion A., Croisier D., Gohier S., Arvieux C., Souala F., Chapplain J.M., Ratajczak M., Rohan J., Faller J.P., Ruyer O., Gendrin V., Toko L., Chirouze C., Hustache-Mathieu L., Faucher J.F., Proust A., Magy-Bertrand N., Gil H., Meaux-Ruault N., Sotto A., Rouanet I., Mauboussin J.M., Doncesco R., Jacques G., May T., Rabaud C., Andre M., Delestan M., Bouillon M.P., Bani-Sadr F., Rouger C., Berger J.L., Nguyen Y., Marchou B., Delobel P., Martin Blondel G., Cuzin L., Biezunski N., Alric L., Bonnet D., Guivarch M., Palacin A., Payssan V., Ajana F., Meybeck A., Viget N., Pugliese P., Roger P.M., Rosenthal E., Durant J., Cua E., Naqvi A., Perbost I., Risso K., Quinsat D., Raphael St., Del Giudice P., Dides P.Y., Sambuc R., Antolini-Bouvenot M.S., Druart P., Meddeb L., Ravaux I., Menard A., Tomei C., Dhiver C., Moreau J., Mokhtari S., Soavi M.J., Tomas V., Bregigeon S., Faucher O., Obry-Roguet V., Ritleng A.S., Petit N., Bartoli C., Ruiz J.M., Blanc D., Allegre T., Sordage M., Riou J.M., Faudon C., Slama B., Zerazhi H., Boulat O., Chebrek S., Beyrne M., Granet Brunello P., Pellissier L., Bonnabel D., Cohen Valensi R., Mouchet B., Mboungou G., Lafeuillade A., Hope-Rapp E., Hittinger G., Philip G., Lambry V., Raf F., Allavena C., Hall N., Reliquet V., Chidiac C., Ferry T., Perpoint T., Miailhes P., Boibieux A., Livrozet J.M., Makhlouf D., Brunel F., Chiarello P., Hoen B., Lamaury I., Fabre I., Samar K., Duvallon E., Clavel C., Stegmann S., Walter V., Adriouch L., Huber F., Vanticlke V., Couppie P., Abel S., Pierre-Francois S., Ricaud C., Rodet R., Wartel G., Sautron C., Poubeau P., Borgherini G., Camuset G., Arasteh K., Kowohl Vivantes S., Schurmann D., Warncke Charite M., Rockstroh J., Wasmuth J., Hass S., Jensen B.O., Feind C., Esser S., Schenk-Westkamp P., Haberl A., Stephan C., Plettenberg A., Kuhlendahl F., Adam A., Weitner L., Schewe K., Goey H., Fenske S., Buhk T., Stellbrink H.J., Hofmann C., Hansen S., Degen O., Heuer M., Stoll M., Gerschmann S., Horst H., Trautmann S., Gillor D., Bogner J., Sonntag B., Salzberger B., Fritzsche C., Adamis G., Antoniadou A., Chini M., Chrysos G., Gikas A., Gogos H.A., Katsarou O., Lazanas M., Metallidis S., Panagopoulos P., Paparizos V., Papastamopoulos V., Paraskevis D., Psychogiou M., Sambatakou H., Sipsas N.V., Pantazis N., Papadopoulos A., Nitsotolis T., Xylomenos G., Marangos M.N., Kouramba A., Kontos A., Lioni A., Tsachouridou O., Kourkounti S., Ganitis A., Barbounakis E., d'Arminio Monforte A., Antinori A., Andreoni M., Castagna A., Castelli F., Cauda R., Di Perri G., Galli M., Iardino R., Ippolito G., Lazzarin A., Marchetti G.C., Rezza G., von Schloesser F., Viale P., Ceccherini-Silberstein F., Cozzi-Lepri A., Lo Caputo S., Mussini C., Puoti M., Perno C.F., Bai F., Balotta C., Bandera A., Bonora S., Borderi M., Calcagno A., Capetti A., Capobianchi M.R., Cicalini S., Cingolani A., Cinque P., Di Biagio A., Gianotti N., Gori A., Guaraldi G., Lapadula G., Lichtner M., Madeddu G., Maggiolo F., Marchetti G., Monno L., Nozza S., Pinnetti C., Quiros Roldan E., Rossotti R., Rusconi S., Santoro M.M., Saracino A., Sarmati L., Fanti I., Galli L., Lorenzini P., Rodano A., Macchia M., Tavelli A., Carletti F., Carrara S., Di Caro A., Graziano S., Petroni F., Prota G., Trufa S., Giacometti A., Costantini A., Barocci V., Angarano G., Milano E., Suardi C., Donati V., Verucchi G., Castelnuovo F., Minardi C., Menzaghi B., Abeli C., Cacopardo B., Celesia B., Vecchiet J., Falasca K., Pan A., Lorenzotti S., Sighinolf L., Segala D., Blanc P., Vichi F., Cassola G., Viscoli C., Alessandrini A., Bobbio N., Mazzarello G., Fondaco L., Bonfanti P., Molteni C., Chiodera A., Milini P., Nunnari G., Pellicano G., Rizzardini G., Cannizzo E.S., Moioli M.C., Piolini R., Bernacchia D., Salpietro S., Tincati C., Puzzolante C., Migliorino C., Sangiovanni V., Borgia G., Esposito V., Di Flumeri G., Gentile I., Rizzo V., Cattelan A.M., Marinello S., Cascio A., Trizzino M., Francisci D., Schiaroli E., Parruti G., Sozio F., Magnani G., Ursitti M.A., Cristaudo A., Vullo V., Acinapura R., Moschese D., Capozzi M., Mondi A., Rivano Capparuccia M., Iaiani G., Latini A., Gagliardini R., Plazzi M.M., De Girolamo G., Vergori A., Cecchetto M., Viviani F., De Vito A., Rossetti B., Montagnani F., Franco A., Fontana Del Vecchio R., Di Giuli C., Caramello P., Orofno G.C., Sciandra M., Bassetti M., Londero A., Manfrin V., Battagin G., Starnini G., Ialungo A., van der Valk M., Geerlings S.E., Goorhuis A., Hovius J.W., Lempkes B., Nellen F.J.B., van der Poll T., Prins J.M., van Vugt M., Wiersinga W.J., Wit F.W.M.N., van Duinen M., van Eden J., Hazenberg A., van Hes A.M.H., Pijnappel F.J.J., Smalhout S.Y., Weijsenfeld A.M., Jurriaans S., Back N.K.T., Zaaijer H.L., Berkhout B., Cornelissen M.T.E., Schinkel C.J., Wolthers K.C., Peters E.J.G., van Agtmael M.A., Bomers M., Sigalof K.C.E., Heitmuller M., Laan L.M., Ang C.W., van Houdt R., Jonges M., van Prehn J., Kuijpers T.W., Pajkrt D., Scherpbier H.J., de Boer C., van der Plas A., van den Berge M., Stegeman A., Baas S., Hage de Loof L., Wintermans B., Veenemans J., Pronk M.J.H., Ammerlaan H.S.M., de Munnik E.S., Jansz A.R., Tjhie J., Wegdam M.C.A., Deiman B., Scharnhorst V., van Eeden A., Brokking W., Elsenburg L.J.M., Nobel H., Damen M., van Kasteren M.E.E., Berrevoets M.A.H., Brouwer A.E., Adams A., de Kruijf-Van de Wiel B.A.F.M., Keelan-Pfaf S., van der Ven B., Buiting A.G.M., Murck J.L., Versteeg D., de Vries-Sluijs T.E.M.S., Bax H.I., van Gorp E.C.M., Nouwen J.L., Rijnders B.J.A., Schurink C.A.M., Verbon A., de Jong-Peltenburg N.C., Bassant N., van Beek J.E.A., Vriesde M., van Zonneveld L.M., van den Berg-Cameron H.J., de Groot J., Boucher C.A.B., Koopmans M.P.G., van Kampen J.J.A., Fraaij P.L.A., van Rossum A.M.C., Vermont C.L., van der Knaap L.C., Visser E., Branger J., Douma R.A., Duijf-Van de Ven C.J.H.M., Schippers E.F., van Nieuwkoop C., van IJperen J.M., Geilings J., van der Hut G., van Burgel N.D., Leyten E.M.S., Gelinck L.B.S., Mollema F., Davids-Veldhuis S., Wildenbeest G.S., Heikens E., Groeneveld P.H.P., Bouwhuis J.W., Lammers A.J.J., Kraan S., van Hulzen A.G.W., Kruiper M.S.M., van der Bliek G.L., Bor P.C.J., Bloembergen P., Wolfagen M.J.H.M., Ruijs G.J.H.M., Kroon F.P., de Boer M.G.J., Scheper H., Jolink H., Dorama W., van Holten N., Claas E.C.J., Wessels E., den Hollander J.G., El Moussaoui R., Pogany K., Kastelijns M., Smit J.V., Smit E., Struik-Kalkman D., Tearno C., van Niekerk T., Pontesilli O., Lowe S.H., Oude Lashof A.M.L., Posthouwer D., Ackens R.P., Burgers K., Schippers J., Weijenberg-Maes B., van Loo I.H.M., Havenith T.R.A., Weijer S., van Vonderen M.G.A., Kampschreur L.M., Faber S., Steeman-Bouma R., Weel J., Kootstra G.J., Delsing C.E., van der Burg-Van de Plas M., Heins H., Kortmann W., van Twillert G., Renckens R., Ruiter-Pronk D., van Truijen-Oud F.A., Cohen Stuart J.W.T., Jansen E.R., Hoogewerf M., Rozemeijer W., van der Reijden W.A., Sinnige J.C., Brinkman K., van den Berk G.E.L., Blok W.L., Frissen P.H.J., Lettinga K.D., Schouten W.E.M., Veenstra J., Vrouenraets S.M.E., Brouwer C.J., Geerders G.F., Hoeksema K., Kleene M.J., Knapen M., van der Meche I.B., Mulder-Seeleman E., Toonen A.J.M., Wijnands S., Kwa D., van Crevel R., van Aerde K., Doferhof A.S.M., Henriet S.S.V., ter Hofstede H.J.M., Hoogerwerf J., Keuter M., Richel O., Albers M., Grintjes-Huisman K.J.T., de Haan M., Marneef M., Strik-Albers R., Rahamat-Langendoen J., Stelma F.F., Burger D., Gisolf E.H., Hassing R.J., Claassen M., ter Beest G., van Bentum P.H.M., Langebeek N., Tiemessen R., Swanink C.M.A., van Lelyveld S.F.L., Soetekouw R., van der Prijt L.M.M., van der Swaluw J., Bermon N., Jansen R., Herpers B.L., Veenendaal D., Verhagen D.W.M., Lauw F.N., van Broekhuizen M.C., van Wijk M., Bierman W.F.W., Bakker M., Kleinnijenhuis J., Kloeze E., Middel A., Scholvinck E.H., Stienstra Y., Verhage A.R., Wouthuyzen-Bakker K.M., Boonstra A., de Groot-De Jonge H., van der Meulen P.A., de Weerd D.A., Niesters H.G.M., van Leer-Buter C.C., Knoester M., Hoepelman A.I.M., Arends J.E., Barth R.E., Bruns A.H.W., Ellerbroek P.M., Mudrikova T., Oosterheert J.J., de Regt M.J.A., Schadd E.M., van Zoelen M.A.D., Aarsman K., Grifoen-Van Santen B.M.G., de Kroon I., van Rooijen C.S.A.M., van Berkel M., Schuurman R., Verduyn-Lunel F., Wensing A.M.J., Bont L.J., Geelen S.P.M., Loefen Y.G.T., Wolfs T.F.W., Nauta N., Zaheri S., Boyd A.C., Bezemer D.O., van Sighem A.I., Smit C., Hillebregt M., de Jong A., Woudstra T., Bergsma D., Meijering R., van de Sande L., Rutkens T., van der Vliet S., de Groot L., van den Akker M., Bakker Y., El Berkaoui A., Bezemer M., Bretin N., Djoechro E., Geerlinks J., Kruijne E., Lodewijk C., Lucas E., van der Meer R., Munjishvili L., Paling F., Peeck B., Ree C., Regtop R., Ruijs Y., Schoorl M., Schnorr P., Tuijn E., Veenenberg L., Witte E.C., Tuk B., Moreno S., del Amo J., Dalmau D., Navarro M.L., Gonzalez M.I., Blanco J.L., Garcia F., Rubio R., Iribarren J.A., Gutierrez F., Vidal F., Berenguer J., Gonzalez J., Sobrino P., Alejos B., Alvarez D., Jarrin I., Moreno C., Munoz-Fernandez M.A., Garcia-Merino I., Rico C.G., de la Fuente J.G., Torre A.G., Portilla J., Merino E., Reus S., Boix V., Giner L., Gadea C., Portilla I., Pampliega M., Diez M., Rodriguez J.C., Sanchez-Paya J., Podzamczer D., Imaz E.F.A., Van Den Eyncle E., Di Yacovo S., Sumoy M., Gomez J.L., Hernandez J., Aleman M.R., Alonso M.D.M., Hernandez M.I., Diaz-Flores F., Garcia D., Pelazas R., Asensi V., Valle E., Carton J.A., Perez V.E., Molina M.J.T., Garcia J.V., Carrera E.P.-C., Pulido F., Bisbal O., Matarranz M., Lagarde M., Rubio-Martin R., Hernando A., Bermejo L., Dominguez L., Arrizabalaga J., Aramburu M.J., Camino X., Rodriguez-Arrondo F., von Wichmann M.A., Tome L.P., Goenaga M.A., Bustinduy M.J., Galparsoro H.A., Ibarguren M., Aguado M., Umerez M., Masia M., Lopez C., Padilla S., Navarro A., Montolio F., Robledano C., Colome J.G., Adsuar A., Pascual R., Carlos F., Martinez M., Garcia J.L., Fernandez M., Garcia E., Muga R., Tor J., Sanvisens A., Bernaldo de Quiros Lopez J.C., Miralles P., Gutierrez I., Ramirez M., Padilla B., Gijon P., Carrero A., Aldamiz-Echevarria T., Tejerina F., Parras F.J., Balsalobre P., Diez C., Peraire J., Vilades C., Veloso S., Vargas M., Lopez-Dupla M., Olona M., Aguilar A., Sirvent J.J., Alba V., Calavia O., Montero M., Lacruz J., Blanes M., Calabuig E., Cuellar S., Lopez J., Salavert M., de la Serna I.B., Arribas J.R., Montes M.L., Pena J.M., Arribas B., Castro J.M., Zamora J., Perez I., Estebanez M., Garcia S., Diaz M., Alcariz N.S., Mingorance J., Montero D., Gonzalez A., Isabel de Jose M., de los Santos I., Sanz J., Salas A., Sarria C., Berrocal A.G., Garcia-Fraile L., Oteo J.A., Blanco J.R., Ibarra V., Metola L., Sanz M., Perez-Martinez L., Pascual A., Ramos C., Arazo P., Gil D., Jaen A., Cairo M., Irigoyen D., Jordano Q., Xercavins M., Martinez-Lacasa J., Velli P., Font R., Sanmarti M., Ibanez L., Rivero M., Casado M.I., Diaz J.A., Uriz J., Reparaz J., Irigoyen C., Arraiza M.J., Segura F., Amengual M.J., Navarro G., Sala M., Cervantes M., Pineda V., Segura V., Navarro M., Anton E., Nogueras M.M., Casado J.L., Dronda F., Moreno A., Elias M.J.P., Lopez D., Gutierrez C., Madrid N., Lamas A., Marti P., de Diaz A., Serrrano S., Donat L., Cano A., Bernal E., Munoz A., Pena A., Munoz L., Parra J., Alvarez M., Chueca N., Guillot V., Vinuesa D., Fernandez J.A., Del Romero J., Rodriguez C., Puerta T., Carrio J.C., Vera M., Ballesteros J., Domingo P., Sambeat M.A., Lamarca K., Mateo G., Gutierrez M., Fernandez I., Antela A., Losada E., Riera M., Penaranda M., Leyes M., Ribas M.A., Campins A.A., Vidal C., Gil L., Fanjul F., Marinescu C., Ribera E., Santos J., Marquez M., Viciana I., Palacios R., Gonzalez C.M., Viciana P., Leal M., Lopez-Cortes L.F., Espinosa N., Munoz J., Zubero M.Z., Baraia-Etxaburu J.M., Ibarra S., Ferrero O., Lopez de Munain J., Camara M.M., Lopez I., de la Pena M., Suarez-Garcia I., Malmierca E., Olalla J., del Arco A., de la Torre J., Prada J.L., Caracuel Z., Lopez-Lirola A.M., Lozano A.B., Fernandez E., Fernandez J.M., Martinez O.J., Vera F.J., Martinez L., Garcia J., Alcaraz B., Jimeno A., Poveda E., Pernas B., Mena A., Grandal M., Castro A., Pedreira J.D., Galera C., Albendin H., Iborra A., Campillo M.A., Vidal A., Amador C., Pasquau F., Ena J., Benito C., Fenoll V., Mohamed-Balghata M.O., Gomez M.A., Alberto de Zarraga M., Rivas M.E., Gorgolas M., Svedhem-Johansson V., Flamholc L., Gisslen M., Hejdeman B., Norgren H., Wendahl S., Global Health, Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, ANS - Neuroinfection & -inflammation, Internal medicine, Medical Microbiology and Infection Prevention, AMS - Rehabilitation & Development, VU University medical center, Amsterdam Gastroenterology Endocrinology Metabolism, Pediatric surgery, Neurology, Amsterdam Neuroscience - Neurodegeneration, Pulmonary medicine, Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, Ethics, Law & Medical humanities, APH - Quality of Care, ACS - Pulmonary hypertension & thrombosis, Amsterdam Neuroscience - Neuroinfection & -inflammation, Amsterdam Reproduction & Development (AR&D), APH - Societal Participation & Health, Pediatrics, HAL-SU, Gestionnaire, National and Kapodistrian University of Athens (NKUA), University College of London [London] (UCL), Public Health Agency of Sweden, University of Zagreb, Santé publique France - French National Public Health Agency [Saint-Maurice, France], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Statens Serum Institut [Copenhagen], Public Health England [London], Università degli Studi di Milano = University of Milan (UNIMI), Instituto de Salud Carlos III [Madrid] (ISC), Istituto Nazionale di Malattie Infettive 'Lazzaro Spallanzani' (INMI), Robert Koch Institute [Berlin] (RKI), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), University of Copenhagen = Københavns Universitet (UCPH), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Hellenic Center for Disease Control and Prevention, Amsterdam UMC - Amsterdam University Medical Center, Austrian Agency for Health and Food Safety (AGES), Department of Infectious Diseases, Institution of Medicine, Karolinska University Hospital and Karolinska Institutet, Istituto Superiore di Sanita [Rome], Stichting HIV Monitoring [Amsterdam], Universiteit van Amsterdam (UvA), University of Athens Medical School [Athens], Vourli, G, Noori, T, Pharris, A, Porter, K, Axelsson, M, Begovac, J, Cazein, F, Costagliola, D, Cowan, S, Croxford, S, Monforte, A, Delpech, V, Diaz, A, Girardi, E, Gunsenheimer-Bartmeyer, B, Hernando, V, Leierer, G, Lot, F, Nunez, O, Obel, N, Op de Coul, E, Paraskeva, D, Patrinos, S, Reiss, P, Schmid, D, Sonnerborg, A, Suligoi, B, Supervie, V, van Sighem, A, Zangerle, R, Touloumi, G, Egle, A, Kanatschnig, M, Ollinger, A, Rieger, A, Schmied, B, Wallner, E, Dewasurendra, D, Gisinger, M, Kitchen, M, Plattner, A, Rieser, E, Sarcletti, M, Greil, R, Schachner, M, Skocic, M, Muller, M, Aichwalder, R, Chromy, D, Grabmeier-Pfstershammer, K, Skoll, M, Touzeau, V, Cichon, P, Wolf-Nussmuller, S, Laferl, H, Zoufaly, A, Genger-Hackl, C, Kapper, A, Schneeberger, T, Trattner, E, Schober, G, Atzl, M, Hartmann, B, Puchhammer-Stockl, E, Berg, J, Appoyer, H, Rappold, M, Strickner, S, Schindelwig, K, Ledergerber, B, Fatkenheuer, G, Gerstof, J, Kronborg, G, Pedersen, C, Larsen, C, Pedersen, G, Mohey, R, Nielsen, L, Weise, L, Kvinesdal, B, Jensen, J, Abgrall, S, Bernard, L, Billaud, E, Boue, F, Boyer, L, Cabie, A, Caby, F, Canestri, A, Cotte, L, de Truchis, P, Duval, X, Duvivier, C, Enel, P, Fischer, H, Gasnault, J, Gaud, C, Grabar, S, Khuong-Josses, M, Launay, O, Marchand, L, Mary-Krause, M, Matheron, S, Melica-Gregoire, G, Melliez, H, Meynard, J, Nacher, M, Pavie, J, Piroth, L, Poizot-Martin, I, Pradier, C, Reynes, J, Rouveix, E, Simon, A, Slama, L, Tattevin, P, Tissot-Dupont, H, Biga, J, Kurth, T, Jacquemet, N, Guiguet, M, Leclercq, S, Lievre, L, Marshall, E, Roul, H, Selinger-Leneman, H, Potard, V, Benveniste, O, Breton, G, Lupin, C, Bourzam, E, Girard, P, Fonquernie, L, Valin, N, Lefebvre, B, Sebire, M, Pialoux, G, Lebrette, M, Tibaut, P, Adda, A, Hamidi, M, Cadranel, J, Lavole, A, Parrot, A, Bouchaud, O, Vignier, N, Mechai, F, Makhlouf, S, Honore, P, Bergmann, J, Delcey, V, Lopes, A, Sellier, P, Parrinello, M, Oksenhendler, E, Gerard, L, Molina, J, Rozenbaum, W, Denis, B, De Castro, N, Lascoux, C, Yazdanpanah, Y, Lariven, S, Joly, V, Rioux, C, Poupard, M, Taverne, B, Sutton, L, Masse, V, Genet, P, Wifaq, B, Gerbe, J, Grefe, S, Dupont, C, Freire Maresca, A, Reimann, E, Bloch, M, Meier, F, Mortier, E, Zeng, F, Montoya, B, Perronne, C, Mathez, D, Marigot-Outtandy, D, Berthe, H, Greder Belan, A, Terby, A, Godin Collet, C, Marque Juillet, S, Ruquet, M, Roussin-Bretagne, S, Colardelle, P, Granier, F, Laurichesse, J, Perronne, V, Akpan, T, Marcou, M, Daneluzzi, V, Veyssier-Belot, C, Masson, H, Welker, Y, Brazille, P, Kahn, J, Zucman, D, Majerholc, C, Fourn, E, Bornarel, D, Chambrin, V, Kansau, I, Raho-Moussa, M, Lelievre, J, Saidani, M, Chesnel, C, Dumont, C, Vittecoq, D, Derradji, O, Bolliot, C, Goujard, C, Teicher, E, Mole, M, Bourdic, K, Salmon, D, Le Jeunne, C, Guet, P, Pietri, M, Pannier Metzger, E, Marcou, V, Loulergue, P, Dupin, N, Morini, J, Deleuze, J, Gerhardt, P, Chanal, J, Weiss, L, Lucas, M, Jung, C, Ptak, M, Viard, J, Ghosn, J, Gazalet, P, Cros, A, Maignan, A, Lortholary, O, Rouzaud, C, Touam, F, Benhadj, K, Consigny, P, Bossi, P, Gergely, A, Cessot, G, Durand, F, Beck-Wirth, G, Michel, C, Benomar, M, Rey, D, Partisani, M, Cheneau, C, Batard, M, Fischer, P, Leclercq, P, Blanc, M, Morand, P, Epaulard, O, Signori-Schmuck, A, Laurichesse, H, Jacomet, C, Vidal, M, Coban, D, Casanova, S, Fresard, A, Guglielminotti, C, Botelho-Nevers, E, Brunon-Gagneux, A, Ronat, V, Verdon, R, Dargere, S, Haustraete, E, Feret, P, Goubin, P, Chavanet, P, Fillion, A, Croisier, D, Gohier, S, Arvieux, C, Souala, F, Chapplain, J, Ratajczak, M, Rohan, J, Faller, J, Ruyer, O, Gendrin, V, Toko, L, Chirouze, C, Hustache-Mathieu, L, Faucher, J, Proust, A, Magy-Bertrand, N, Gil, H, Meaux-Ruault, N, Sotto, A, Rouanet, I, Mauboussin, J, Doncesco, R, Jacques, G, May, T, Rabaud, C, Andre, M, Delestan, M, Bouillon, M, Bani-Sadr, F, Rouger, C, Berger, J, Nguyen, Y, Marchou, B, Delobel, P, Martin Blondel, G, Cuzin, L, Biezunski, N, Alric, L, Bonnet, D, Guivarch, M, Palacin, A, Payssan, V, Ajana, F, Meybeck, A, Viget, N, Pugliese, P, Roger, P, Rosenthal, E, Durant, J, Cua, E, Naqvi, A, Perbost, I, Risso, K, Quinsat, D, Raphael, S, Del Giudice, P, Dides, P, Sambuc, R, Antolini-Bouvenot, M, Druart, P, Meddeb, L, Ravaux, I, Menard, A, Tomei, C, Dhiver, C, Moreau, J, Mokhtari, S, Soavi, M, Tomas, V, Bregigeon, S, Faucher, O, Obry-Roguet, V, Ritleng, A, Petit, N, Bartoli, C, Ruiz, J, Blanc, D, Allegre, T, Sordage, M, Riou, J, Faudon, C, Slama, B, Zerazhi, H, Boulat, O, Chebrek, S, Beyrne, M, Granet Brunello, P, Pellissier, L, Bonnabel, D, Cohen Valensi, R, Mouchet, B, Mboungou, G, Lafeuillade, A, Hope-Rapp, E, Hittinger, G, Philip, G, Lambry, V, Raf, F, Allavena, C, Hall, N, Reliquet, V, Chidiac, C, Ferry, T, Perpoint, T, Miailhes, P, Boibieux, A, Livrozet, J, Makhlouf, D, Brunel, F, Chiarello, P, Hoen, B, Lamaury, I, Fabre, I, Samar, K, Duvallon, E, Clavel, C, Stegmann, S, Walter, V, Adriouch, L, Huber, F, Vanticlke, V, Couppie, P, Abel, S, Pierre-Francois, S, Ricaud, C, Rodet, R, Wartel, G, Sautron, C, Poubeau, P, Borgherini, G, Camuset, G, Arasteh, K, Kowohl Vivantes, S, Schurmann, D, Warncke Charite, M, Rockstroh, J, Wasmuth, J, Hass, S, Jensen, B, Feind, C, Esser, S, Schenk-Westkamp, P, Haberl, A, Stephan, C, Plettenberg, A, Kuhlendahl, F, Adam, A, Weitner, L, Schewe, K, Goey, H, Fenske, S, Buhk, T, Stellbrink, H, Hofmann, C, Hansen, S, Degen, O, Heuer, M, Stoll, M, Gerschmann, S, Horst, H, Trautmann, S, Gillor, D, Bogner, J, Sonntag, B, Salzberger, B, Fritzsche, C, Adamis, G, Antoniadou, A, Chini, M, Chrysos, G, Gikas, A, Gogos, H, Katsarou, O, Lazanas, M, Metallidis, S, Panagopoulos, P, Paparizos, V, Papastamopoulos, V, Paraskevis, D, Psychogiou, M, Sambatakou, H, Sipsas, N, Pantazis, N, Papadopoulos, A, Nitsotolis, T, Xylomenos, G, Marangos, M, Kouramba, A, Kontos, A, Lioni, A, Tsachouridou, O, Kourkounti, S, Ganitis, A, Barbounakis, E, d'Arminio Monforte, A, Antinori, A, Andreoni, M, Castagna, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Marchetti, G, Rezza, G, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Cozzi-Lepri, A, Lo Caputo, S, Mussini, C, Puoti, M, Perno, C, Bai, F, Balotta, C, Bandera, A, Bonora, S, Borderi, M, Calcagno, A, Capetti, A, Capobianchi, M, Cicalini, S, Cingolani, A, Cinque, P, Di Biagio, A, Gianotti, N, Gori, A, Guaraldi, G, Lapadula, G, Lichtner, M, Madeddu, G, Maggiolo, F, Monno, L, Nozza, S, Pinnetti, C, Quiros Roldan, E, Rossotti, R, Rusconi, S, Santoro, M, Saracino, A, Sarmati, L, Fanti, I, Galli, L, Lorenzini, P, Rodano, A, Macchia, M, Tavelli, A, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petroni, F, Prota, G, Trufa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Milano, E, Suardi, C, Donati, V, Verucchi, G, Castelnuovo, F, Minardi, C, Menzaghi, B, Abeli, C, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolf, L, Segala, D, Blanc, P, Vichi, F, Cassola, G, Viscoli, C, Alessandrini, A, Bobbio, N, Mazzarello, G, Fondaco, L, Bonfanti, P, Molteni, C, Chiodera, A, Milini, P, Nunnari, G, Pellicano, G, Rizzardini, G, Cannizzo, E, Moioli, M, Piolini, R, Bernacchia, D, Salpietro, S, Tincati, C, Puzzolante, C, Migliorino, C, Sangiovanni, V, Borgia, G, Esposito, V, Di Flumeri, G, Gentile, I, Rizzo, V, Cattelan, A, Marinello, S, Cascio, A, Trizzino, M, Francisci, D, Schiaroli, E, Parruti, G, Sozio, F, Magnani, G, Ursitti, M, Cristaudo, A, Vullo, V, Acinapura, R, Moschese, D, Capozzi, M, Mondi, A, Rivano Capparuccia, M, Iaiani, G, Latini, A, Gagliardini, R, Plazzi, M, De Girolamo, G, Vergori, A, Cecchetto, M, Viviani, F, De Vito, A, Rossetti, B, Montagnani, F, Franco, A, Fontana Del Vecchio, R, Di Giuli, C, Caramello, P, Orofno, G, Sciandra, M, Bassetti, M, Londero, A, Manfrin, V, Battagin, G, Starnini, G, Ialungo, A, van der Valk, M, Geerlings, S, Goorhuis, A, Hovius, J, Lempkes, B, Nellen, F, van der Poll, T, Prins, J, van Vugt, M, Wiersinga, W, Wit, F, van Duinen, M, van Eden, J, Hazenberg, A, van Hes, A, Pijnappel, F, Smalhout, S, Weijsenfeld, A, Jurriaans, S, Back, N, Zaaijer, H, Berkhout, B, Cornelissen, M, Schinkel, C, Wolthers, K, Peters, E, van Agtmael, M, Bomers, M, Sigalof, K, Heitmuller, M, Laan, L, Ang, C, van Houdt, R, Jonges, M, van Prehn, J, Kuijpers, T, Pajkrt, D, Scherpbier, H, de Boer, C, van der Plas, A, van den Berge, M, Stegeman, A, Baas, S, Hage de Loof, L, Wintermans, B, Veenemans, J, Pronk, M, Ammerlaan, H, de Munnik, E, Jansz, A, Tjhie, J, Wegdam, M, Deiman, B, Scharnhorst, V, van Eeden, A, Brokking, W, Elsenburg, L, Nobel, H, Damen, M, van Kasteren, M, Berrevoets, M, Brouwer, A, Adams, A, de Kruijf-Van de Wiel, B, Keelan-Pfaf, S, van der Ven, B, Buiting, A, Murck, J, Versteeg, D, de Vries-Sluijs, T, Bax, H, van Gorp, E, Nouwen, J, Rijnders, B, Schurink, C, Verbon, A, de Jong-Peltenburg, N, Bassant, N, van Beek, J, Vriesde, M, van Zonneveld, L, van den Berg-Cameron, H, de Groot, J, Boucher, C, Koopmans, M, van Kampen, J, Fraaij, P, van Rossum, A, Vermont, C, van der Knaap, L, Visser, E, Branger, J, Douma, R, Duijf-Van de Ven, C, Schippers, E, van Nieuwkoop, C, van IJperen, J, Geilings, J, van der Hut, G, van Burgel, N, Leyten, E, Gelinck, L, Mollema, F, Davids-Veldhuis, S, Wildenbeest, G, Heikens, E, Groeneveld, P, Bouwhuis, J, Lammers, A, Kraan, S, van Hulzen, A, Kruiper, M, van der Bliek, G, Bor, P, Bloembergen, P, Wolfagen, M, Ruijs, G, Kroon, F, de Boer, M, Scheper, H, Jolink, H, Dorama, W, van Holten, N, Claas, E, Wessels, E, den Hollander, J, El Moussaoui, R, Pogany, K, Kastelijns, M, Smit, J, Smit, E, Struik-Kalkman, D, Tearno, C, van Niekerk, T, Pontesilli, O, Lowe, S, Oude Lashof, A, Posthouwer, D, Ackens, R, Burgers, K, Schippers, J, Weijenberg-Maes, B, van Loo, I, Havenith, T, Weijer, S, van Vonderen, M, Kampschreur, L, Faber, S, Steeman-Bouma, R, Weel, J, Kootstra, G, Delsing, C, van der Burg-Van de Plas, M, Heins, H, Kortmann, W, van Twillert, G, Renckens, R, Ruiter-Pronk, D, van Truijen-Oud, F, Cohen Stuart, J, Jansen, E, Hoogewerf, M, Rozemeijer, W, van der Reijden, W, Sinnige, J, Brinkman, K, van den Berk, G, Blok, W, Frissen, P, Lettinga, K, Schouten, W, Veenstra, J, Vrouenraets, S, Brouwer, C, Geerders, G, Hoeksema, K, Kleene, M, Knapen, M, van der Meche, I, Mulder-Seeleman, E, Toonen, A, Wijnands, S, Kwa, D, van Crevel, R, van Aerde, K, Doferhof, A, Henriet, S, ter Hofstede, H, Hoogerwerf, J, Keuter, M, Richel, O, Albers, M, Grintjes-Huisman, K, de Haan, M, Marneef, M, Strik-Albers, R, Rahamat-Langendoen, J, Stelma, F, Burger, D, Gisolf, E, Hassing, R, Claassen, M, ter Beest, G, van Bentum, P, Langebeek, N, Tiemessen, R, Swanink, C, van Lelyveld, S, Soetekouw, R, van der Prijt, L, van der Swaluw, J, Bermon, N, Jansen, R, Herpers, B, Veenendaal, D, Verhagen, D, Lauw, F, van Broekhuizen, M, van Wijk, M, Bierman, W, Bakker, M, Kleinnijenhuis, J, Kloeze, E, Middel, A, Scholvinck, E, Stienstra, Y, Verhage, A, Wouthuyzen-Bakker, K, Boonstra, A, de Groot-De Jonge, H, van der Meulen, P, de Weerd, D, Niesters, H, van Leer-Buter, C, Knoester, M, Hoepelman, A, Arends, J, Barth, R, Bruns, A, Ellerbroek, P, Mudrikova, T, Oosterheert, J, de Regt, M, Schadd, E, van Zoelen, M, Aarsman, K, Grifoen-Van Santen, B, de Kroon, I, van Rooijen, C, van Berkel, M, Schuurman, R, Verduyn-Lunel, F, Wensing, A, Bont, L, Geelen, S, Loefen, Y, Wolfs, T, Nauta, N, Zaheri, S, Boyd, A, Bezemer, D, Smit, C, Hillebregt, M, de Jong, A, Woudstra, T, Bergsma, D, Meijering, R, van de Sande, L, Rutkens, T, van der Vliet, S, de Groot, L, van den Akker, M, Bakker, Y, El Berkaoui, A, Bezemer, M, Bretin, N, Djoechro, E, Geerlinks, J, Kruijne, E, Lodewijk, C, Lucas, E, van der Meer, R, Munjishvili, L, Paling, F, Peeck, B, Ree, C, Regtop, R, Ruijs, Y, Schoorl, M, Schnorr, P, Tuijn, E, Veenenberg, L, Witte, E, Tuk, B, Moreno, S, del Amo, J, Dalmau, D, Navarro, M, Gonzalez, M, Blanco, J, Garcia, F, Rubio, R, Iribarren, J, Gutierrez, F, Vidal, F, Berenguer, J, Gonzalez, J, Sobrino, P, Alejos, B, Alvarez, D, Jarrin, I, Moreno, C, Munoz-Fernandez, M, Garcia-Merino, I, Rico, C, de la Fuente, J, Torre, A, Portilla, J, Merino, E, Reus, S, Boix, V, Giner, L, Gadea, C, Portilla, I, Pampliega, M, Diez, M, Rodriguez, J, Sanchez-Paya, J, Podzamczer, D, Imaz, E, Van Den Eyncle, E, Di Yacovo, S, Sumoy, M, Gomez, J, Hernandez, J, Aleman, M, Alonso, M, Hernandez, M, Diaz-Flores, F, Garcia, D, Pelazas, R, Asensi, V, Valle, E, Carton, J, Perez, V, Molina, M, Garcia, J, Carrera, E, Pulido, F, Bisbal, O, Matarranz, M, Lagarde, M, Rubio-Martin, R, Hernando, A, Bermejo, L, Dominguez, L, Arrizabalaga, J, Aramburu, M, Camino, X, Rodriguez-Arrondo, F, von Wichmann, M, Tome, L, Goenaga, M, Bustinduy, M, Galparsoro, H, Ibarguren, M, Aguado, M, Umerez, M, Masia, M, Lopez, C, Padilla, S, Navarro, A, Montolio, F, Robledano, C, Colome, J, Adsuar, A, Pascual, R, Carlos, F, Martinez, M, Fernandez, M, Garcia, E, Muga, R, Tor, J, Sanvisens, A, Bernaldo de Quiros Lopez, J, Miralles, P, Gutierrez, I, Ramirez, M, Padilla, B, Gijon, P, Carrero, A, Aldamiz-Echevarria, T, Tejerina, F, Parras, F, Balsalobre, P, Diez, C, Peraire, J, Vilades, C, Veloso, S, Vargas, M, Lopez-Dupla, M, Olona, M, Aguilar, A, Sirvent, J, Alba, V, Calavia, O, Montero, M, Lacruz, J, Blanes, M, Calabuig, E, Cuellar, S, Lopez, J, Salavert, M, de la Serna, I, Arribas, J, Montes, M, Pena, J, Arribas, B, Castro, J, Zamora, J, Perez, I, Estebanez, M, Garcia, S, Diaz, M, Alcariz, N, Mingorance, J, Montero, D, Gonzalez, A, Isabel de Jose, M, de los Santos, I, Sanz, J, Salas, A, Sarria, C, Berrocal, A, Garcia-Fraile, L, Oteo, J, Ibarra, V, Metola, L, Sanz, M, Perez-Martinez, L, Pascual, A, Ramos, C, Arazo, P, Gil, D, Jaen, A, Cairo, M, Irigoyen, D, Jordano, Q, Xercavins, M, Martinez-Lacasa, J, Velli, P, Font, R, Sanmarti, M, Ibanez, L, Rivero, M, Casado, M, Diaz, J, Uriz, J, Reparaz, J, Irigoyen, C, Arraiza, M, Segura, F, Amengual, M, Navarro, G, Sala, M, Cervantes, M, Pineda, V, Segura, V, Anton, E, Nogueras, M, Casado, J, Dronda, F, Moreno, A, Elias, M, Lopez, D, Gutierrez, C, Madrid, N, Lamas, A, Marti, P, de Diaz, A, Serrrano, S, Donat, L, Cano, A, Bernal, E, Munoz, A, Pena, A, Munoz, L, Parra, J, Alvarez, M, Chueca, N, Guillot, V, Vinuesa, D, Fernandez, J, Del Romero, J, Rodriguez, C, Puerta, T, Carrio, J, Vera, M, Ballesteros, J, Domingo, P, Sambeat, M, Lamarca, K, Mateo, G, Gutierrez, M, Fernandez, I, Antela, A, Losada, E, Riera, M, Penaranda, M, Leyes, M, Ribas, M, Campins, A, Vidal, C, Gil, L, Fanjul, F, Marinescu, C, Ribera, E, Santos, J, Marquez, M, Viciana, I, Palacios, R, Gonzalez, C, Viciana, P, Leal, M, Lopez-Cortes, L, Espinosa, N, Munoz, J, Zubero, M, Baraia-Etxaburu, J, Ibarra, S, Ferrero, O, Lopez de Munain, J, Camara, M, Lopez, I, de la Pena, M, Suarez-Garcia, I, Malmierca, E, Olalla, J, del Arco, A, de la Torre, J, Prada, J, Caracuel, Z, Lopez-Lirola, A, Lozano, A, Fernandez, E, Martinez, O, Vera, F, Martinez, L, Alcaraz, B, Jimeno, A, Poveda, E, Pernas, B, Mena, A, Grandal, M, Castro, A, Pedreira, J, Galera, C, Albendin, H, Iborra, A, Campillo, M, Vidal, A, Amador, C, Pasquau, F, Ena, J, Benito, C, Fenoll, V, Mohamed-Balghata, M, Gomez, M, Alberto de Zarraga, M, Rivas, M, Gorgolas, M, Svedhem-Johansson, V, Flamholc, L, Gisslen, M, Hejdeman, B, Norgren, H, and Wendahl, S
- Subjects
Male ,0301 basic medicine ,Psychological intervention ,Human immunodeficiency virus (HIV) ,Medizin ,Continuum of care ,Europe ,HIV infection ,Key population ,Sex ,Anti-Retroviral Agents ,Continuity of Patient Care ,European Union ,HIV ,Humans ,HIV Infections ,medicine.disease_cause ,key population ,0302 clinical medicine ,HIV Infection ,030212 general & internal medicine ,Men having sex with men ,media_common ,education.field_of_study ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Transmission (medicine) ,Infectious Diseases ,AcademicSubjects/MED00290 ,HIV infection, continuum of care, sex, key population, Europe ,Microbiology (medical) ,Population ,Socio-culturale ,03 medical and health sciences ,Acquired immunodeficiency syndrome (AIDS) ,SDG 3 - Good Health and Well-being ,medicine ,media_common.cataloged_instance ,European union ,education ,Pandemics ,continuum of care ,sex ,business.industry ,SARS-CoV-2 ,COVID-19 ,medicine.disease ,030112 virology ,Major Articles and Commentaries ,Anti-Retroviral Agent ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Demography - Abstract
Background High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. Methods A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed who ever initiated ART; and proportion of those ever treated who achieved viral suppression at their last visit. Results We estimated that 87% of PLHIV were diagnosed; 92% of those diagnosed had ever initiated ART; and 91% of those ever on ART, or 73% of all PLHIV, were virally suppressed. Corresponding figures for men having sex with men were: 86%, 93%, 93%, 74%; for people who inject drugs: 94%, 88%, 85%, 70%; and for heterosexuals: 86%, 92%, 91%, 72%. The proportion suppressed of all PLHIV ranged from 59% to 86% across countries. Conclusions The EU is close to the 90-90-90 target and achieved the UNAIDS target of 73% of all PLHIV virally suppressed, significant progress since 2013 when 60% of all PLHIV were virally suppressed. Strengthening of testing programs and treatment support, along with prevention interventions, are needed to achieve HIV epidemic control., Standardized definitions were used to estimate a 4-stage continuum of human immunodeficiency virus (HIV) care in 11 European Union (EU) countries in 2016. The EU is close to the 90-90-90 target, with the main challenge being the percentage of undiagnosed infections.
- Published
- 2020
- Full Text
- View/download PDF
29. Is the rate of virological failure to cART continuing to decline in recent calendar years?
- Author
-
Rusconi, S., Santoro, M. M., Gianotti, N., Antinori, A., Bonora, S., Cingolani, A., Ceccherini Silberstein, F., Tavelli, A., d'Arminio Monforte, A., Cozzi-Lepri, A., Cacopardo, B., B M, Celesia, Nunnari, G., Rusconi, S., Santoro, M. M., Gianotti, N., Antinori, A., Bonora, S., Cingolani, A., Ceccherini Silberstein, F., Tavelli, A., d'Arminio Monforte, A., Cozzi-Lepri, A., Icona Foundation Study, Group, and Castagna, A.
- Subjects
Adult ,Male ,0301 basic medicine ,Cart ,Pediatrics ,medicine.medical_specialty ,Anti-HIV Agents ,030106 microbiology ,hiv ,HIV Infections ,Settore MED/17 - MALATTIE INFETTIVE ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Risk Factors ,Virology ,Humans ,Medicine ,In patient ,Treatment Failure ,030212 general & internal medicine ,Viral suppression ,Poisson regression ,art ,High rate ,business.industry ,Antiretroviral therapy, viral suppression, tolerability, resistance, cohort ,Middle Aged ,Viral Load ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Virological failure ,Calendar period ,Infectious Diseases ,resistant ,Italy ,Cohort ,symbols ,Drug Therapy, Combination ,Female ,business - Abstract
Background: Despite the high rate of virological success of combined antiretroviral therapy (cART), HIV infected individuals continue to fail. In this contest, it is unclear whether having previously experienced virological failure (VF)of cART remains an important predictor of future risk of VF in people receiving cART in modern times. We investigated the rate of VF and factors potentially associated with this event in 9220 HIV-1 infected patients enrolled in the Icona Cohort who showed a stable viral suppression on modern cART regimens after January 1, 2006. Methods: We investigated two main exposure factors: current calendar period (2006–2009; 2010–2013; 2014–2017)and number of VFs (0; 1–3; >3)prior to baseline. Relative rates of VF were estimated from fitting a Poisson regression model. Results: Seven-hundred-seventy-nine patients experienced VF over follow-up for an overall rate of 2.08 per 100 person years of follow-up (PYFU, 95%CI: 1.93–2.22). The rate of VF increased with higher numbers of previous VFs: patients with >3 previous VFs had a rate of 4.87 (4.10–5.78), 2.75-fold higher than that observed in patients without any previous VF (p < 0.001). The rate of VF was lower in recent years: 3.81 (3.36, 4.32)in 2006–2009; 1.36 (1.20–1.53)in 2014–2017 (p < 0.001). Other factors independently associated with lower risk of VF were Italian origin, longer history of virological suppression, and university education level. Conclusions: In HIV-infected patients virologically suppressed after January 2006, the rate of VF continues to show a decline even in the most recent years. Previous VFs should be carefully considered.
- Published
- 2019
- Full Text
- View/download PDF
30. Anxiety and depression symptoms after virological clearance of COVID‐19: A cross‐sectional study in Milan, Italy
- Author
-
Francesca Bai, Elena Vegni, Alessandro Tavelli, Debora Mondatore, Daniele Tomasoni, Diletta Barbanotti, Camilla Falcinella, Roberto Castoldi, Antonella d'Arminio Monforte, Giulia Marchetti, and Giovanni Mulè
- Subjects
Adult ,Male ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Cross-sectional study ,Short Communication ,Short Communications ,Anxiety ,Hospital Anxiety and Depression Scale ,03 medical and health sciences ,0302 clinical medicine ,Disease severity ,COVID‐19 ,Surveys and Questionnaires ,Virology ,Internal medicine ,Prevalence ,Humans ,Medicine ,030212 general & internal medicine ,Pathological ,Depression (differential diagnoses) ,Aged ,Depression ,business.industry ,COVID-19 ,Middle Aged ,Anxiety and depression symptoms ,Cross-Sectional Studies ,Infectious Diseases ,Italy ,Symptom persistence ,Female ,030211 gastroenterology & hepatology ,medicine.symptom ,business - Abstract
Prevalence of anxiety/depression was investigated in 105 COVID‐19 patients at 1‐3 months from virological clearance by Hospital Anxiety and Depression Scale (HADS‐A/D). 30% of patients displayed pathological HADS‐A/D, 52.4% showed persistent symptoms. Pathological HADS‐A/D patients more commonly reported symptom persistence, even after adjustment for age, gender, disease severity. Psychological assessments should be encouraged in COVID‐19 patients’ follow‐up. This article is protected by copyright. All rights reserved.
- Published
- 2020
- Full Text
- View/download PDF
31. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The 'STORE' Study
- Author
-
Alessandra Vergori, Elio Manzillo, Roberta Termini, Andrea Antinori, Diego Ripamonti, Antonella dʼArminio Monforte, Christof Stingone, Nicola Gianotti, Stefano Savinelli, Benedetto Maurizio Celesia, Francesco Castelli, Renato Maserati, Teresa Santantonio, Giancarlo Orofino, Barbara Menzaghi, Francesco Rucci, Maria Vittoria Cossu, Roberto Cauda, Gaetana Sterrantino, Anna Maria Cattelan, Alessia Uglietti, Andrea Gori, Stefano Rusconi, Daniela Mancusi, and Stefano Bonora
- Subjects
Adult ,Male ,medicine.medical_specialty ,Settore M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICA ,Anti-HIV Agents ,effectiveness ,HIV Infections ,030312 virology ,darunavir ,cobicistat ,ritonavir ,HIV ,STORE ,virologically suppressed ,Gastroenterology ,03 medical and health sciences ,Internal medicine ,HIV Seropositivity ,medicine ,Humans ,darunavir/ritonavir ,Pharmacology (medical) ,Prospective Studies ,Adverse effect ,Prospective cohort study ,Darunavir ,therapy ,0303 health sciences ,Ritonavir ,business.industry ,Cobicistat ,darunavir/cobicistat ,HIV Protease Inhibitors ,Middle Aged ,Viral Load ,Clinical Science ,Regimen ,Infectious Diseases ,Tolerability ,haart ,HIV-1 ,RNA, Viral ,Female ,business ,Viral load ,medicine.drug - Abstract
Objective: This study investigates the effectiveness and tolerability of switching to a darunavir/cobicistat (DRV/c)-based antiretroviral regimen from a ritonavir-boosted protease inhibitor (PI/r)-based regimen in virologically suppressed HIV-positive patients. DRV trough values were also investigated. Setting: Prospective, multicenter, single-country, noninterventional cohort study. Methods: This study included patients on a PI/r-based ART for at least 12 months having plasma HIV-1 RNA
- Published
- 2020
- Full Text
- View/download PDF
32. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study
- Author
-
Alessandra Brocchieri, Marta Borghi, Angelo Pan, Mariella Di Marco, Silvia Colombo, Chiara Molteni, Natalia Terreni, Paolo Poggio, Alberto Colombo, De Silvestri Annalisa, Riccardo Centenaro, Luisa Pasulo, Paolo Viganò, Maria Cristina Vinci, Marie Graciella Pigozzi, Stefano Fagiuoli, Pietro Lampertico, Sergio Lazzaroni, Sherrie Bhoori, Massimo Zuin, Franco Noventa, Alessio Aghemo, Barbara Menzaghi, Andrea Lombardi, Franco Maggiolo, I. Fanetti, Alessia Giorgini, Massimo Puoti, Emanuela Messina, Paolo Grossi, Roberta D'Ambrosio, Pietro Invernizzi, Monia Mendeni, Daniele Bella, E. Dionigi, Ombretta Spinelli, Maria Teresa Taddei, Pietro Pozzoni, Antonella d'Arminio Monforte, Elisabetta Buscarini, Angiola Spinetti, Serena Zaltron, D'Ambrosio, R, Pasulo, L, Giorgini, A, Spinetti, A, Messina, E, Fanetti, I, Puoti, M, Aghemo, A, Vigano, P, Vinci, M, Menzaghi, B, Lombardi, A, Pan, A, Pigozzi, M, Grossi, P, Lazzaroni, S, Spinelli, O, Invernizzi, P, Maggiolo, F, Terreni, N, Monforte, A, Poggio, P, Taddei, M, Colombo, S, Pozzoni, P, Molteni, C, Brocchieri, A, Bhoori, S, Buscarini, E, Centenaro, R, Mendeni, M, Colombo, A, Di Marco, M, Dionigi, E, Bella, D, Borghi, M, Zuin, M, Zaltron, S, Noventa, F, Annalisa, D, Lampertico, P, and Fagiuoli, S
- Subjects
Male ,Sustained Virologic Response ,Sofosbuvir ,Hepacivirus ,Kidney ,urologic and male genital diseases ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,MED/12 - GASTROENTEROLOGIA ,eGFR ,Aged, 80 and over ,Hepatitis C ,Middle Aged ,medicine.anatomical_structure ,Italy ,030220 oncology & carcinogenesis ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Glomerular Filtration Rate ,Cohort study ,medicine.drug ,Adult ,medicine.medical_specialty ,SVR ,Genotype ,Renal function ,CKD ,Antiviral Agents ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Renal Insufficiency, Chronic ,Aged ,Retrospective Studies ,Hepatology ,business.industry ,Ribavirin ,Retrospective cohort study ,Hepatitis C, Chronic ,medicine.disease ,Logistic Models ,chemistry ,business ,Kidney disease - Abstract
Background: Sofosbuvir (SOF)-based regimens have been associated with renal function worsening in HCV patients with estimated glomerular filtration rate (eGFR) ≤ 45 ml/min, but further investigations are lacking. Aim: To assess renal safety in a large cohort of DAA-treated HCV patients with any chronic kidney disease (CKD). Methods: All HCV patients treated with DAA in Lombardy (December 2014–November 2017) with available kidney function tests during and off-treatment were included. Results: Among 3264 patients [65% males, 67% cirrhotics, eGFR 88 (9–264) ml/min], CKD stage was 3 in 9.5% and 4/5 in 0.7%. 79% and 73% patients received SOF and RBV, respectively. During DAA, eGFR declined in CKD-1 (p < 0.0001) and CKD-2 (p = 0.0002) patients, with corresponding rates of CKD stage reduction of 25% and 8%. Conversely, eGFR improved in lower CKD stages (p < 0.0001 in CKD-3a, p = 0.0007 in CKD-3b, p = 0.024 in CKD-4/5), with 33–45% rates of CKD improvement. Changes in eGFR and CKD distribution persisted at SVR. Baseline independent predictors of CKD worsening at EOT and SVR were age (p < 0.0001), higher baseline CKD stages (p < 0.0001) and AH (p = 0.010 and p < 0.0001, respectively). Conclusions: During DAA, eGFR significantly declined in patients with preserved renal function and improved in those with lower CKD stages, without reverting upon drug discontinuation.
- Published
- 2020
- Full Text
- View/download PDF
33. Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances
- Author
-
Francesca Bai, Stefano Bonora, Davide Paolo Bernasconi, Francesco Castelli, Andrea Gori, Nicola Squillace, Giuseppe Lapadula, Emanuele Focà, Guglielmo Migliorino, Antonella d'Arminio Monforte, Alessandra Bandera, Antonio Di Biagio, Lapadula, G, Bernasconi, D, Bai, F, Foca, E, Di Biagio, A, Bonora, S, Castelli, F, Squillace, N, Bandera, A, Monforte, A, Migliorino, G, and Gori, A
- Subjects
Cyclopropanes ,Male ,antiretroviral treatment ,0301 basic medicine ,Atripla ,HIV Infections ,law.invention ,Efficacy ,Pittsburgh Sleep Quality Index ,chemistry.chemical_compound ,Cognition ,0302 clinical medicine ,Randomized controlled trial ,immune system diseases ,law ,neurotoxicity ,neurocognitive impairment ,Emtricitabine ,Immunology and Allergy ,central nervous system side effects ,030212 general & internal medicine ,Eviplera ,Complera ,efavirenz ,rilpivirine ,toxicity ,Drug Substitution ,central nervous system side effect ,virus diseases ,Middle Aged ,Viral Load ,Infectious Diseases ,Alkynes ,Rilpivirine ,RNA, Viral ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Efavirenz ,Anti-HIV Agents ,Immunology ,03 medical and health sciences ,Physical medicine and rehabilitation ,medicine ,Humans ,Tenofovir ,business.industry ,Benzoxazines ,030104 developmental biology ,chemistry ,Quality of Life ,Sleep ,business ,Neurocognitive - Abstract
Background: Efavirenz (EFV) association with neurocognitive impairment is debated. Whether switching away from EFV improves neurocognitive performances is still controversial.Methods:In a randomized open-label controlled trial, patients under effective treatment with tenofovir disoproxil-fumarate (TDF), emtricitabine (FTC) and EFV, who had altered neurocognitive assessment (z-transformed score below -1 in at least one cognitive domain), depression, anxiety or low sleep-quality, were randomized 1:1 to immediate or delayed (24-weeks) switch to TDF/FTC/rilpivirine (RPV). Treatment efficacy, neurocognitive function, symptoms and quality of life were evaluated 12, 24 and 48 weeks after randomization.Findings:Seventy-four patients were randomized to immediate (36 patients) or delayed switch (38 patients). At baseline, 63 and 25% of patients had z-scores below -1 in at least one or two neurocognitive domains, 31.1, 17.6 and 44.6% had significant depression or anxiety symptoms or low sleep quality. At week 24 (primary end-point), overall neurocognitive improvement was observed, with no statistically significant differences between arms, neither considering the global z score (between arms difference +0.1; P=0.458), nor domain-specific z scores. Patients switching away from EFV had significant greater improvement of sleep quality index (between-arm difference -1.5; P=0.011), self-reported cognitive failures (-6.2; P=0.001) and CNS symptoms score (-5; P=0.002), but not of anxiety or depression. No protocol defined virological failure, grade at least 3 lab abnormalities or drug-related serious adverse events were reported.Conclusion:Our results do not support the hypothesis that switching to RPV improves cognitive function in patient under stable treatment with EFV. Nonetheless, improvements in neuropsychiatric symptoms, sleep quality and self-perceived cognition were observed.
- Published
- 2020
- Full Text
- View/download PDF
34. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium
- Author
-
Byonanebye, Dathan M., Polizzotto, Mark N., Neesgaard, Bastian, Sarcletti, Mario, Matulionyte, Raimonda, Braun, Dominique L., Castagna, Antonella, de Wit, Stéphane, Wit, Ferdinand, Fontas, Eric, Vehreschild, J. rg Janne, Vesterbacka, Jan, Greenberg, Lauren, Hatleberg, Camilla, Garges, Harmony, Gallant, Joel, Volny Anne, Alain, Öllinger, Angela, Mozer-Lisewska, Iwona, Surial, Bernard, Spagnuolo, Vincenzo, Necsoi, Coca, van der Valk, Marc, Mocroft, Amanda, Law, Matthew, Ryom, Lene, Petoumenos, Kathy, Hillebregt, M., Rose, N., Hutchinson, J., Zangerle, R., Appoyer, H., Delforge, M., Stephan, C., Bucht, M., Chkhartishvili, N., Chokoshvili, O., Mussini, C., Borghi, V., Pradier, C., Dollet, K., Caissotti, C., Casabona, J., Miro, J. M., Smith, C., Lampe, F., Johnson, M., Burns, F., Chaloner, C., Lazzarin, A., Poli, A., Sönnerborg, A., Falconer, K., Svedhem, V., Günthard, H., Ledergerber, B., Bucher, H., Scherrer, A., Wasmuth, J. C., Rockstroh, J., Fätkenheuer, G., Stecher, M., Schulze, N., Franke, B., Rooney, J., McNicholl, I., Vannappagari, V., Wandeler, G., Lundgren, J., Kowalska, J., Raben, D., Mocroft, A., Peters, L., Williams, E. D., Necsoi, C., D’Arminio Monforte, A., Bruguera, A., Dedes, Nikos, Mendao, Luis, Larsen, J. F., Jaschinski, N., Jakobsen, M. L., Bruun, T., Bojesen, A., Hansen, E. V., Traytel, A. K., Elsing, T. W., Kristensen, D., Weide, T., Bansi-Matharu, L., Pelchen-Matthews, A., Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, APH - Digital Health, APH - Personalized Medicine, and APH - Global Health
- Subjects
Adult ,Aged, 80 and over ,HIV ,antiretroviral agents ,hypertension ,integrase inhibitors ,Adolescent ,Anti-HIV Agents ,Health Policy ,Incidence ,virus diseases ,610 Medicine & health ,HIV Infections ,Integrase Inhibitors ,Infectious Diseases ,Anti-Retroviral Agents ,Hypertension ,Humans ,Reverse Transcriptase Inhibitors ,Pharmacology (medical) ,HIV Integrase Inhibitors - Abstract
OBJECTIVE To compare the incidence of hypertension in people living with HIV receiving integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) versus non-nucleoside reverse transcriptase inhibitors (NNRTIs) or boosted protease inhibitors (PIs) in the RESPOND consortium of HIV cohorts. METHODS Eligible people with HIV were aged ���18��years who initiated a new three-drug ART regimen for the first time (baseline), did not have hypertension, and had at least two follow-up blood pressure (BP) measurements. Hypertension was defined as two consecutive systolic BP measurements ���140��mmHg and/or diastolic BP ���90��mmHg or initiation of antihypertensives. Multivariable Poisson regression was used to determine adjusted incidence rate ratios (aIRRs) of hypertension, overall and in those who were ART na��ve or experienced at baseline. RESULTS Overall, 4606 people living with HIV were eligible (INSTIs��3164, NNRTIs��807, PIs��635). The median baseline systolic BP, diastolic BP, and age were 120 (interquartile range [IQR] 113-130) mmHg, 78 (70-82) mmHg, and 43 (34-50) years, respectively. Over 8380.4 person-years (median follow-up 1.5 [IQR 1.0-2.7]��years), 1058 (23.0%) participants developed hypertension (incidence rate 126.2/1000 person-years, 95% confidence interval [CI] 118.9-134.1). Participants receiving INSTIs had a higher incidence of hypertension than those receiving NNRTIs (aIRR 1.76; 95% CI 1.47-2.11), whereas the incidence was no different in those receiving PIs (aIRR 1.07; 95% CI 0.89-1.29). The results were similar when the analysis was stratified by ART status at baseline. CONCLUSION Although unmeasured confounding and channelling bias cannot be excluded, INSTIs were associated with a higher incidence of hypertension than were NNRTIs, but rates were similar to those of PIs overall, in ART-na��ve and ART-experienced participants within RESPOND.
- Published
- 2022
- Full Text
- View/download PDF
35. Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)
- Author
-
Ilaria Mastrorosa, Roberta Gagliardini, Francesco Segala, Annalisa Mondi, Patrizia Lorenzini, Carlotta Cerva, Eleonora Taddei, Francesca Bai, Alessandra Vergori, Negri Marcantonio, Carmela Pinnetti, Stefania Cicalini, Rita Murri, Valentina Mazzotta, Marta Camici, Silvia Mosti, Teresa Bini, Gaetano Maffongelli, Alessia Beccacece, Eugenia Milozzi, Marco Iannetta, Silvia Lamonica, Marisa Fusto, Maria Maddalena Plazzi, Sandrine Ottou, Miriam Lichtner, Massimo Fantoni, Massimo Andreoni, Loredana Sarmati, Roberto Cauda, Enrico Girardi, Emanuele Nicastri, Antonella D'Arminio Monforte, Fabrizio Palmieri, Antonella Cingolani, Francesco Vaia, Andrea Antinori, and ESCAPE Study Group
- Subjects
History ,Polymers and Plastics ,Business and International Management ,Industrial and Manufacturing Engineering - Published
- 2022
- Full Text
- View/download PDF
36. Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings
- Author
-
Juan Berenguer, Christoph Wyen, M. John Gill, Sophie Abgrall, Ard van Sighem, Matthias Cavassini, Sophie Grabar, Jordi Casabona, Margaret T May, Julia del Amo, Antonella d'Arminio Monforte, Robert Zangerle, John Stover, Niels Obel, Jonathan A C Sterne, Fabrice Bonnet, Adam Trickey, Medical Research Council (Reino Unido), Department for International Development (Reino Unido), NIH - National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Estados Unidos), National Institute for Health Research (Reino Unido), Unión Europea, Agence Nationale de Recherches sur le sida et les hépatites virales (Francia), Institut National de la Santé et de la Recherche Médicale (Francia), Ministero della Salute (Italia), Ministerio de Sanidad y Consumo (España), Ministerio de Ciencia e Innovación (España), Red de Investigación Cooperativa en Investigación en Sida (España), Swiss National Science Foundation, University of Bristol [Bristol], Stichting HIV Monitoring [Amsterdam], Universiteit van Amsterdam (UvA), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Descartes - Paris 5 (UPD5), Hôpital Cochin [AP-HP], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital General Universitario 'Gregorio Marañón' [Madrid], Instituto de Investigación Sanitaria Gregorio Marañón [Madrid, Spain] ( IiSGM), University Hospital of Cologne [Cologne], Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), CIBER de Epidemiología y Salud Pública (CIBERESP), Università degli Studi di Milano = University of Milan (UNIMI), Ospedale San Paolo-Polo Universitario, ASST Santi Paolo e Carlo, Milan, Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Université de Lausanne = University of Lausanne (UNIL), Instituto de Salud Carlos III [Madrid] (ISC), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), University of Calgary, Department of Infectious Diseases [Rigshospitalet], Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, Gestionnaire, Hal Sorbonne Université, Medical Research Council (United Kingdom), Department for International Development (United Kingdom), National Institute on Alcohol Abuse and Alcoholism (United States), National Institute for Health Research (United Kingdom), European Union, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (France), Institut National de la Santé et de la Recherche Médicale (France), and Red Española de Investigación en SIDA
- Subjects
Adult ,Male ,0301 basic medicine ,Anti-HIV Agents ,[SDV]Life Sciences [q-bio] ,Immunology ,Population ,HIV Infections ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Acquired immunodeficiency syndrome (AIDS) ,Risk Factors ,death ,cause-specific ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Mortality ,education ,United Nations Programme on HIV/AIDS ,education.field_of_study ,Models, Statistical ,business.industry ,Developed Countries ,Mortality rate ,duration ,HIV ,cohort ,Middle Aged ,medicine.disease ,Confidence interval ,3. Good health ,AIDS ,[SDV] Life Sciences [q-bio] ,Europe ,Anti-HIV Agents/therapeutic use ,Europe/epidemiology ,Female ,HIV Infections/drug therapy ,HIV Infections/mortality ,Mortality/trends ,Editorial ,030104 developmental biology ,Infectious Diseases ,Cohort ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,business ,Developed country ,Demography ,Cohort study - Abstract
Supplemental Digital Content is available in the text, Introduction: HIV cohort data from high-income European countries were compared with the UNAIDS Spectrum modelling parameters for these same countries to validate mortality rates and excess mortality estimates for people living with HIV (PLHIV) on antiretroviral therapy (ART). Methods: Data from 2000 to 2015 were analysed from the Antiretroviral Therapy Cohort Collaboration (ART-CC) for Austria, Denmark, France, Italy, the Netherlands, Spain, and Switzerland. Flexible parametric models were used to compare all-cause mortality rates in the ART-CC and Spectrum. The percentage of AIDS-related deaths and excess mortality (both are the same within Spectrum) were compared, with excess mortality defined as that in excess of the general population mortality. Results: Analyses included 94 026 PLHIV with 585 784 person-years of follow-up, from which there were 5515 deaths. All-cause annual mortality rates in Spectrum for 2000–2003 were 0.0121, reducing to 0.0078 in 2012–2015, whilst the ART-CC's corresponding annual mortality rates were 0.0151 [95% confidence interval (95% CI): 0.0130–0.0171] reducing to 0.0049 (95% CI: 0.0039–0.0060). The percentage of AIDS-related deaths in Spectrum was 74.7% in 2000–2003, dropping to 43.6% in 2012–2015. In the ART-CC, AIDS-related mortality constitutes 45.3% (95% CI: 38.4–52.9%) of mortality in 2000–2003 and 26.7% (95% CI: 19–46%) between 2012 and 2015. Excess mortality in the ART-CC was broadly similar to the Spectrum estimates, dropping from 75.3% (95% CI: 60.3–95.2%) in 2000–2003 to 30.7% (95% CI: 25.5–63.7%) in 2012–2015. Conclusion: All-cause mortality assumptions for PLHIV on ART in high-income European settings should be adjusted in Spectrum to be higher in 2000–2003 and decline more quickly to levels currently captured for recent years.
- Published
- 2019
- Full Text
- View/download PDF
37. Reorienting health systems to care for people with HIV beyond viral suppression
- Author
-
Georg M. N. Behrens, Udi Davidovich, Jeffrey V. Lazarus, Kelly Safreed-Harmon, Natasha Azzopardi-Muscat, Teymur Noori, Meaghan Kall, Jane Anderson, Julia del Amo, Antonella d'Arminio Monforte, and Kholoud Porter
- Subjects
0301 basic medicine ,Gerontology ,Civil society ,Epidemiology ,Service delivery framework ,Immunology ,Human immunodeficiency virus (HIV) ,HIV Infections ,Context (language use) ,Comorbidity ,medicine.disease_cause ,03 medical and health sciences ,Life Expectancy ,0302 clinical medicine ,Quality of life (healthcare) ,Virology ,medicine ,Humans ,030212 general & internal medicine ,Viral suppression ,Delivery of Health Care, Integrated ,business.industry ,Health services research ,Continuity of Patient Care ,Viral Load ,030112 virology ,Infectious Diseases ,Quality of Life ,Life expectancy ,Health Services Research ,business - Abstract
The effectiveness of antiretroviral therapy and its increasing availability globally means that millions of people living with HIV now have a much longer life expectancy. However, people living with HIV have disproportionately high incidence of major comorbidities and reduced health-related quality of life. Health systems must respond to this situation by pioneering care and service delivery models that promote wellness rather than mere survival. In this Series paper, we review evidence about the emerging challenges of the care of people with HIV beyond viral suppression and identify four priority areas for action: integrating HIV services and non-HIV services, reducing HIV-related discrimination in health-care settings, identifying indicators to monitor health systems' progress toward new goals, and catalysing new forms of civil society engagement in the more broadly focused HIV response that is now needed worldwide. Furthermore, in the context of an increasing burden of chronic diseases, we must consider the shift that is underway in the HIV field in relation to burgeoning policy and programmatic efforts to promote healthy ageing.
- Published
- 2019
- Full Text
- View/download PDF
38. In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy
- Author
-
Salpini, R, D’Anna, S, Alkhatib, M, Piermatteo, L, Tavelli, A, Quiros-Roldan, E, Cingolani, A, Papalini, C, Carrara, S, Puoti, M, Sarmati, L, d’Arminio Monforte, A, Ceccherini-Silberstein, A, Perno, C, and Svicher, V
- Subjects
Hepatology ,Settore MED/06 - Published
- 2022
- Full Text
- View/download PDF
39. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium
- Author
-
Coca Valentina Necsoi, Lauren Greenberg, Claudine Duvivier, Matthew Law, Katharina Grabmeier-Pfistershammer, Nikos Dedes, Jörg J. Vehreschild, Camilla Muccini, Jan-Christian Wasmuth, Antonella d'Arminio Monforte, Andrew N. Phillips, Gordana Dragovic, Jens D Lundgren, Eric Fontas, Andreas Knudsen, Jan Vesterbacka, Dominique L Braun, Christoph Stephan, Mario Sarcletti, Lene Ryom, Jennifer F Hoy, Huldrych F. Günthard, Nikoloz Chkhartishvili, Vani Vannappagari, Lars Peters, Bastian Neesgaard, Amanda Mocroft, Daniel Elbirt, Josep M. Llibre, Colette Smith, Giovanni Guaraldi, José M. Miró, Cristina Mussini, Stéphane De Wit, Antonella Castagna, Ferdinand W. N. M. Wit, Cristiana Oprea, Joel E. Gallant, Natalie Bolokadze, Loveleen Bansi-Matharu, Ole Kirk, Bansi-Matharu, L., Phillips, A., Oprea, C., Grabmeier-Pfistershammer, K., Gunthard, H. F., De Wit, S., Guaraldi, G., Vehreschild, J. J., Wit, F., Law, M., Wasmuth, J. -C., Chkhartishvili, N., d'Arminio Monforte, A., Fontas, E., Vesterbacka, J., Miro, J. M., Castagna, A., Stephan, C., Llibre, J. M., Neesgaard, B., Greenberg, L., Smith, C., Kirk, O., Duvivier, C., Dragovic, G., Lundgren, J., Dedes, N., Knudsen, A., Gallant, J., Vannappagari, V., Peters, L., Elbirt, D., Sarcletti, M., Braun, D. L., Necsoi, C., Mussini, C., Muccini, C., Bolokadze, N., Hoy, J., Mocroft, A., and Ryom, L.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Epidemiology ,Immunology ,HIV Infections ,Weight Gain ,Tenofovir alafenamide ,Body Mass Index ,Cohort Studies ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Virology ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Prospective Studies ,Prospective cohort study ,0303 health sciences ,030306 microbiology ,business.industry ,Australia ,Lamivudine ,Middle Aged ,Raltegravir ,medicine.disease ,3. Good health ,Europe ,Infectious Diseases ,chemistry ,Anti-Retroviral Agents ,Cohort ,Dolutegravir ,HIV-1 ,Female ,business ,medicine.drug ,Cohort study - Abstract
Background Weight gain effects of individual antiretroviral drugs are not fully understood. We investigated associations between a prespecified clinically significant increase (>7%) in body-mass index (BMI) and contemporary antiretroviral use. Methods The International Cohort Consortium of Infectious Diseases (RESPOND) is a prospective, multicohort collaboration, including data from 17 well established cohorts and over 29 000 people living with HIV. People with HIV under prospective follow-up from Jan 1, 2012, and older than 18 years were eligible for inclusion. Each cohort contributed a predefined minimum number of participants related to the size of the specific cohort (with a minimum of 1000 participants). Participants were required to have CD4 cell counts and HIV viral load measurement in the 12 months before or within 3 months after baseline. For all antiretroviral drugs received at or after RESPOND entry, changes from pre-antiretroviral BMI levels (baseline) were considered at each BMI measurement during antiretroviral treatment. We used logistic regression to identify individual antiretrovirals that were associated with first occurrence of a more than 7% increase in BMI from pre-antiretroviral BMI. We adjusted analyses for time on antiretrovirals, pre-antiretroviral BMI, demographics, geographical region, CD4 cell count, viral load, smoking status, and AIDS at baseline. Findings 14 703 people were included in this study, of whom 7863 (53middot5%) had a more than 7% increase in BMI. Compared with lamivudine, use of dolutegravir (odds ratio [OR] 1middot27, 95% CI 1middot17-1middot38), raltegravir (1middot37, 1middot20-1middot56), and tenofovir alafenamide (1middot38, 1middot22-1middot35) was significantly associated with a more than 7% BMI increase, as was low pre-antiretroviral BMI (2middot10, 1middot91-2middot31 for underweight vs healthy weight) and Black ethnicity (1middot61, 1middot47-1middot76 vs White ethnicity). Higher CD4 count was associated with a reduced risk of BMI increase (0middot97, 0middot96-0middot98 per 100 cells per mu L increase). Relative to lamivudine, dolutegravir without tenofovir alafenamide (OR 1middot21, 95% CI 1middot19-1middot32) and tenofovir alafenamide without dolutegravir (1middot33, 1middot15-1middot53) remained independently associated with a more than 7% increase in BMI; the associations were higher when dolutegravir and tenofovir alafenamide were used concomitantly (1middot79, 1middot52-2middot11, and 1middot70, 1middot44-2middot01, respectively). Interpretation Clinicians and people with HIV should be aware of associations between weight gain and use of dolutegravir, tenofovir alafenamide, and raltegravir, particularly given the potential consequences of weight gain, such as insulin resistance, dyslipidaemia, and hypertension. Funding The CHU St Pierre Brussels HIV Cohort, The Austrian HIV Cohort Study, The Australian HIV Observational Database, The AIDS Therapy Evaluation in the Netherlands national observational HIV cohort, The EuroSIDA cohort, The Frankfurt HIV Cohort Study, The Georgian National AIDS Health Information System, The Nice HIV Cohort, The ICONA Foundation, The Modena HIV Cohort, The PISCIS Cohort Study, The Swiss HIV Cohort Study, The Swedish InfCare HIV Cohort, The Royal Free HIV Cohort Study, The San Raffaele Scientific Institute, The University Hospital Bonn HIV Cohort and The University of Cologne HIV Cohorts, ViiV Healthcare, and Gilead Sciences. Copyright (c) 2021 Elsevier Ltd. All rights reserved.
- Published
- 2021
- Full Text
- View/download PDF
40. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART
- Author
-
Squillace, Nicola, Lorenzini, Patrizia, Lapadula, Giuseppe, Bandera, Alessandra, Cozzi Lepri, Alessandro, Rusconi, Stefano, Puoti, Massimo, Castagna, Antonella, Antinori, Andrea, Gori, Andrea, D'arminio Monforte, Antonella, Moroni M, Andreoni M, Angarano G, Antinori A, D'arminio Monforte A, Castelli F, Cauda R, Di Perri G, Galli M, Iardino R, Ippolito G, Lazzarin A, Perno Cf, Von Schloesser F, Viale P, Castagna A, Ceccherini-silberstein F, Cozzi-lepri A, Girardi E, Lo Caputo S, Mussini C, Puoti M, Ammassari A, Balotta C, Bonfanti P, Bonora S, Borderi M, Capobianchi Mr, Cingolani A, Cinque P, De Luca A, Di Biagio A, Gianotti N, Gori A, Guaraldi G, Lapadula G, Lichtner M, Madeddu G, Maggiolo F, Marchetti G, Marcotullio S, Monno L, Quiros Roldan E, Rusconi S, Saracino A, Cicconi P, Fanti I, Galli L, Lorenzini P, Rodano A, Shanyinda M, Tavelli A, Giacometti A, Costantini A, Mazzoccato S, Santoro C, Suardi C, Vanino E, Verucchi G, Minardi C, Quirino T, Abeli C, Manconi Pe, Piano P, Vecchiet J, Falasca K, Sighinolfi L, Segala D, Mazzotta F, Cassola G, Viscoli C, Alessandrini A, Piscopo R, Mazzarello G, Mastroianni C, Belvisi V, Caramma I, Chiodera A, Castelli Ap, Rizzardini G, Ridolfo Al, Piolini R, Salpietro S, Carenzi L, Moioli Mc, Tincati C, Puzzolante C, Abrescia N, Chirianni A, Borgia G, Guida Mg, Gargiulo M, Gentile I, Orlando R, Baldelli F, Francisci D, Parruti G, Ursini T, Magnani G, Ursitti Ma, Vullo V, D'avino A, Gallo L, Nicastri E, Acinapura R, Capozzi M, Libertone R, Tebano G, Zaccarelli M, Viviani F, Sasset L, Mura Ms, Rossetti B, Caramello P, Orofino Gc, Sciandra M, Bassetti M, Londero A, Pellizzer G, Manfrin V., Squillace, Nicola, Lorenzini, Patrizia, Lapadula, Giuseppe, Bandera, Alessandra, Cozzi lepri, Alessandro, Rusconi, Stefano, Puoti, Massimo, Castagna, Antonella, Antinori, Andrea, Gori, Andrea, D'arminio Monforte, Antonella, Squillace, N, Lorenzini, P, Lapadula, G, Bandera, A, Cozzi-Lepri, A, Rusconi, S, Puoti, M, Castagna, A, Antinori, A, Gori, A, d'Arminio Monforte, A, Cozzi Lepri, Alessandro, Moroni, M, Andreoni, M, Angarano, G, D'arminio Monforte, A, Castelli, F, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Perno, Cf, Von Schloesser, F, Viale, P, Ceccherini-silberstein, F, Cozzi-lepri, A, Girardi, E, Lo Caputo, S, Mussini, C, Ammassari, A, Balotta, C, Bonfanti, P, Bonora, S, Borderi, M, Capobianchi, Mr, Cingolani, A, Cinque, P, De Luca, A, Di Biagio, A, Gianotti, N, Guaraldi, G, Lichtner, M, Madeddu, G, Maggiolo, F, Marchetti, G, Marcotullio, S, Monno, L, Quiros Roldan, E, Saracino, A, Cicconi, P, Fanti, I, Galli, L, Rodano, A, Shanyinda, M, Tavelli, A, Giacometti, A, Costantini, A, Mazzoccato, S, Santoro, C, Suardi, C, Vanino, E, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, Pe, Piano, P, Vecchiet, J, Falasca, K, Sighinolfi, L, Segala, D, Mazzotta, F, Cassola, G, Viscoli, C, Alessandrini, A, Piscopo, R, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Chiodera, A, Castelli, Ap, Rizzardini, G, Ridolfo, Al, Piolini, R, Salpietro, S, Carenzi, L, Moioli, Mc, Tincati, C, Puzzolante, C, Abrescia, N, Chirianni, A, Borgia, G, Guida, Mg, Gargiulo, M, Gentile, I, Orlando, R, Baldelli, F, Francisci, D, Parruti, G, Ursini, T, Magnani, G, Ursitti, Ma, Vullo, V, D'Avino, A, Gallo, L, Nicastri, E, Acinapura, R, Capozzi, M, Libertone, R, Tebano, G, Zaccarelli, M, Viviani, F, Sasset, L, Mura, M, Rossetti, B, Caramello, P, Orofino, Gc, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, and Manfrin, V.
- Subjects
Liver Cirrhosis ,Male ,0301 basic medicine ,HIV Infections ,Adult ,Anti-Retroviral Agents ,Antiretroviral Therapy, Highly Active ,Diabetes Mellitus ,Female ,Hepatitis C Antibodies ,Humans ,Lipoproteins, HDL ,Middle Aged ,Retrospective Studies ,Risk Assessment ,Triglycerides ,Triglyceride ,Gastroenterology ,chemistry.chemical_compound ,0302 clinical medicine ,High-density lipoprotein ,Retrospective Studie ,HIV Infection ,Pharmacology (medical) ,030212 general & internal medicine ,individual ,hiv-infected patient ,dysfunction ,Diabetes Mellitu ,cohort ,high-density-lipoprotein ,c virus-infection ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Not available ,Infectious Diseases ,Cohort ,symbols ,Human ,Microbiology (medical) ,medicine.medical_specialty ,HDL ,Lipoproteins ,Liver Cirrhosi ,Antiretroviral Therapy ,insulin-resistance ,NO ,03 medical and health sciences ,symbols.namesake ,Insulin resistance ,Diabetes mellitus ,Internal medicine ,medicine ,Highly Active ,Poisson regression ,Risk factor ,Pharmacology ,business.industry ,association ,cholesterol ,Retrospective cohort study ,medicine.disease ,030104 developmental biology ,Endocrinology ,chemistry ,Relative risk ,Anti-Retroviral Agent ,Hepatitis C Antibodie ,business - Abstract
Objectives Our primary aim was to study diabetes mellitus (DM) arising during combination ART (cART) and to attempt to identify associations between these cases and triglycerides (TRG) and the TRG to HDL-cholesterol (TRG/HDL) ratio. Our secondary aim was to analyse the association between DM development and hepatic fibrosis. Methods This was a retrospective cohort study. Patients from the Icona Foundation study initiating first-line cART between 1997 and 2013 were selected and observed until new-onset DM or most recent clinical follow-up. The predictive value of TRG and TRG/HDL ratio levels on DM was evaluated using multivariable Poisson regression models. Results Three-thousand, five-hundred and forty-six patients (males, 73.7%; median age, 38 years; median BMI, 23.1 kg/m2; and hepatitis C virus antibody positive, 22.1%) were included. Of these, 80 developed DM over 13 911 person-years of follow-up (PYFU), corresponding to 5.7 cases per 1000 PYFU (95% CI = 4.6–7.1). At multivariable analysis, latest TRG/HDL ratio, when high, was associated with significant increases in DM risk [relative risk (RR) = 1.63; 95% CI = 1.32–2.01 per 10 points higher], while current TRG, in contrast, was associated with new-onset DM only at crude analysis. Advanced liver fibrosis (defined as fibrosis-4 index >3.25) was also shown to be an independent risk factor for DM (RR = 2.91; 95% CI = 1.10–7.72). Conclusions High TRG/HDL ratio predicted risk of new-onset DM, independently of other traditional risk factors. Furthermore, our findings suggest that advanced hepatic fibrosis, estimated using the fibrosis-4 score, could provide an additional predictor for DM.
- Published
- 2016
- Full Text
- View/download PDF
41. Neurology of COVID-19
- Author
-
Daniele Velardo, Sara Meoni, Valeria Isella, Nicolaja Girone, Delfina Tosi, Alessandro Innocenti, Orsola Gambini, Francesca Bai, Maria Paola Canevini, Chiara Manfredi, Roberta Ferrucci, Tommaso Bocci, Gaetano Bulfamante, Carlo Ferrarese, Paola Alberti, Beatrice Benatti, Laura Campiglio, Alessandro Padovani, Alessandro Pezzini, Gemma Tumminelli, Alberto Benussi, Elio Clemente Agostoni, Veronica Nisticò, Giulia Michela Pellegrino, Maria Donata Benedetti, Vincenzo Silani, Giacomo P. Comi, Simone Beretta, Gianluca Costamagna, Laura Bertolasi, Valentina Chiesa, Andrea Pilotto, Chiara Vannicola, Giuseppe Francesco Sferrazza Papa, Luca Valvassori, Fabrizio Luiso, Michelangelo Dini, Valentina Toto, Carla Uggetti, Alberto Priori, Elena Moro, Davide Chiumello, Stefano Centanni, Giulia Marchetti, Francesca Lanzani, Benedetta Demartini, Emma Scelzo, Matteo Bonifazi, Laura Carpenito, Laura Brighina, Ilaria Viganò, Marco Scarabello, Roberta Rovito, Antonella d'Arminio Monforte, Angelo Cascio Rizzo, Elisabetta De Bernardi, Giuditta Giussani, and Bernardo Dell'Osso
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Direct response ,medicine ,Psychiatry ,Cognitive impairment ,European region ,business ,Subject matter - Abstract
The authors will present a comprehensive account of the neurological aspects of SARS-CoV-2 infection. The aim is to provide a practical clinical book which will serve as a guide for clinicians from all specialties involved in the management of COVID-19 patients. The authors share the extensive clinical experience gained in major hospitals in Lombardy, the first European region to face the COVID-19 emergency in 2020. All are recognized international experts in their respective fields and have been involved in the management of COVID-19 cases from the very beginning of the Italian SARS-CoV-2 outbreak. The text begins with a description of pathobiological and pathophysiological aspects related to the involvement of the nervous system, moving on to the discussion of the neurological complications observed in COVID-19 patients; these range from central to peripheral symptoms, and can occur in the acute or post-acute phases of the disease. Further topics are: neuropathology, seizures and EEG, neuroimaging, delirium, encephalomyelitis, stroke, psychopathology and psychiatry, neuropsychology and cognitive impairment, neuromuscu-lar disorders, and the impact of COVID-19 on other pre-existing neurological disorders. In addi-tion, the book will discuss the new developments in teleneurology approaches, which have been a direct response to the ongoing pandemic. Finally, the possible neurological complications of the COVID-19 vaccines and the neurological complications in children will be considered.Each chapter will present a critical review of the existing literature concerning the specific subject matter, followed by practical clinical recommendations, as well as personal considerations based on the experience gained by each author during the course of the COVID-19 pandemic.Neurology of COVID-19 will be an original and innovative reference book for clinicians of all the specialties involved in the management of patients with SARS-CoV-2 infection. ________________________________________________ List of chapters ________________________________________________
- Published
- 2021
- Full Text
- View/download PDF
42. Persistence of High Percentage of Peripheral Activated CD8+ T Cells Predict Cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects
- Author
-
Debora, Mondatore, Francesca, Bai, Matteo, Augello, Marco, Giovenzana, Andrea, Pisani Ceretti, Valeria, Bono, Enrico, Opocher, Antonella, d'Arminio Monforte, Giulia Carla, Marchetti, and Camilla, Tincati
- Abstract
People with HIV are at increased risk of human papillomavirus (HPV) disease progression, given the persistence of immune activation and residual inflammation despite effective combination antiretroviral therapy (cART). Whether a low CD4:CD8 T-cell ratio, known to mirror peripheral immune dysfunction, is associated with squamous intraepithelial lesions (SILs) is unknown.This was a retrospective cohort study on cART-treated HIV-positive subjects undergoing screening for HPV-related dysplasia (anal/cervical cytology and HPV genotyping). SIL was defined as the presence of either atypical squamous cells of undetermined significance (ASCUS), low-grade SILs, or high-grade SILs. Demographic and viro-immunological parameters (T-cell count, CD4:CD8 T-cell ratio, CD8+ CD38+ T-cell percentage) at the time of screening were analyzed by the chi-square test, Mann-Whitney test, and multivariate logistic regression analysis.A total of 419 cART-treated subjects were included. Half of the patients had cervical/anal SIL. Individuals with SIL were more commonly males, were men who have sex with men, were coinfected withHPV infection is the major driver of dysplasia in the setting of HIV infection. In this study, CD8+ CD38+ T cells were an independent predictor of dysplasia in cART-treated subjects, while CD4:CD8 T-cell ratio was not. In the setting of HIV-HPV coinfection, CD4:CD8 T-cell ratio may not fully capture the alterations of HPV-specific immunity.
- Published
- 2021
43. Monkeypox epidemic in prisons: How to prevent it?
- Author
-
Cocco, N., Sebastiani, T., Giuliani, R., Cereda, D., D'Arminio Monforte, A., Tavoschi, L., and Ranieri, R.
- Subjects
Oncology ,Health Policy ,Internal Medicine - Published
- 2022
- Full Text
- View/download PDF
44. Management of Chronic Hepatitis B in HIV-Coinfected Patients
- Author
-
Massimo Fasano, Maria Cristina Poliseno, Josè Ramon Fiore, Sergio Lo Caputo, Antonella D’Arminio Monforte, and Teresa Antonia Santantonio
- Subjects
Hepatitis B virus ,Hepatitis B, Chronic ,Infectious Diseases ,Anti-HIV Agents ,Coinfection ,Virology ,Liver Neoplasms ,Humans ,HIV Infections ,Antiviral Agents - Abstract
Hepatitis B virus infection occurs in approximately 7% of people living with HIV (PLWH), with substantial regional variation and higher prevalence among intravenous drug users. Early studies on the natural history of HIV/HBV coinfection demonstrated that in coinfected patients, chronic hepatitis B (CHB) has a more rapid progression than in HBV-monoinfected patients, leading to end-stage liver disease complications, including hepatocellular carcinoma. Therefore, the adequate management of CHB is considered a priority in HIV-coinfected patients. Several guidelines have highlighted this issue and have provided recommendations for preventing and treating HBV infection. This article discusses the management of liver disease in patients with HIV/HBV coinfection and summarizes the current and future therapeutic options for treating chronic hepatitis B in this setting.
- Published
- 2022
- Full Text
- View/download PDF
45. Hepatitis Delta in HIV: changes in attitude to testing and disease burden over time
- Author
-
G. Brancaccio, M. Shanyinde, M. Puoti, Giovanni B. Gaeta, A. D'Arminio Monforte, A. Vergori, S. Rusconi, A. Mazzarelli, A. Castagna, A. Antinori, and A. Cozzi-Lepri
- Subjects
Hepatology ,Gastroenterology - Published
- 2022
- Full Text
- View/download PDF
46. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy
- Author
-
Saracino, Annalisa, Zaccarelli, Mauro, Lorenzini, Patrizia, Bandera, Alessandra, Marchetti, Giulia, Castelli, Francesco, Gori, Andrea, Girardi, Enrico, Mussini, Cristina, Bonfanti, Paolo, Ammassari, Adriana, D'Arminio Monforte, Antonella, Moroni, M., Andreoni, M., Angarano, G., Antinori, A., D'Arminio Monforte, A., Castelli, F., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., Von Schloesser, F., Viale, P., Castagna, A., Ceccherini-Silberstein, F., Cozzi-Lepri, A., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bonfanti, P., Bonora, S., Borderi, M., Capobianchi, M. R., Cingolani, A., Cinque, P., De Luca, A., Di Biagio, A., Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Maggiolo, F., Marchetti, G., Marcotullio, S., Monno, L., Quiros Roldan, E., Rusconi, S., Saracino, A., Cicconi, P., Fanti, I., Galli, L., Lorenzini, P., Shanyinda, M., Tavelli, A., Giacometti, A., Costantini, A., Mazzoccato, S., Santoro, C., Suardi, C., Vanino, E., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Cassola, G., Viscoli, C., Alessandrini, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Guida, M. G., Gargiulo, M., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Vullo, V., D'Avino, A., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Tebano, G., Zaccarelli, M., Viviani, F., Sasset, L., Mura, M. S., Rossetti, B., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Saracino, A., Zaccarelli, M., Lorenzini, P., Bandera, A., Marchetti, G., Castelli, F., Gori, A., Girardi, E., Mussini, C., Bonfanti, P., Ammassari, A., D'Arminio Monforte, A., Moroni, M., Andreoni, M., Angarano, G., Antinori, A., Cauda, R., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, C. F., Von Schloesser, F., Viale, P., Castagna, A., Ceccherini-Silberstein, F., Cozzi-Lepri, A., Lo Caputo, S., Puoti, M., Balotta, C., Bonora, S., Borderi, M., Capobianchi, M. R., Cingolani, A., Cinque, P., De Luca, A., Di Biagio, A., Gianotti, N., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Maggiolo, F., Marcotullio, S., Monno, L., Quiros Roldan, E., Rusconi, S., Cicconi, P., Fanti, I., Galli, L., Shanyinda, M., Tavelli, A., Giacometti, A., Costantini, A., Mazzoccato, S., Santoro, C., Suardi, C., Vanino, E., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Mazzotta, F., Cassola, G., Viscoli, C., Alessandrini, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, A. P., Rizzardini, G., Ridolfo, A. L., Piolini, R., Salpietro, S., Carenzi, L., Moioli, M. C., Tincati, C., Puzzolante, C., Abrescia, N., Chirianni, A., Borgia, G., Guida, M. G., Gargiulo, M., Gentile, I., Orlando, R., Baldelli, F., Francisci, D., Parruti, G., Ursini, T., Magnani, G., Ursitti, M. A., Vullo, V., D'Avino, A., Gallo, L., Nicastri, E., Acinapura, R., Capozzi, M., Libertone, R., Tebano, G., Viviani, F., Sasset, L., Mura, M. S., Rossetti, B., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Saracino, A, Zaccarelli, M, Lorenzini, P, Bandera, A, Marchetti, G, Castelli, F, Gori, A, Girardi, E, Mussini, C, Bonfanti, P, Ammassari, A, D'Arminio Monforte, A, Moroni, M, Andreoni, M, Angarano, G, Antinori, A, Cauda, R, Di Perri, G, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, Perno, C, Von Schloesser, F, Viale, P, Castagna, A, Ceccherini-Silberstein, F, Cozzi-Lepri, A, Lo Caputo, S, Puoti, M, Balotta, C, Bonora, S, Borderi, M, Capobianchi, M, Cingolani, A, Cinque, P, De Luca, A, Di Biagio, A, Gianotti, N, Guaraldi, G, Lapadula, G, Lichtner, M, Madeddu, G, Maggiolo, F, Marcotullio, S, Monno, L, Quiros Roldan, E, Rusconi, S, Cicconi, P, Fanti, I, Galli, L, Shanyinda, M, Tavelli, A, Giacometti, A, Costantini, A, Mazzoccato, S, Santoro, C, Suardi, C, Vanino, E, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, P, Piano, P, Vecchiet, J, Falasca, K, Sighinolfi, L, Segala, D, Mazzotta, F, Cassola, G, Viscoli, C, Alessandrini, A, Piscopo, R, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Chiodera, A, Castelli, A, Rizzardini, G, Ridolfo, A, Piolini, R, Salpietro, S, Carenzi, L, Moioli, M, Tincati, C, Puzzolante, C, Abrescia, N, Chirianni, A, Borgia, G, Guida, M, Gargiulo, M, Gentile, I, Orlando, R, Baldelli, F, Francisci, D, Parruti, G, Ursini, T, Magnani, G, Ursitti, M, Vullo, V, D'Avino, A, Gallo, L, Nicastri, E, Acinapura, R, Capozzi, M, Libertone, R, Tebano, G, Viviani, F, Sasset, L, Mura, M, Rossetti, B, Caramello, P, Orofino, G, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Bandera, Alessandra, Perno, C.F., Capobianchi, M.R., Manconi, P.E., Castelli, A.P., Ridolfo, A.L., Moioli, M.C., Guida, M.G., Ursitti, M.A., Mura, M.S., Orofino, G.C., and on behalf of the Icona Foundation Study, Group
- Subjects
Male ,0301 basic medicine ,Social Determinants of Health ,HIV Infections ,Socioeconomic Factor ,Health Services Accessibility ,Social determinant ,Men who have sex with men ,Cohort Studies ,0302 clinical medicine ,Risk Factors ,Universal Health Insurance ,Epidemiology ,Medicine ,HIV Infection ,030212 general & internal medicine ,lcsh:Public aspects of medicine ,Middle Aged ,Antiretroviral therapy ,Treatment Outcome ,Anti-Retroviral Agents ,Italy ,Antiretroviral therapy, HIV, ICONA, Social determinants ,Cohort ,HIV ,ICONA ,Social determinants ,Public Health, Environmental and Occupational Health ,Female ,Public Health ,Human ,Research Article ,Cohort study ,Adult ,medicine.medical_specialty ,NO ,03 medical and health sciences ,Humans ,Social determinants of health ,Risk factor ,business.industry ,Risk Factor ,Environmental and Occupational Health ,antiretroviral therapy ,hiv ,icona ,social determinants ,public health ,environmental and occupational health ,lcsh:RA1-1270 ,030112 virology ,Discontinuation ,Regimen ,Socioeconomic Factors ,Anti-Retroviral Agent ,Cohort Studie ,business ,Demography - Abstract
Background: Social determinants are known to be a driving force of health inequalities, even in high income countries. Aim of our study was to determine if these factors can limit antiretroviral therapy (ART) access, outcome and retention in care of people living with HIV (PLHIV) in Italy. Methods: All ART naïve HIV+ patients (pts) of Italian nationality enrolled in the ICONA Cohort from 2002 to 2016 were included. The association of socio-demographic characteristics (age, sex, risk factor for HIV infection, educational level, occupational status and residency area) with time to: ART initiation (from the first positive anti-HIV test), ART regimen discontinuation, and first HIV-RNA < 50 cp/mL, were evaluated by Cox regression analysis, Kaplan Meier method and log-rank test. Results: A total of 8023 HIV+ pts (82% males, median age at first pos anti-HIV test 36 years, IQR: 29-44) were included: 6214 (77.5%) started ART during the study period. Women, people who inject drugs (PWID) and residents in Southern Italy presented the lowest levels of education and the highest rate of unemployment compared to other groups. Females, pts aged > 50 yrs., unemployed vs employed, and people with lower educational levels presented the lowest CD4 count at ART initiation compared to other groups. The overall median time to ART initiation was 0.6 years (yrs) (IQR 0.1-3.7), with a significant decrease over time [2002-2006 = 3.3 yrs. (0.2-9.4); 2007-2011 = 1.0 yrs. (0.1-3.9); 2012-2016 = 0.2 yrs. (0.1-2.1), p < 0.001]. By multivariate analysis, females (p < 0.01) and PWID (p < 0.001), presented a longer time to ART initiation, while older people (p < 0.001), people with higher educational levels (p < 0.001), unemployed (p = 0.02) and students (p < 0.001) were more likely to initiate ART. Moreover, PWID, unemployed vs stable employed, and pts. with lower educational levels showed a lower 1-year probability of achieving HIV-RNA suppression, while females, older patients, men who have sex with men (MSM), unemployed had higher 1-year risk of first-line ART discontinuation. Conclusions: Despite median time to ART start decreased from 2002 to 2016, socio-demographic factors still contribute to disparities in ART initiation, outcome and durability.
- Published
- 2018
- Full Text
- View/download PDF
47. Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy - The CHILI study
- Author
-
Paola Rodari, Francesca Tamarozzi, Stefano Tais, Monica Degani, Francesca Perandin, Dora Buonfrate, Emanuele Nicastri, Luciana Lepore, Maria Letizia Giancola, Stefania Carrara, Alessandro Tavelli, Alessandro Cozzi-Lepri, Antonella D'Arminio Monforte, Ronaldo Silva, and Andrea Angheben
- Subjects
Settore MED/17 - Malattie Infettive ,opportunistic infection ,Trypanosoma cruzi ,Public Health, Environmental and Occupational Health ,Emigrants and Immigrants ,HIV Infections ,migrants ,Infectious Diseases ,Cross-Sectional Studies ,Latin America ,Italy ,Chagas disease ,HIV/AIDS ,Strongyloides stercoralis ,Prevalence ,Strongyloidiasis ,Humans ,Chagas Disease - Abstract
Screening HIV-positive migrants for neglected tropical diseases having potential for life-threatening reactivation, such as Chagas disease and strongyloidiasis is not widely implemented. We evaluated the prevalence of these infections among a large cohort of HIV-infected migrants from Latin America living in Italy.Cross-sectional study evaluating the prevalence of Trypanosoma cruzi and Strongyloides stercoralis infections in HIV-infected migrants from Latin America enrolled in the Italian Cohort of Antiretroviral-Naïve patients (ICONA) between 1997 and 2018, based on serology performed on sera stored in the ICONA Foundation biobank. Screening for Chagas disease was performed using two commercial ELISA complemented by commercial Immunoblot and CLIA if discordant. Strongyloidiasis was evaluated using a commercial ELISA.389 patients were analysed. Fifteen (3.86%) had at least one positive Chagas ELISA test. Prevalence of Chagas disease was 0.5% or 1.29% depending on the confirmatory technique. Serology for strongyloidiasis was positive in 16 (4.11%) patients. Only Nadir CD4The accuracy of seroassays for Chagas disease and strongyloidiasis in HIV-positive patients is unclear. To avoid missing potentially life-threatening infections, we suggest implementing additional diagnostic strategies in at-risk patients with inconclusive serology results.
- Published
- 2021
48. Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study
- Author
-
Caterina Biassoni, Lodovica Battaglioli, Andrea Renzelli, Antonella d'Arminio Monforte, Andrea Cona, Lidia Gazzola, Ottavia Viganò, Giulia Marchetti, Alessandro Tavelli, Francesca Bai, Daniele Tesoro, Teresa Bini, Marina Allegrini, Benedetta Varisco, and Alessandro Za
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Multivariate analysis ,Coronavirus disease 2019 (COVID-19) ,bloodstream infections ,corticosteroid therapy ,RM1-950 ,Biochemistry ,Microbiology ,Article ,Internal medicine ,Epidemiology ,medicine ,bacterial super-infections ,Pharmacology (medical) ,In patient ,General Pharmacology, Toxicology and Pharmaceutics ,Prospective cohort study ,business.industry ,Incidence (epidemiology) ,COVID-19 ,bacterial infections and mycoses ,antimicrobial stewardship ,Infectious Diseases ,Corticosteroid therapy ,Therapeutics. Pharmacology ,business ,human activities ,Cohort study - Abstract
With the aim of describing the burden and epidemiology of community-acquired/healthcare-associated and hospital-acquired bloodstream infections (CA/HCA-BSIs and HA-BSIs) in patients hospitalised with COVID-19, and evaluating the risk factors for BSIs and their relative impact on mortality, an observational cohort study was performed on patients hospitalised with COVID-19 at San Paolo Hospital in Milan, Italy from 24 February to 30 November 2020. Among 1351 consecutive patients hospitalised with COVID-19, 18 (1.3%) had CA/HCA-BSI and 51 (3.8%) HA-BSI for a total of 82 episodes of BSI. The overall incidence of HA-BSI was 3.3/1000 patient-days (95% CI 2.4–4.2). Patients with HA-BSI had a longer hospital stay compared to CA/HCA-BSI and no-BSI groups (27 (IQR 21–35) vs. 12 (7–29) vs. 9 (5–17) median-days, p <, 0.001) but a similar in-hospital mortality (31% vs. 33% vs. 25%, p = 0.421). BSI was not associated with an increased risk of mortality (CA/HCA-BSI vs. non-BSI aOR 1.27 95% CI 0.41–3.90, p = 0.681, HA-BSI vs. non-BSI aOR 1.29 95% CI 0.65–2.54, p = 0.463). Upon multivariate analysis, NIMV/CPAP (aOR 2.09, 95% CI 1.06–4.12, p = 0.034), IMV (aOR 5.13, 95% CI 2.08–12.65, p <, 0.001) and corticosteroid treatment (aOR 2.11, 95% CI 1.06–4.19, p = 0.032) were confirmed as independent factors associated with HA-BSI. Development of HA-BSI did not significantly affect mortality. Patients treated with corticosteroid therapy had double the risk of developing BSI.
- Published
- 2021
49. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL
- Author
-
Bruno Cacopardo, M. A. Ursitti, Claudio Maria Mastroianni, Emanuele Nicastri, R. Piolini, A. Antinori, Giustino Parruti, S. Truffa, Ivan Gentile, Giovanni Cassola, E. Girardi, I. Caramma, Andrea Calcagno, Laura Monno, A d'Arminio Monforte, R. Acinapura, Francesca Ceccherini-Silberstein, A. Di Biagio, Gabriella Verucchi, Alessandra Latini, Simone Marcotullio, Nicola Gianotti, C. Balotta, Camilla Tincati, M. C. Moioli, Alessandro Tavelli, Pietro Caramello, Carmen Rita Santoro, C. Abeli, A. Londero, F. Di Martino, R. Iardino, Stefano Bonora, M. Andreoni, A. Costantini, Raffaella Libertone, F. von Schloesser, G. Prota, Annalisa Saracino, Maria Grazia Cecchetto, Antonio Cristaudo, Mauro Zaccarelli, Carmela Pinnetti, Fabrizio Carletti, N. Abrescia, Andrea Giacometti, L. Gallo, Paolo Bonfanti, G. Angarano, E. Quiros Roldan, G. Pellizzer, F. Petrone, Giovanni Mazzarello, Silvia Nozza, R. Orlando, Franco Baldelli, Giovanni Guaraldi, Paola Meraviglia, Laura Sighinolfi, S. Carrara, D. Segala, Giuliano Rizzardini, C. Suardi, P. Piano, Mauro Sciandra, Daniela Francisci, A. De Luca, Patrizia Lorenzini, Paola Cinque, Tiziana Quirino, S. Graziano, Cristina Mussini, Massimo Galli, Giuseppe Ippolito, S. Lo Caputo, Benedetto Maurizio Celesia, C. Valeriani, Matteo Bassetti, Maria Rosaria Capobianchi, Claudio Viscoli, Vinicio Manfrin, Alessandro Chiodera, Alessandra Bandera, Guglielmo Borgia, Cinzia Puzzolante, Stefano Rusconi, Leonardo Calza, Valeria Belvisi, Francesca Vichi, Serena Quartu, Roberto Cauda, J. Vecchiet, Antonio Chirianni, A. Di Caro, P.E. Manconi, Stefania Cicalini, G. Magnani, M. Lichtner, Milensu Shanyinde, Stefano Savinelli, M. Puoti, Giulia Marchetti, Laura Carenzi, Carlo Federico Perno, Annalisa Ridolfo, G. Di Perri, F. Maggiolo, A Castagna, G. Orofino, Roberto Rossotti, Francesco Mazzotta, Gianmaria Baldin, Giovanni Lapadula, A. Rodano, V. Donati, Barbara Rossetti, F. Viviani, Adriana Ammassari, N. Bobbio, Adriano Lazzarin, C. Minardi, A. Alessandrini, Katia Falasca, Maria Stella Mura, Tamara Ursini, Andrea Gori, A. Cingolani, L. Maddaloni, Alessandro Cozzi-Lepri, Francesco Castelli, Iuri Fanti, Giordano Madeddu, E. Quiros, P. Viale, Marco Borderi, M. Capozzi, and Vincenzo Vullo
- Subjects
Adult ,Male ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Anti-HIV Agents ,Hepatitis C virus ,Renal function ,Integrase inhibitor ,HIV Infections ,medicine.disease_cause ,Rate ratio ,03 medical and health sciences ,0302 clinical medicine ,Antiretroviral Therapy, Highly Active ,Internal medicine ,Clinical endpoint ,Humans ,Medicine ,Pharmacology (medical) ,Treatment Failure ,030212 general & internal medicine ,Retrospective Studies ,Pharmacology ,AIDS-Related Opportunistic Infections ,Coinfection ,business.industry ,Retrospective cohort study ,Middle Aged ,Viral Load ,030112 virology ,CD4 Lymphocyte Count ,Discontinuation ,Treatment Outcome ,Infectious Diseases ,Cohort ,Female ,business - Abstract
ObjectivesOur aim was to investigate the durability of different initial regimens in patients starting ART with CD4+ counts 5 log10 copies/mL.MethodsThis was a retrospective study of HIV-infected patients prospectively followed in the ICONA cohort. Those who started ART with boosted protease inhibitors (bPIs), NNRTIs or integrase strand transfer inhibitors (InSTIs), with CD4+ 5 log10 copies/mL, were included. The primary endpoint was treatment failure (TF), a composite endpoint defined as virological failure (VF, first of two consecutive HIV-RNA >50 copies/mL after 6 months of treatment), discontinuation of class of the anchor drug or death. Independent associations were investigated by Poisson regression analysis in a model including age, gender, mode of HIV transmission, CDC stage, HCV and HBV co-infection, pre-treatment HIV-RNA, CD4+ count and CD4+/CD8+ ratio, ongoing opportunistic disease, fibrosis FIB-4 index, estimated glomerular filtration rate, haemoglobin, platelets, neutrophils, calendar year of ART initiation, anchor drug class (treatment group) and nucleos(t)ide backbone.ResultsA total of 1195 patients fulfilled the inclusion criteria: 696 started ART with a bPI, 315 with an InSTI and 184 with an NNRTI. During 2759 person-years of follow up, 642 patients experienced TF. Starting ART with bPIs [adjusted incidence rate ratio (aIRR) (95% CI) 1.62 (1.29–2.03) versus starting with NNRTIs; P ConclusionsIn patients starting ART with 5 log10 HIV-RNA copies/mL, the durability of regimens based on InSTIs was longer than that of NNRTI- and bPI-based regimens.
- Published
- 2019
- Full Text
- View/download PDF
50. SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues
- Author
-
Matteo D’Antonio, Jennifer P. Nguyen, Timothy D. Arthur, Hiroko Matsui, Agnieszka D’Antonio-Chronowska, Kelly A. Frazer, Benjamin M. Neale, Mark Daly, Andrea Ganna, Christine Stevens, Gita A. Pathak, Shea J. Andrews, Masahiro Kanai, Mattia Cordioli, Juha Karjalainen, Renato Polimanti, Matti Pirinen, Nadia Harerimana, Kumar Veerapen, Brooke Wolford, Huy Nguyen, Matthew Solomonson, Rachel G. Liao, Karolina Chwialkowska, Amy Trankiem, Mary K. Balaconis, Caroline Hayward, Anne Richmond, Archie Campbell, Marcela Morris, Chloe Fawns-Ritchie, Joseph T. Glessner, Douglas M. Shaw, Xiao Chang, Hannah Polikowski, Petty E. Lauren, Hung-Hsin Chen, Zhu Wanying, Hakon Hakonarson, David J. Porteous, Jennifer Below, Kari North, Joseph B. McCormick, Paul R.H.J. Timmers, James F. Wilson, Albert Tenesa, Kenton D’Mellow, Shona M. Kerr, Mari E.K. Niemi, Lindokuhle Nkambul, Kathrin Aprile von Hohenstaufen, Ali Sobh, Madonna M. Eltoukhy, Amr M. Yassen, Mohamed A.F. Hegazy, Kamal Okasha, Mohammed A. Eid, Hanteera S. Moahmed, Doaa Shahin, Yasser M. El-Sherbiny, Tamer A. Elhadidy, Mohamed S. Abd Elghafar, Jehan J. El-Jawhari, Attia A.S. Mohamed, Marwa H. Elnagdy, Amr Samir, Mahmoud Abdel-Aziz, Walid T. Khafaga, Walaa M. El-Lawaty, Mohamed S. Torky, Mohamed R. El-shanshory, Chiara Batini, Paul H. Lee, Nick Shrine, Alexander T. Williams, Martin D. Tobin, Anna L. Guyatt, Catherine John, Richard J. Packer, Altaf Ali, Robert C. Free, Xueyang Wang, Louise V. Wain, Edward J. Hollox, Laura D. Venn, Catherine E. Bee, Emma L. Adams, Ahmadreza Niavarani, Bahareh Sharififard, Rasoul Aliannejad, Ali Amirsavadkouhi, Zeinab Naderpour, Hengameh Ansari Tadi, Afshar Etemadi Aleagha, Saeideh Ahmadi, Seyed Behrooz Mohseni Moghaddam, Alireza Adamsara, Morteza Saeedi, Hamed Abdollahi, Abdolmajid Hosseini, Pajaree Chariyavilaskul, Monpat Chamnanphon, Thitima B. Suttichet, Vorasuk Shotelersuk, Monnat Pongpanich, Chureerat Phokaew, Wanna Chetruengchai, Watsamon Jantarabenjakul, Opass Putchareon, Pattama Torvorapanit, Thanyawee Puthanakit, Pintip Suchartlikitwong, Nattiya Hirankarn, Voraphoj Nilaratanakul, Pimpayao Sodsai, Ben M. Brumpton, Kristian Hveem, Cristen Willer, Wei Zhou, Tormod Rogne, Erik Solligard, Bjørn Olav Åsvold, Malak Abedalthagafi, Manal Alaamery, Saleh Alqahtani, Dona Baraka, Fawz Al Harthi, Ebtehal Alsolm, Leen Abu Safieh, Albandary M. Alowayn, Fatimah Alqubaishi, Amal Al Mutairi, Serghei Mangul, Abdulraheem Alshareef, Mona Sawaji, Mansour Almutairi, Nora Aljawini, Nour Albesher, Yaseen M. Arabi, Ebrahim S. Mahmoud, Amin K. Khattab, Roaa T. Halawani, Ziab Z. Alahmadey, Jehad K. Albakri, Walaa A. Felemban, Bandar A. Suliman, Rana Hasanato, Laila Al-Awdah, Jahad Alghamdi, Deema AlZahrani, Sameera AlJohani, Hani Al-Afghani, May Alrashed, Nouf AlDhawi, Hadeel AlBardis, Sarah Alkwai, Moneera Alswailm, Faisal Almalki, Maha Albeladi, Iman Almohammed, Eman Barhoush, Anoud Albader, Salam Massadeh, Abdulaziz AlMalik, Sara Alotaibi, Bader Alghamdi, Junghyun Jung, Mohammad S. Fawzy, Yunsung Lee, Per Magnus, Lill-Iren S. Trogstad, Øyvind Helgeland, Jennifer R. Harris, Massimo Mangino, Tim D. Spector, Duncan Emma, Sandra P. Smieszek, Bartlomiej P. Przychodzen, Christos Polymeropoulos, Vasilios Polymeropoulos, Mihael H. Polymeropoulos, Israel Fernandez-Cadenas, Jordi Perez-Tur, Laia Llucià-Carol, Natalia Cullell, Elena Muiño, Jara Cárcel-Márquez, Marta L. DeDiego, Lara Lloret Iglesias, Anna M. Planas, Alex Soriano, Veronica Rico, Daiana Agüero, Josep L. Bedini, Francisco Lozano, Carlos Domingo, Veronica Robles, Francisca Ruiz-Jaén, Leonardo Márquez, Juan Gomez, Eliecer Coto, Guillermo M. Albaiceta, Marta García-Clemente, David Dalmau, Maria J. Arranz, Beatriz Dietl, Alex Serra-Llovich, Pere Soler, Roger Colobrán, Andrea Martín-Nalda, Alba Parra Martínez, David Bernardo, Silvia Rojo, Aida Fiz-López, Elisa Arribas, Paloma de la Cal-Sabater, Tomás Segura, Esther González-Villa, Gemma Serrano-Heras, Joan Martí-Fàbregas, Elena Jiménez-Xarrié, Alicia de Felipe Mimbrera, Jaime Masjuan, Sebastian García-Madrona, Anna Domínguez-Mayoral, Joan Montaner Villalonga, Paloma Menéndez-Valladares, Daniel I. Chasman, Julie E. Buring, Paul M. Ridker, Giulianini Franco, Howard D. Sesso, JoAnn E. Manson, Joseph R. Glessner, Carolina Medina-Gomez, Andre G. Uitterlinden, M. Arfan Ikram, Kati Kristiansson, Sami Koskelainen, Markus Perola, Kati Donner, Katja Kivinen, Aarno Palotie, Samuli Ripatti, Sanni Ruotsalainen, Mari Kaunisto, null FinnGen, Tomoko Nakanishi, Guillaume Butler-Laporte, Vincenzo Forgetta, David R. Morrison, Biswarup Ghosh, Laetitia Laurent, Alexandre Belisle, Danielle Henry, Tala Abdullah, Olumide Adeleye, Noor Mamlouk, Nofar Kimchi, Zaman Afrasiabi, Nardin Rezk Branka Vulesevic, Meriem Bouab, Charlotte Guzman, Louis Petitjean, Chris Tselios, Xiaoqing Xue, Erwin Schurr, Jonathan Afilalo, Marc Afilalo, Maureen Oliveira, Bluma Brenner, Pierre Lepage, Jiannis Ragoussis, Daniel Auld, Nathalie Brassard, Madeleine Durand, Michaël Chassé, Daniel E. Kaufmann, G. Mark Lathrop, Vincent Mooser, J. Brent Richards, Rui Li, Darin Adra, Souad Rahmouni, Michel Georges, Michel Moutschen, Benoit Misset, Gilles Darcis, Julien Guiot, Julien Guntz, Samira Azarzar, Stéphanie Gofflot, Yves Beguin, Sabine Claassen, Olivier Malaise, Pascale Huynen, Christelle Meuris, Marie Thys, Jessica Jacques, Philippe Léonard, Frederic Frippiat, Jean-Baptiste Giot, Anne-Sophie Sauvage, Christian Von Frenckell, Yasmine Belhaj, Bernard Lambermont, Sara Pigazzini, Lindokuhle Nkambule, Michelle Daya, Jonathan Shortt, Nicholas Rafaels, Stephen J. Wicks, Kristy Crooks, Kathleen C. Barnes, Christopher R. Gignoux, Sameer Chavan, Triin Laisk, Kristi Läll, Maarja Lepamets, Reedik Mägi, Tõnu Esko, Ene Reimann, Lili Milani, Helene Alavere, Kristjan Metsalu, Mairo Puusepp, Andres Metspalu, Paul Naaber, Edward Laane, Jaana Pesukova, Pärt Peterson, Kai Kisand, Jekaterina Tabri, Raili Allos, Kati Hensen, Joel Starkopf, Inge Ringmets, Anu Tamm, Anne Kallaste, Pierre-Yves Bochud, Carlo Rivolta, Stéphanie Bibert, Mathieu Quinodoz, Dhryata Kamdar, Noémie Boillat, Semira Gonseth Nussle, Werner Albrich, Noémie Suh, Dionysios Neofytos, Véronique Erard, Cathy Voide, null FHoGID, null RegCOVID, null P-PredictUs, null SeroCOVID, null CRiPSI, Rafael de Cid, Iván Galván-Femenía, Natalia Blay, Anna Carreras, Beatriz Cortés, Xavier Farré, Lauro Sumoy, Victor Moreno, Josep Maria Mercader, Marta Guindo-Martinez, David Torrents, Manolis Kogevinas, Judith Garcia-Aymerich, Gemma Castaño-Vinyals, Carlota Dobaño, Alessandra Renieri, Francesca Mari, Chiara Fallerini, Sergio Daga, Elisa Benetti, Margherita Baldassarri, Francesca Fava, Elisa Frullanti, Floriana Valentino, Gabriella Doddato, Annarita Giliberti, Rossella Tita, Sara Amitrano, Mirella Bruttini, Susanna Croci, Ilaria Meloni, Maria Antonietta Mencarelli, Caterina Lo Rizzo, Anna Maria Pinto, Giada Beligni, Andrea Tommasi, Laura Di Sarno, Maria Palmieri, Miriam Lucia Carriero, Diana Alaverdian, Stefano Busani, Raffaele Bruno, Marco Vecchia, Mary Ann Belli, Nicola Picchiotti, Maurizio Sanarico, Marco Gori, Simone Furini, Stefania Mantovani, Serena Ludovisi, Mario Umberto Mondelli, Francesco Castelli, Eugenia Quiros-Roldan, Melania Degli Antoni, Isabella Zanella, Massimo Vaghi, Stefano Rusconi, Matteo Siano, Francesca Montagnani, Arianna Emiliozzi, Massimiliano Fabbiani, Barbara Rossetti, Elena Bargagli, Laura Bergantini, Miriana D’Alessandro, Paolo Cameli, David Bennett, Federico Anedda, Simona Marcantonio, Sabino Scolletta, Federico Franchi, Maria Antonietta Mazzei, Susanna Guerrini, Edoardo Conticini, Luca Cantarini, Bruno Frediani, Danilo Tacconi, Chiara Spertilli, Marco Feri, Alice Donati, Raffaele Scala, Luca Guidelli, Genni Spargi, Marta Corridi, Cesira Nencioni, Leonardo Croci, Maria Bandini, Gian Piero Caldarelli, Paolo Piacentini, Elena Desanctis, Silvia Cappelli, Anna Canaccini, Agnese Verzuri, Valentina Anemoli, Agostino Ognibene, Alessandro Pancrazzi, Maria Lorubbio, Antonella D’Arminio Monforte, Federica Gaia Miraglia, Massimo Girardis, Sophie Venturelli, Andrea Cossarizza, Andrea Antinori, Alessandra Vergori, Arianna Gabrieli, Agostino Riva, Daniela Francisci, Elisabetta Schiaroli, Francesco Paciosi, Pier Giorgio Scotton, Francesca Andretta, Sandro Panese, Renzo Scaggiante, Francesca Gatti, Saverio Giuseppe Parisi, Stefano Baratti, Matteo Della Monica, Carmelo Piscopo, Mario Capasso, Roberta Russo, Immacolata Andolfo, Achille Iolascon, Giuseppe Fiorentino, Massimo Carella, Marco Castori, Giuseppe Merla, Gabriella Maria Squeo, Filippo Aucella, Pamela Raggi, Carmen Marciano, Rita Perna, Matteo Bassetti, Antonio Di Biagio, Maurizio Sanguinetti, Luca Masucci, Serafina Valente, Marco Mandalà, Alessia Giorli, Lorenzo Salerni, Patrizia Zucchi, Pierpaolo Parravicini, Elisabetta Menatti, Tullio Trotta, Ferdinando Giannattasio, Gabriella Coiro, Fabio Lena, Domenico A. Coviello, Cristina Mussini, Enrico Martinelli, Sandro Mancarella, Luisa Tavecchia, Lia Crotti, Chiara Gabbi, Marco Rizzi, Franco Maggiolo, Diego Ripamonti, Tiziana Bachetti, Maria Teresa La Rovere, Simona Sarzi-Braga, Maurizio Bussotti, Stefano Ceri, Pietro Pinoli, Francesco Raimondi, Filippo Biscarini, Alessandra Stella, Kristina Zguro, Katia Capitani, Claudia Suardi, Simona Dei, Gianfranco Parati, Sabrina Ravaglia, Rosangela Artuso, Giordano Bottà, Paolo Di Domenico, Ilaria Rancan, Antonio Perrella Francesco Bianchi, Davide Romani, Paola Bergomi, Emanuele Catena, Riccardo Colombo, Marco Tanfoni, Antonella Vincenti, Claudio Ferri, Davide Grassi, Gloria Pessina, Mario Tumbarello, Massimo Di Pietro, Ravaglia Sabrina, Sauro Luchi, Chiara Barbieri, Donatella Acquilini, Elena Andreucci, Francesco Vladimiro Segala, Giusy Tiseo, Marco Falcone, Mirjam Lista, Monica Poscente, Oreste De Vivo, Paola Petrocelli, Alessandra Guarnaccia, Silvia Baroni, Albert V. Smith, Andrew P. Boughton, Kevin W. Li, Jonathon LeFaive, Aubrey Annis, Anne E. Justice, Tooraj Mirshahi, Geetha Chittoor, Navya Shilpa Josyula, Jack A. Kosmicki, Manuel A.R. Ferreira, Joseph B. Leader, Dave J. Carey, Matthew C. Gass, Julie E. Horowitz, Michael N. Cantor, Ashish Yadav, Aris Baras, Goncalo R. Abecasis, David A. van Heel, Karen A. Hunt, Dan Mason, Qin Qin Huang, Sarah Finer, null Genes & Health Research Team, Bhavi Trivedi, Christopher J. Griffiths, Hilary C. Martin, John Wright, Richard C. Trembath, Nicole Soranzo, Jing Hua Zhao, Adam S. Butterworth, John Danesh, Emanuele Di Angelantonio, Lude Franke Marike Boezen, Patrick Deelen, Annique Claringbould, Esteban Lopera, Robert Warmerdam, Judith.M. Vonk, Irene van Blokland, Pauline Lanting, Anil P.S. Ori, Brooke Wolford Sebastian Zöllner, Jiongming Wang, Andrew Beck, Gina Peloso, Yuk-Lam Ho, Yan V. Sun, Jennifer E. Huffman, Christopher J. O’Donnell, Kelly Cho, Phil Tsao, J. Michael Gaziano, Michel (M.G.) Nivard, Eco (E.J.C.) de geus, Meike Bartels, Jouke Jan Hottenga, Scott T. Weiss, Elizabeth W. Karlson, Jordan W. Smoller, Robert C. Green, Yen-Chen Anne Feng, Josep Mercader, Shawn N. Murphy, James B. Meigs, Ann E. Woolley, Emma F. Perez, Daniel Rader, Anurag Verma, Marylyn D. Ritchie, Binglan Li, Shefali S. Verma, Anastasia Lucas, Yuki Bradford, Hugo Zeberg, Robert Frithiof, Michael Hultström, Miklos Lipcsey, Lindo Nkambul, Nicolas Tardif, Olav Rooyackers, Jonathan Grip, Tomislav Maricic, Konrad J. Karczewski, Elizabeth G. Atkinson, Kristin Tsuo, Nikolas Baya, Patrick Turley, Rahul Gupta, Shawneequa Callier, Raymond K. Walters, Duncan S. Palmer, Gopal Sarma, Nathan Cheng, Wenhan Lu, Sam Bryant, Claire Churchhouse, Caroline Cusick, Jacqueline I. Goldstein, Daniel King, Cotton Seed, Hilary Finucane, Alicia R. Martin, F. Kyle Satterstrom, Daniel J. Wilson, Jacob Armstrong, Justine K. Rudkin, Gavin Band, Sarah G. Earle, Shang-Kuan Lin, Nicolas Arning, Derrick W. Crook, David H. Wyllie, Anne Marie O’Connell, Chris C.A. Spencer, Nils Koelling, Mark J. Caulfield, Richard H. Scott, Tom Fowler, Loukas Moutsianas, Athanasios Kousathanas, Dorota Pasko, Susan Walker, Augusto Rendon, Alex Stuckey, Christopher A. Odhams, Daniel Rhodes, Georgia Chan, Prabhu Arumugam, Catherine A. Ball, Eurie L. Hong, Kristin Rand, Ahna Girshick, Harendra Guturu, Asher Haug Baltzell, Genevieve Roberts, Danny Park, Marie Coignet, Shannon McCurdy, Spencer Knight, Raghavendran Partha, Brooke Rhead, Miao Zhang, Nathan Berkowitz, Michael Gaddis, Keith Noto, Luong Ruiz, Milos Pavlovic, Laura G. Sloofman, Alexander W. Charney, Noam D. Beckmann, Eric E. Schadt, Daniel M. Jordan, Ryan C. Thompson, Kyle Gettler, Noura S. Abul-Husn, Steven Ascolillo, Joseph D. Buxbaum, Kumardeep Chaudhary, Judy H. Cho, Yuval Itan, Eimear E. Kenny, Gillian M. Belbin, Stuart C. Sealfon, Robert P. Sebra, Irene Salib, Brett L. Collins, Tess Levy, Bari Britvan, Katherine Keller, Lara Tang, Michael Peruggia, Liam L. Hiester, Kristi Niblo, Alexandra Aksentijevich, Alexander Labkowsky, Avromie Karp, Menachem Zlatopolsky, Michael Preuss, Ruth J.F. Loos, Girish N. Nadkarni, Ron Do, Clive Hoggart, Sam Choi, Slayton J. Underwood, Paul O’Reilly, Laura M. Huckins, Marissa Zyndorf, AII - Infectious diseases, Amsterdam Neuroscience - Neuroinfection & -inflammation, and Neurology
- Subjects
Medical Physiology ,Gene Expression ,Genome-wide association study ,Genome ,Severity of Illness Index ,colocalization ,Gene expression ,Databases, Genetic ,Ethnicity ,2.1 Biological and endogenous factors ,GWAS ,Aetiology ,Biology (General) ,Lung ,Genetics ,Chromosome Mapping ,Single Nucleotide ,Organ Specificity ,Biotechnology ,Cell type ,QH301-705.5 ,Quantitative Trait Loci ,Single-nucleotide polymorphism ,Biology ,eQTL ,Polymorphism, Single Nucleotide ,Article ,General Biochemistry, Genetics and Molecular Biology ,Databases ,Genetic ,SNP ,Humans ,Genetic Predisposition to Disease ,COVID-19 Host Genetics Initiative ,Polymorphism ,Gene ,COVID-19 ,SARS-CoV-2 ,Gene Expression Profiling ,Prevention ,Human Genome ,Computational Biology ,Genetic Variation ,Good Health and Well Being ,Expression quantitative trait loci ,Biochemistry and Cell Biology ,Transcriptome ,Genome-Wide Association Study - Abstract
Variability in SARS-CoV-2 susceptibility and COVID-19 disease severity between individuals is partly due to genetic factors. Here, we identify 4 genomic loci with suggestive associations for SARS-CoV-2 susceptibility and 19 for COVID-19 disease severity. Four of these 23 loci likely have an ethnicity-specific component. Genome-wide association study (GWAS) signals in 11 loci colocalize with expression quantitative trait loci (eQTLs) associated with the expression of 20 genes in 62 tissues/cell types (range: 1:43 tissues/gene), including lung, brain, heart, muscle, and skin as well as the digestive system and immune system. We perform genetic fine mapping to compute 99% credible SNP sets, which identify 10 GWAS loci that have eight or fewer SNPs in the credible set, including three loci with one single likely causal SNP. Our study suggests that the diverse symptoms and disease severity of COVID-19 observed between individuals is associated with variants across the genome, affecting gene expression levels in a wide variety of tissue types., Graphical abstract, D’Antonio et al. characterize associations between GWAS signals for COVID-19 disease and eQTLs in 69 human tissues to identify causal variants and their underlying molecular mechanisms. They show that diverse symptoms and disease severity of COVID-19 are associated with variants affecting gene expression in a wide variety of tissues.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.